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Abstract 
 
The highly conserved Notch signalling pathway plays a major role in both metazoan 
development and adult tissue renewal. Deregulation of this pathway is linked to 
several diseases, including cancer. Various strategies for Notch signalling inhibition 
are now being investigated as promising new approaches for cancer therapy. Notch 
receptor activation results in the release of the Notch cytoplasmic domain (N
IC
) which 
translocates to the nucleus to bind the transcription factor CSL. Subsequent 
recruitment of MAML-1 is necessary to form the active complex that initiates 
transcription of Notch target genes. In this study, the strategy used to inhibit Notch 
signalling consists of blocking the CSL-N
IC
-MAML tripartite complex formation by 
targeting MAML-1 interactions with N
IC
 and CSL. The first tool is a fusion protein 
composed of the membrane translocating protein Antennapedia (Antp) and a 
dominant negative version of MAML-1 (DN-MAML1). A Notch activity reporter-
gene assay revealed that addition of Antp-DN-MAML1 leads to a dose dependent 
decrease in luminescence, corresponding to an inhibition of Notch signalling. At the 
transcriptional level, treatment of MDA-MB-231 and bone marrow dendritic cells 
with Antp-DN-MAML1 resulted in a significant decrease in the mRNA levels of 
Notch target gene Hes1. In a cell proliferation assay, addition of Antp-DN-MAML1 
had a strong growth-inhibitory effect when added to MDA-MB-231 breast cancer 
cells. Our in vitro data is further supported by preclinical studies where administration 
of Antp-DN-MAML1 halted MDA-MB-231 tumour growth. The second strategy of 
Notch signalling inhibition presented here attempts the intranuclear delivery of single-
chain variable-fragment (scFv) antibodies fused to Antp. Suitable scFvs were selected 
from a phage display library for their ability to bind residues 13–74 of MAML-1. This 
constitutes the minimal portion of MAML-1 necessary to form the active tripartite 
complex, therefore we expect any scFvs that bind this portion to inhibit downstream 
signalling. Our study illustrates two novel strategies for inhibition of Notch signalling 
at the transcriptional level which represent potential future therapeutic alternatives. 
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1.1 Notch signalling 
 
1.1.1 The Notch signalling pathway 
Over 90 years ago, the observation of notches at the wing margin in Drosophila 
melanogaster by the Morgan group lead to the discovery of the Notch gene (Morgan 
1917). Subsequently, loss of function experiments revealed a “neurogenic” phenotype 
caused by Notch. In particular, cells programmed to become epidermis form neural 
tissue instead. At the start of the 1980’s, it was found that the Notch gene encodes a 
300 kDa single-pass transmembrane receptor.  
The highly conserved Notch signalling pathway plays a major role both in metazoan 
development and adult tissue renewal. Transmission of Notch signals, which requires 
cell to cell contact, can influence cell proliferation, cell death and cell differentiation. 
Drosophila have a single Notch receptor and two Notch ligands, Delta and Serrate. In 
mammals, four single-pass transmembrane Notch receptors (Notch 1-4) and five 
ligands (Delta-like 1, 3, 4 and Serrate-like Jagged 1, 2) have been identified so far.  
 
1.1.2 Notch receptors 
Receptor synthesis involves the proteolytic cleavage at site 1 (S1) of large single 
polypeptide precursors by a Furin-like convertase in the Golgi (Logeat et al., 1998) 
resulting in the release of two receptor fragments which re-assemble non-covalently 
on the cell surface (Blaumueller et al., 1997). While transiting through the Golgi, 
Notch receptors can be glycosylated by glycosyl-transferases such as Fringe (Haines 
and Irvine, 2003). This post-translational modification affects the response to different 
ligand subfamilies. As illustrated in Figure 1.1, the Notch extracellular portion 
includes 29-36 tandem epidermal growth factor (EGF)-like repeats, some of which are 
involved in interactions with the Notch ligands. In particular, repeats 11-12 are 
required for trans interactions with ligands displayed on adjacent cells. In contrast, 
EGF repeats 24-29 are involved in cis inhibition by ligands expressed in the same 
cell. The ability of certain EGF repeats to bind calcium ions influences the structure 
and affinity of Notch in ligand binding and can affect signalling efficiency (Cordle et 
al., 2008). The extracellular portion of the receptor also contains a unique negative 
regulatory region (NRR), composed of three cysteine-rich Lin12-Notch repeats (LNR) 
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and a heterodimerisation domain. The NRR functions to prevent receptor activation in 
the absence of ligands.  
The end of the receptor single transmembrane domain contains a C-terminal “stop 
translocation” signal composed of 3-4 arginine/lysine residues. In the intracellular 
portion we find a RAM (RBP-J associated module) domain which forms a high-
affinity binding module of 12-20 amino acids centered on a conserved WxP motif. 
The RAM domain is linked to seven ankyrin repeats (ANK domain) by a long, 
unstructured linker comprising a nuclear localisation sequence. The ANK domain is 
made up of two α helices linked by a short turn followed by a β-hairpin motif. After 
the ANK domain, we find a bipartite nuclear localisation sequence and a 
transactivation domain. The C-terminal end of the receptor contains conserved 
proline/glutamic acid/serine/threonine-rich motifs (PEST) that include degradation 
signals (degrons) to regulate the stability of N
IC
. Phosphorylation of PEST results in 
proteolytic degradation of N
IC
 via E3 ligase recognition and ubiquitination (Fryer et 
al., 2004). 
 
1.1.3 Notch ligands 
Canonical Notch ligands in mammals are type I transmembrane proteins (reviewed in 
(D'Souza et al., 2008), characterised by three related structural motifs: an N-terminal 
DSL (Delta/Serrate/LAG-2) motif and 6-16 EGF-like repeats (including both calcium 
and non-calcium binding). DSL ligands are classified depending on the 
presence/absence of a cysteine-rich domain (Jagged/Serrate or Delta, respectively). It 
is interesting to note that recent work by our laboratory led to the identification of 
Jagged 1 as a ligand for CD46 in humans (Le Friec et al., 2012). 
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Figure 1.1: The structure of mammalian Notch receptors and ligands. All proteins are 
type I transmembrane and contain EGF-like domains. Extracellularly, the Notch 
receptors contain LIN-12-Notch repeats (LNR) close to the cell membrane and Notch 
ligands are characterised by DSL domains at the N-terminus. The ligands intracellular 
domains are very short in contrast with Notch receptors that present large modular 
intracellular domains (N
IC
).  
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1.1.4 The canonical pathway 
Receptor activation results in its cleavage by the TNF-alpha converting enzyme 
(TACE), a member of the ‘a disintegrin and metalloprotease’ (ADAM) family (Brou 
et al., 2000; Mumm et al., 2000). Cleavage at site 2 (S2) occurs circa 12 amino acids 
before the transmembrane domain in a site deeply buried within the negative 
regulatory region. The release of the Notch ectodomain results in the formation of a 
membrane-tethered intermediate called Notch extracellular truncation (NEXT). This 
is a substrate for the protease, γ-secretase, an enzyme complex containing presenilin, 
nicastrin, PEN2 and APH1 (Saxena et al., 2001). This second cleavage (S3-S4) 
releases the Notch intracellular domain (N
IC
) which translocates to the nucleus to bind 
CSL (also called RBP-J, CBF1, Su(H) in flies and LAG-1 in C.elegans) (Tamura et 
al., 1995) (Figure 1.2). This DNA binding protein can normally be found in a complex 
with ubiquitous corepressor (CoR) proteins and histone deacetylases (HDACs) (Kao 
et al., 1998) (see Section 1.1.5).  In these conditions CSL acts as a transcription 
repressor. However, the binding of N
IC
 to CSL displaces this inhibitory complex and 
coactivators such as Mastermind-like (MAML) are then recruited (Petcherski and 
Kimble, 2000; Wu et al., 2000).  
 
1.1.4.1 Mastermind 
Three MAML members (MAML 1-3) have been described in mammals (Lin et al., 
2002; Wu et al., 2002). Wu et al. found that the three MAML genes are widely 
expressed in adult tissues whereas different expression patterns are observed in mouse 
early spinal cord development. The three MAML proteins include an N-terminal basic 
domain for binding to the Notch ankyrin repeat portion. They also share a C-terminal 
transcriptional activation domain. Co-immunoprecipitation experiments confirmed 
that each MAML protein is able to form a complex with the N
IC
 of each Notch 
receptor and CSL. Some differences were observed between the three MAML. For 
example, MAML-3 binds less efficiently to the N
IC
 derived from Notch-1. In addition, 
MAML-3 functions more efficiently as a coactivator with the Notch4 N
IC
 to 
transactivate a Notch target Hes1 promoter construct. Also, MAML3 does not 
significantly amplify transcription of the Hes1 gene upon induction with Jagged2 and 
Delta1 Notch ligands. In the context of human malignancies, genetic rearrangements 
of MAML-2 were first identified in a subset of salivary gland tumours (Tonon et al., 
2003). Abnormal expression of MAML-2 also contributes to the activation of Notch 
 20 
signalling in human lymphomas. In recent years, research efforts have focused mainly 
on MAML-1. This protein is also the main focus of this study. However, it is 
important to keep in mind that the difference between the three MAML proteins may 
partly be responsible for the diversity of biological effects observed upon Notch 
activation.  
Mastermind proteins are approximately 1000 amino acids long but only a minor 
portion is involved in interactions with CSL and N
IC
 (Petcherski and Kimble, 2000; 
Nam et al., 2003). The importance of Mastermind as a whole is highlighted by studies 
employing truncated versions of Mastermind which act in a dominant-negative 
fashion, completely blocking all Notch target expression. Wu et al. showed that both 
MAML-1 (1-302) and MAML-1 (124-1016) reduce activation of Hes1 in vitro (Wu et 
al., 2000). The mutants are defective in transactivation and Notch binding, 
respectively. The dominant-negative effect of MAML-1 (1-302) observed by Wu et 
al., confirms the observations of Helms et al. in Drosophila where C-terminal 
truncations of Mastermind affect Notch pathway function in eye and wing 
development (Helms et al., 1999). A study in Xenopus embryos, showed that the C-
terminal portion of Mastermind is crucial for contacts with CBP/p300 and 
transcriptional activation (Fryer et al., 2002). In fact, mutant Mastermind lacking the 
p300 interaction domain (amino acids 75-301) acts as a dominant-negative inhibitor 
(Fryer et al., 2002). A subsequent study demonstrated that MAML-1 (13-74) was the 
minimal domain necessary for the formation of a tripartite complex with N
IC
 and CSL 
on DNA (Weng et al., 2003). In fact, shorter MAML truncations (22-74, 13-63 and 
13-52) showed weak association with binding partners. MAML (13-74) was also the 
minimal portion required for strong dominant-negative activity which suppressed 
growth and survival of T-ALL cells. This study provides the proof-of-concept for 
Notch inhibition by disruption of MAML for a therapeutic benefit.    
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Figure 1.2: The Notch signalling pathway. Taken from (Kopan, 2012). 
 
Formation of the CSL- N
IC
-MAML ternary complex, shown in Figure 1.3, is 
mandatory to activate transcription of Notch target genes. Understanding how the 
complex is assembled at the molecular level is crucial for the design of an inhibitory 
strategy. CSL consists of N-terminal and C-terminal Rel homology domains (NTD 
and CTD) with a central β trefoil domain (BTD) (Kovall and Hendrickson, 2004). 
NTD and CTD have β sheet secondary structure with folding into immunoglobulin-
like domains. The NTD and BTD function together to recognise and bind specific 
 22 
CTD 
NTD 
BTD 
DNA sequences, interacting with the major and minor groove, respectively (Kovall 
and Hendrickson, 2004). N
IC
 is composed of multiple domains of which only the 
RAM and ANK domains are involved in the interactions within the tripartite complex 
(Nam et al., 2003). The RAM domain of N
IC
 binds with high affinity (Kd in 
nanomolar range) to the BTD of CSL (Wilson and Kovall, 2006; Nam et al., 2006). 
ANK and CTD come together forming a binding groove for the N-terminal helical 
region of the MAML-1 polypeptide. MAML-1 also interacts with the NTD through its 
C-terminal. In particular, a β-hairpin loop structure in NTD (NTD-loop) assumes an 
open conformation induced by RAM binding to BTD. This conformational change 
allows binding of the C-terminal Mastermind helix. It is important to note that 
residues 13–74 constitute the minimal MAML-1 region necessary to form complexes 
with N
IC
 and CSL (Weng et al., 2003).  
Recent studies suggest that aside from the canonical pathway, CSL-independent 
signalling also occurs (reviewed in (Andersen et al., 2012). The non-canonical Notch 
pathway interacts with the Wnt pathway by regulating active β-catenin levels. In order 
to control cellular activity outside the nucleus, Notch is proposed to interact with 
other protein such as Numb and Numblike. Non-canonical Notch signalling has been 
reported to be particularly important in the immune system as illustrated by studies in 
our laboratory (Gentle et al., 2012).      
 
Figure 1.3: The CSL- N
IC
-MAML-1 ternary complex. CSL is composed of the NTD 
(brown) and CTD (orange) (N-terminal and C-terminal Rel homology domains) plus 
the BTD (light green) (β trefoil domain). ANK (purple) = NIC ankyrin domain. 
MAML-1 (dark green) and DNA (blue) are also shown. Figure adapted from Nam et 
al. (2006). 
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1.1.5 The CSL repressor complex 
The CSL repressor complex is composed of various elements (reviewed in (Borggrefe 
and Oswald, 2009) (Figure 1.2). Firstly, the SHARP/MINT protein (Oswald et al., 
2002; VanderWielen et al., 2011) was characterised in vivo during B- and T-cell 
development (Tsuji et al., 2007; Yabe et al., 2007; Kuroda et al., 2003). The 
evolutionary conserved SPOC domain at the C-terminal of SHARP can recruit 
various corepressor proteins such as CtIP/CtBP, ETPO and SMRT (Oswald et al., 
2005; Salat et al., 2008; Shi et al., 2001). Other elements of the repressor complex 
include KyoT2 which is proposed to recruit Ring1 and other polycomb group (PcG) 
proteins (Taniguchi et al., 1998; Qin et al., 2004; Qin et al., 2005). Another protein 
CIR is thought to establish a HDAC-containing complex via SAP30 or NKAP (Hsieh 
et al., 1999; Pajerowski et al., 2009). 
 
1.1.6 Regulation of Notch signalling 
It is important to understand the mechanisms that regulate the amplitude and timing of 
Notch signalling since these are the basis for the cellular context dependency of the 
Notch response. Figure 1.2 illustrates the complexity of this system which affects 
many downstream processes. The E3 ubiquitin ligases Deltex and Nedd4 in addition 
to Numb and α-adaptin regulate the levels of Notch receptors on the cell membrane. 
Nedd4 is thought to modify Notch to target it for degradation and is therefore 
considered as a negative regulator of signalling. Studies in Drosophila showed that 
Deltex was able to antagonise the negative effect of Nedd4 thus promoting Notch 
signalling (Matsuno et al., 1995; Hori et al., 2004). Interestingly, studies in 
mammalian cells (lymphoid cells and neurons) showed the opposite effect with 
Deltex antagonising Notch (Itoh et al., 2003; Sestan et al., 1999). Numb, a negative 
regulator of Notch signalling, interacts with the ear domain of α-adaptin, a member of 
the adaptor protein-2 (AP2) complex which connects cargoes (Numb-Notch) to the 
clathrin coat of endocytic vesicles (Berdnik et al., 2002). Regulation of ligand 
activation involves E3 ubiquitin ligases such as Neur and Mindbomb (Mib) that 
process the ligand intracellular portion to induce epsin-mediated endocytosis (Chitnis, 
2006; Le Borgne et al., 2005).  
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1.1.7 Epigenetic regulation of Notch target genes 
Epigenetics is the study of changes in gene expression by modifications that do not 
involve any change in the underlying DNA sequence. These modifications are for 
example the acetylation and methylation of histone tails. The mechanisms of Notch 
epigenetic regulation are still unclear but several histone-modifying enzymes are 
involved in the regulation of Notch target genes. For example, the histone 
acetyltransferase (HAT) p300 is found in complex with CSL/N
IC
 acting as a positive 
co-factor (Oswald et al., 2001; Wallberg et al., 2002). Functional interactions between 
Notch and PCAF and GCN5 have also been described (Kurooka and Honjo, 2000). 
On the other hand, histone deacetylases were found to be involved in the repression of 
Notch signalling by the SHARP complex (Kao et al., 1998; Oswald et al., 2002).  
   
1.1.8 Notch target genes 
Despite the variety of outcomes observed upon activation of the Notch receptors, only 
a limited number of Notch target genes have been identified.  The hairy/enhancer of 
split (Hes) genes are highly conserved proteins, regulated by Notch in various cellular 
contexts (Jarriault et al., 1995). Hes proteins are helix-loop-helix transcription factors 
that act as transcriptional repressors (Fischer and Gessler, 2007). Evidence supporting 
the direct link between Notch and Hes genes includes: a) The Hes1, Hes5 and Hes7 
promoters can be activated by a constitutively active mutant of the Notch1 receptor. 
The Hey1, Hey2 and HeyL promoters (Hes subfamily, YRPW common motif) are 
also activated (Jarriault et al., 1995; Nishimura et al., 1998; Maier and Gessler, 2000; 
Iso et al., 2003) b) endogenous Hey1 and Hey2 are upregulated by N
IC
 in a variety of 
cell lines (Iso et al., 2001). These results were confirmed in experiments using Notch-
ligand expressing cells to achieve more physiological levels of Notch signalling 
activation (Shawber et al., 1996; Jarriault et al., 1998). Treatment with the protein 
synthesis inhibitor cyclo-hexamide excludes any secondary effects.  c) When T-cell 
leukemia cell lines, characterised by constitutively active Notch signalling, were 
treated with the γ-secretase inhibitor DAPT, microarray analysis identified Hes genes 
as direct targets (Weng et al., 2006).  
Overall, Hes genes are considered to be the best characterised Notch target genes. 
NRARP and Deltex-1 have also been characterised as Notch target genes and they 
function as potent negative regulators of Notch signalling (Izon et al., 2002; Lamar et 
al., 2001). A variety of Notch target genes were identified for their involvement in 
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cancer such as c-Myc (Weng et al., 2006; Satoh et al., 2004; Palomero et al., 2006) 
and cyclin D1 (Ronchini and Capobianco, 2001). Other target genes include: NFκB2 
(Oswald et al., 1998), Ifi-202, Ifi-204, Ifi-D3, ADAM19 (Deftos et al., 2000), Notch1, 
Notch3 (Weng et al., 2006), bcl-2 (Deftos et al., 1998), E2A (Ordentlich et al., 1998) 
and HoxA 5,9 and 10 (Weerkamp et al., 2006). 
 
1.1.8.1 Hes1 
Hes1 is the best-characterised Notch target gene. This transcriptional repressor 
contains a basic-helix-loop-helix (bHLH) DNA binding domain which interacts with 
conserved N-box sites (CACNAG). Hes1 recruits co-repressors such as TLE1-4 and 
histone deacetylases to repress expression of target genes including Hes1 itself 
(Fischer and Gessler, 2007; Iso et al., 2003). This negative feedback loop regulation 
explains the oscillatory expression of Hes1 mRNA and protein observed both in vitro 
and in vivo (Hirata et al., 2002; Iso et al., 2003; William et al., 2007).    
    
1.1.9 Notch and cancer 
The first link between Notch and cancer was unveiled in patients affected by T-cell 
acute lymphoblastic leukemias (T-ALL) where a 9:7 chromosomal translocation 
results in the production of human Notch1 receptors defective in their extracellular 
portion and therefore constitutively active (Ellisen et al., 1991). Although this 
translocation was only found in approximately 10% of T-ALL cases, it was later 
discovered that most patients present activating mutations in the Notch1 locus. These 
mutations cause ligand-independent activation of Notch1 and increased stability of the 
N
IC
.  In humans, abnormal expression levels of Notch receptors and their ligands has 
now been reported in a vast number of solid tumours (Table 1.1). Nevertheless, a 
causative role for Notch signalling in tumorigenesis is yet elusive. In contrast with T -
ALL, no convincing evidence is available for genetic alterations in Notch genes in 
solid cancers. It is interesting to note that a tumour suppressor function has also been 
reported for Notch signalling in mouse keratinocytes, pancreatic and hepalocellular 
carcinoma, and small-cell lung cancer (Koch and Radtke, 2007). This suggests a 
strong dependence on the cellular, temporal and spatial context and crosstalk with 
other signalling pathways. 
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Table 1.1: Accumulated evidence of Notch involvement in cancer  
Tumour type 
Notch signalling 
component involved 
Role of Notch Reference 
Breast cancer 
Increased expression of 
Notch receptors 
and Hes1, Hes5 
Tumour progression 
(Mittal et al., 
2009) 
Notch1 activation 
Drug resistance and tumor 
progression 
(Lee et al., 2008) 
N
IC 
accumulation Tumour progression 
(Stylianou et al., 
2006) 
Colorectal 
cancer 
Notch1 activation Chemoresistance 
(Meng et al., 
2009) 
Increased expression Jgd1, 
Notch1, Hes1 
Tumour progression 
(Reedijk et al., 
2008) 
Increased Jgd1 Oncogenic 
(Guilmeau et al., 
2010) 
Prostate cancer Increased Jgd1 
Tumour progression 
(metastases and 
recurrence) 
(Santagata et al., 
2004) 
Liver cancer 
Notch3 Drug resistance 
(Giovannini et al., 
2009) 
Increased expression of 
Notch3, Jgd1, DLL1, Hes1 
Tumour progression 
(Giovannini et al., 
2006) 
Pancreatic 
cancer 
Notch3 Drug resistance 
(Yao and Qian, 
2010) 
Overexpression of 
Notch1,2; Jgd2;DLL3,4 
Oncogenic and tumour 
progression 
(Mullendore et 
al., 2009) 
Glioblastoma 
Notch1,2 Radioresistance 
(Wang et al., 
2010) 
Increased expression of 
Notch1,3; Hes1,2; Hey1 
Tumour progression 
(Hulleman et al., 
2009) 
DLL1, Jgd1 Tumour progression 
(Purow et al., 
2005) 
Cervical cancer Notch Drug resistance 
(Song et al., 
2008) 
Squamous cell 
carcinoma 
Notch1 
Tumour progression 
(metastasis) 
(Joo et al., 2009) 
Amplification and 
overexpression of Jgd1, 
DLL1, Notch4 
Tumour progression 
(Snijders et al., 
2005) 
Head and neck Notch1 Drug resistance (Gu et al., 2010) 
Medulloblastoma Notch2, Hes1 Tumour progression (Fan et al., 2004) 
Melanoma Notch1 
Tumour maintenance and 
progression 
(Liu et al., 2006) 
Lung cancer 
Numb 
Oncogenic/tumour 
progression 
(Westhoff et al., 
2009) 
Notch3, Jgd1 interactions Tumour progression (Lin et al., 2010) 
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 1.1.9.1 Notch and angiogenesis 
The importance of the Notch signalling pathway in angiogenesis is reflected by the 
common expression of Notch receptors and ligands in the vasculature. During the 
angiogenesis process in a normal context, vascular endothelial growth factor (VEGF) 
stimulates the formation of new vessels by increasing the presence of DLL4-
expressing tip cells that originate from a pre-existing vessel (Claxton and Fruttiger, 
2004). These cells are followed by Notch expressing motile and proliferative 
endothelial tube cells that form the lumen of the new vessel. In order to decrease 
vessel sprouting and branching, DLL4 expressed on the tip cells, binds and activates 
Notch on the tube cells resulting in a downregulation of the VEGF receptor 2 
(VEGFR2) (Hellstrom et al., 2007; Suchting et al., 2007). Tumour cells are known to 
secrete high levels of VEGF which results in increased expression of DLL4 by 
endothelial cells in the stroma (Mailhos et al., 2001; Patel et al., 2006). When VEGF 
activity is blocked, DLL4 expression decreases (Thurston et al., 2007; Patel et al., 
2005). Inhibition of DLL4 dependent Notch signalling on neighbouring endothelial 
cells, leads to a considerable reduction in tumour growth accompanied by increased 
formation of non-functional vessels (Noguera-Troise et al., 2006). The latter effect 
might be explained by the disruption of the DLL4 negative feedback loop. This is 
encouraging for the use of VEGF inhibitors in combination with Notch signalling 
inhibitors for a successful anti-angiogenic therapy.  
 
 1.1.9.2 Notch and breast cancer 
The first evidence of the oncogenic consequences of de-regulated Notch signalling in 
solid tumours comes from studies on the mouse mammary tumour virus (MMTV). 
MMTV does not carry oncogenes like retroviruses, but its insertion into the genome 
interferes with normal gene expression leading to the formation of mammary tumours. 
A particular insertion site was identified as the Notch4 locus with resulting expression 
of a truncated version of the Notch4 receptor missing the majority of the extracellular 
portion (Gallahan and Callahan, 1987; Uyttendaele et al., 1996; Gallahan and 
Callahan, 1997). In vivo experiments with transgenic mice expressing the truncated 
Notch4 confirmed a direct link between de-regulated Notch signalling and the 
development of mammary tumours (Jhappan et al., 1992; Gallahan et al., 1996; Raafat 
et al., 2004; Dievart et al., 1999). MMTV insertions have also been observed in the 
Notch1 locus but with a reduced frequency (Dievart et al., 1999). This insertion 
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results in the expression of a truncated version of the receptor. Microarray studies 
identified the proto-oncogene c-Myc as a direct target gene of Notch1-induced 
mammary tumours (Klinakis et al., 2006). When examining human breast cancer 
samples, coexpression of Notch1 and c-Myc was observed reinforcing the idea that c-
Myc is a direct Notch1 target gene (Efstratiadis et al., 2007). In addition elevated 
Notch1 and Jagged1 expression levels correlate with poor prognosis of breast cancer 
patients (Reedijk et al., 2005). 
Studies on a negative regulator of Notch signalling named Numb, highlighted the 
importance of aberrant Notch signalling in human breast cancer (Jafar-Nejad et al., 
2002; Roegiers and Jan, 2004). Loss of Numb expression was observed in most breast 
cancer cell lines and in approximately half of the tumours examined in the clinic 
including many aggressive forms (Pece et al., 2004). Interestingly, increased levels of 
N
IC
 were detected in 20 breast cancer samples from which Numb was absent 
(Stylianou et al., 2006). 
 
 1.1.9.3 Notch and drug resistance – Rationale for combinatorial therapies 
Acquiring resistance to chemotherapeutic drugs is a crucial advantage to cancer cells 
for their survival. Resistance is usually achieved by the activation of survival 
pathways or the inhibition of apoptotic pathways. As Notch plays a key role in cell 
survival, this pathway is proposed to be involved in drug resistance. Upon treatment 
of colorectal cancer with platinum-based antineoplastic agent oxaliplatin, Notch and 
other survival pathways (PI3K-AKT) are activated. Blocking Notch signalling using 
γ-secretase inhibitors (GSIs) sensitises cells to oxaliplatin (Meng et al., 2009). 
Combination of taxanes and GSIs has been proposed for colon cancer therapy after 
observation of mitotic arrest in resistant cancer cells upon inhibition of Notch 
(Akiyoshi et al., 2008). In pancreatic cancer, synergistic anti-tumour effects were 
observed for GSI in combination with rapamycin due to increased inhibition of the 
PI3K/AKT/mTOR pathway (Vo et al., 2011). In ErbB2-positive breast cancer cells, 
Notch signalling is inactive and tumours are not sensitive to GSI treatment. Treatment 
with trastuzumab (Herceptin
®
) was shown to induce upregulation of Notch activity as 
cells become resistant to the treatment. However, combination treatment with 
trastuzumab and GSI led to apoptosis of the cells (Osipo et al., 2008). In another 
model, oestrogen receptor (ER)-negative breast cancer cells show elevated expression 
of survivin, increased proliferation and reduced apoptosis. Upon GSI treatment, 
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growth of these tumours is reduced suggesting a role for the Notch pathway in 
maintaining these tumours (Lee et al., 2008). 
The Notch pathway has also been implicated in resistance to radiation. Wang et al. 
showed that Notch inhibition using GSIs makes glioma stem cells more radiosensitive 
by reducing AKT activity (Wang et al., 2010). Overall, accumulated evidence 
suggests a role for Notch signalling in drug resistance, hence the use of GSIs as 
combination therapies. Further research on the cross talk between Notch signalling 
and other signalling pathways is pivotal to the design of successful therapies.    
 
1.1.10 Therapeutic targeting of the Notch pathway 
As evidence accumulates for the implication of Notch in a variety of cancers (Table 
1.1), there has been an equal effort to generate inhibitors of this pathway for tumour 
therapy (Table 1.2). In vitro, a variety of strategies have been employed to inhibit 
Notch signalling. These include antisense Notch (Garces et al., 1997), RNA 
interference (Fan et al., 2004; Purow et al., 2005), soluble receptor decoys that 
sequester Notch ligands to prevent receptor binding (Garces et al., 1997; Nickoloff et 
al., 2002) and dominant negative versions of MAML of CSL that affect 
transcriptional activation of Notch target genes (Weng et al., 2003; Duncan et al., 
2005). The best described strategy for inhibition of Notch signalling is the use of γ -
secretase inhibitors. This consists in inhibiting the S3-S4 cleavage to prevent release 
of the N
IC
. One of these inhibitors, referred to as MK0752 (Merck) (Figure 1.4), 
showed severe intestinal toxicity when tested in a phase I clinical trial for T-cell acute 
lymphoblastic leukemia. These ‘off target’ effects can be explained by the fact that γ-
secretase has many substrates other than the Notch receptor. In addition, the inhibitors 
may target other proteases which are involved in a multitude of cellular functions. 
Interestingly, in a mouse model of T-ALL, a reduction of toxic effects is observed 
when administering GSI in parallel with gluco-corticoids. This combination therapy is 
as effective as GSI alone. GSIs have also been proposed as a therapeutic agent for 
estrogen receptor-positive breast cancer. In fact, in this type of cancer, initial therapy 
with anti-estrogens or aromatase inhibitors results in a dependence on Notch 
signalling. GSI has also been proposed as a potential therapy for triple-negative breast 
cancer cells due to their cancer stem cell characteristics.     
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Table 1.2: Preclinical and Clinical trials of therapeutic agents targeting Notch 
signalling in cancer  
Type Compound Condition Progress References 
γ-secretase 
inhibitor 
R04929097 
(Roche) 
Breast cancer 
Brain and CNS 
tumours 
Colorectal cancer 
Melanoma 
Solid Tumours 
T-cell leukemia 
Phase I 
clinical 
trials 
(Gounder and 
Schwartz, 
2012) 
MRK-003 
(Merck & Co) 
Breast cancer 
T-cell leukemia 
tumour xenografts 
Preclinical 
studies 
(Tammam et 
al., 2009; 
Pandya et al., 
2011) 
MK-0752 
(Merck & Co) 
Brain and CNS 
tumours  
Breast cancer 
Neoplasms 
Pancreatic cancer 
T-cell leukemia 
Phase I 
clinical 
trials  
(Gounder and 
Schwartz, 
2012) 
PF-03084014 
(Pfizer) 
Neoplasms 
Lymphoid leukemia 
Solid tumours 
T-cell leukemia 
Phase I 
clinical 
trial 
(Wei et al., 
2010) 
Immunotherapy 
OMP-59R5  
α-Notch mAb 
(OncoMed 
Pharmaceutics) 
Solid tumours 
Phase I 
clinical 
trial 
 
OMP-21M18 
α-DLL4 mAb 
(OncoMed 
Pharmaceutics) 
Colorectal cancer 
Pancreatic cancer 
Small cell lung 
cancer 
Solid tumours 
Phase I 
clinical 
trials 
(Fischer et 
al., 2011) 
NRR1 and 
NRR2  
α -Notch1 
mAbs 
(Genentech 
and Elelixis) 
Anaplastic 
carcinoma 
Breast carcinoma 
Colon carcinoma 
tumour xenografts 
Preclinical 
study 
(Wu et al.) 
NRR1 α-
Notch1 mAb 
(Merck & Co) 
T-cell leukemia 
T-ALL cell line 
In vitro 
study 
(Aste-
Amezaga et 
al., 2010) 
NRR3 α-
Notch3 mAb 
HEK293T cell line 
In vitro 
study 
(Li et al., 
2008) 
A5226A Anti-
Nicastrin mAb 
T-cell leukemia 
T-ALL tumour 
xenografts 
Preclinical 
study 
(Hayashi et 
al., 2012) 
Peptide 
inhibitor 
stapled peptide 
(Aileron 
Therapeutics) 
T-cell leukemia 
T-ALL tumour 
xenografts 
Preclinical 
study 
(Moellering 
et al., 2009) 
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Figure 1.4: Structure of the MK-0752 γ-secretase inhibitor. 
 
Another target for cancer therapy is the Notch ligand DLL4 because of its 
involvement in the process of angiogenesis (section 1.1.9.1). In vivo studies showed 
severe disruption of the vasculature following DLL4 mutation (Duarte et al., 2004) 
whereas heterozygous deletion of DLL4 is mostly lethal (Suchting et al., 2007). Anti-
DLL4 antibodies have been generated and in vitro studies demonstrated their anti-
tumour activities (Hoey et al., 2009).  Anti-DLL4 antibodies are currently in phase I 
clinical trials where development of angiomas and neo-vascular tuft formation were 
reported in patients (Ridgway et al., 2006; Yan et al., 2010).  Antibodies have also 
been used to modulate Notch signalling by targeting individual Notch receptors. In 
contrast to pan-Notch inhibitors, the advantages of a targeted strategy include 
potential reduction in side effects. Gastrointestinal toxicity is potentially minimised 
also because therapeutic antibodies can be delivered through the bloodstream in 
contrast with GSIs that were designed to be administered orally. In some cancers, 
oncogenicity can be related to a particular Notch paralogue, found to be mutated or 
deregulated. For example, abnormal Notch1 activity is implicated in T-ALL whereas 
Notch3 is implicated in certain lung cancers. These conditions are best suited for a 
targeted inhibition of Notch signalling. Antibodies have been developed that modulate 
Notch signalling by the extracellular negative regulatory region (NRR) of Notch 1, 2 
and 3 (Li et al., 2008). Upon ligand binding, the NRR of Notch normally undergoes a 
conformation change to facilitate ADAM protease cleavage (Wu et al., 2010; Li et al., 
2008; Aste-Amezaga et al., 2010). These antibodies successfully inhibit Notch 
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signalling at low concentrations. Wu et al. (2010) employed phage display to select 
antibodies that inhibit Notch1 only or Notch2 only. They emphasise that inhibition of 
either receptor alone reduces or avoids intestinal toxicity. Aste-Amezaga et al. (2010) 
showed how antibodies directed at the Notch1 NRR successfully inhibited signalling 
from Notch1 receptors with characteristic NRR mutations observed in T-ALL. 
The ligand-binding site of Notch1 and Notch3 is also the target of specific antibodies 
to inhibit Notch downstream signalling. However, higher antibody concentrations are 
necessary for a successful inhibition effect. Several antibodies targeted at Notch are 
now undergoing preclinical development with one anti-Notch mAb in Phase I clinical 
trials (OMP-59R5 OncoMed Pharmaceuticals). 
Antibodies could also be targeted to the γ-secretase complex. A recent study 
described the use of an antibody against the extracellular domain of Nicastrin, a 
component of γ-secretase. They showed how the antibody was able to inhibit γ-
secretase activity by competing with substrate binding. The antibody affected 
proliferation of T-ALL cells in vitro and in vivo (Hayashi et al., 2012). Targeting γ-
secretase with antibodies remains challenging due to the heterogeneity of the 
complex. In fact, permutation of the members means that six different complexes are 
possible depending on the involvement of Presenilin-1 or -2, Aph-1AS, Aph-1AL or 
Aph-1B. 
When designing a strategy for inhibition of Notch signalling it is important to keep in 
mind the possible disruption of other pathways. For example, one could target other 
components of the Notch pathway such as ADAM10/17 proteases or Notch 
glycosylation enzymes but these are also key components of other signalling 
pathways.  
In the nuclear setting, inhibition of the tripartite complex formation (CSL- N
IC
-
MAML) has also been attempted. Moellering et al. (Moellering et al., 2009) 
engineered a membrane permeable MAML-1 peptide by chemical modification and 
cross-linking of two residues. This stapled peptide interferes with endogenous 
MAML-1 to inhibit assembly of the active transcriptional complex resulting in global 
repression of Notch1 signalling.  Blocking formation of the CSL-N
IC
-MAML1 
complex inhibits proliferation of T-cell acute lymphoblastic leukemia cells in vitro 
and in vivo. The ‘stapled peptide’ technology is now being developed by AILERON 
therapeutics.  
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1.1.11 Mastermind-like: transcriptional co-activator in other signal transduction 
pathways 
There is emerging evidence for Notch-independent functions of MAML proteins. The 
most relevant to this study is the interaction between MAML-1 and p53 (Zhao et al., 
2007). p53 is a tumour suppressor  that induces cell-cycle arrest and apoptosis in 
response to cellular stresses such as DNA damage, hypoxia and oncogene activation 
(Lakin and Jackson, 1999). Mutations in p53 are observed in approximately half of 
cancer patients. A recent study by Zhao et al., illustrates how MAML-1 co-activates 
p53-dependent gene expression. Immunoprecipitation studies showed that MAML-1 
interacts with p53. In addition, MAML-1 was identified in activator complexes bound 
to the native promoter of the p53 target genes p21, Bax and GADD45. The p21 
protein, able to block cell cycle progression at G1, is an intermediate by which p53 
inhibits cellular proliferation. MAML-1 overexpression enhanced p53-dependent gene 
induction. In contrast, MAML-1 knockdown resulted in a decrease in p53-dependent 
gene expression. MAML-1 overexpression leads to an accumulation of p53 protein. 
This is not due to an increase in mRNA levels but to the ability of MAML-1 to 
stabilise the p53 protein thus increasing its half-life. More specifically, MAML-1 
increases the levels of p53 phosphorylation and acetylation upon DNA damage. 
Several studies have focused on increasing tumour suppression as a strategy for 
cancer therapy. Delivery of p53 in tumours has been achieved with both retroviral and 
adenoviral vectors, resulting in a significant reduction of growth (reviewed in (Roth et 
al., 1999)). Delivery of p21 by adenovirus resulted in significant inhibition of tumour 
growth by cell cycle arrest at G0/G1 (Katayose et al., 1995; Prabhu et al., 1996). 
However, viral delivery is limited in its applications and safety concerns have been 
raised (Somia and Verma, 2000). 
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1.2 Antibodies as “magic bullets” 
 
1.2.1 Antibody structure 
Antibodies are essential components of the mammalian immune system, produced by 
B lymphocytes, which allow the initiation of an adaptive response upon specific 
recognition of a foreign substance such as pathogenic organisms and toxins (Reichert, 
2001). Antibodies are classified into five groups: IgG, IgD, IgE, IgA and IgM. The 
first type, IgG, is the most relevant to this study for its use as a therapeutic agent 
(Weiner et al., 2010). The IgG family is divided into four subgroups (IgG1 to IgG4) 
with IgG1 being the preferred format for therapeutic use (Isaacs, 2009).  
Immunoglobulin G (IgG) is a 150 kDa glycoprotein composed of four chains 
connected through disulphide bonds (Porter, 1973) (Figure 1.5). In particular, IgG is 
composed of two identical light chains (25 kDa each) and two heavy chains (50 kDa 
each). Treatment with the papain enzyme cleaves above the hinge region to separate 
the 50kDa Fab (fragment antigen-binding) fragment and the 50kDa Fc (fragment 
crystallisable) domain. The light chain is composed of the variable light (VL) domain 
at the N-terminal end and the constant light (CL) domain at the C-terminal end. The 
heavy chain is composed of two constant (CH) domains in the Fc portion and a 
constant and a N-terminal variable (VH) domain in the Fab portion. The variable 
domains VH and VL are responsible for recognition and binding of a specific antigen 
through the complimentary determining regions (CDRs). The binding of IgG is 
bivalent as it targets the same epitope using each Fab arm. The Fc domain translates 
binding into a biological response by activating complement, inducing phagocytosis 
or triggering antibody-dependent cellular cytotoxicity.   
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Figure 1.5: The IgG molecule at a glance: The IgG antibody is composed of two 
heavy chains (blue) and two light chains (yellow), connected through disulphide 
bonds (red). Each chain is divided into variable and constant domains. The Fab 
fragment is involved in binding whereas the Fc elicits effector functions.  
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1.2.2 Monoclonal antibodies 
The first monoclonal antibodies were produced from mouse hybridomas generated by 
the fusion of B-lymphocytes with myeloma cells (Kohler and Milstein, 1975). The use 
of mouse monoclonal antibodies in the clinic revealed patients’ immunogenic 
responses with release of human anti-mouse antibodies (HAMA) (Schroeder et al., 
1990). These side effects triggered the development of chimeric (human constant 
domains) (Morrison et al., 1984), humanised (mouse CDRs only) (Jones et al., 1986) 
and then fully human mAbs (Figure 1.6). The first humanised mAb approved in 1997 
for use in the clinic is Daclizumab (Zenapax
®
) which is directed at CD25 to 
ameliorate acute organ rejection (Ekberg et al., 1999).  The generation of fully human 
mAbs was possible thanks to transgenic mice and phage display technologies. 
Adalimumab (Humira
®
) targeting TNF-α for the treatment of rheumatoid arthritis was 
originally derived from phage display and approved in 2002 (Scheinfeld, 2003). 
Panitumumab (Vectibix
®
) targeting EGFR for treatment of colon cancer was 
developed using transgenic mice and approved in 2006 (Chu, 2006).   
 
 
 
murine IgG chimeric IgG humanised IgG human IgG
 
 
Figure 1.6: The evolution of monoclonal antibodies: from murine (blue) to fully 
human (orange). 
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1.2.3 Antibody formats  
A variety of recombinant antibody fragments have now been generated as alternatives 
to the whole IgG format (Figure 1.7). Examples of these include the monovalent 
single chain variable fragment (scFv), the monovalent Fab fragment and other 
variants such as diabodies, triabodies and minibodies. These fragments are generated 
by combining critical V-domains of the parental IgG antibody, chosen on the basis of 
their final use. For example, the scFv consists in the combination of the variable 
regions of the IgG heavy and light chains linked together with a short linker. Thus, the 
scFv is still able to specifically recognise the antigen but it can not recruit cytotoxic 
effector functions due to the lack of the Fc region. If the linker between the two scFv 
domains is short (3 residues), this construct associates with another scFv molecule to 
form a diabody. The combination of two different scFvs allows the formation of bi-
specific diabodies. If the linker is less than three residues long, scFvs associate into 
triabodies. Another variant of scFvs are minibodies in which the heavy- and light- 
chain variable regions are part of the same polypeptide chain including the heavy-
chain hinge region and one heavy-chain constant domain. scFvs can also be linked to 
a multitude of molecules such as radionuclides for radioimmunotherapy (Davies, 
2007), photosensitisers for photodynamic therapy (Bhatti et al., 2008), toxins 
(Chaudhary et al., 1989), and cytokines (Trachsel et al., 2007). The advantages of a 
smaller antibody construct are varied and include the lower cost of production and 
advantageous bio-distribution and blood pharmacokinetic properties. Lower costs of 
production are achieved as scFvs and fusions can be expressed in E.coli and yeast 
systems.  
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Figure 1.7: Dissection of the naturally occurring antibody into a large variety of 
recombinant antibody fragments. bs: bi-specific; dAb: single domain antibody; ds: 
disulphide; scFv: single-chain antibody fragment. Adapted from Deonarain (2008). 
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1.2.4 Immunotherapy 
The high antigen binding affinity, specificity and modular structure that characterise 
antibodies, make them an excellent tool for immunotherapy. The term immunotherapy 
includes classical treatments such as vaccination and passive immunisation using 
serum, but also the use of monoclonal antibodies of which 34 were approved for 
therapeutic use as of March 2012 (Reichert, 2012). Out of these, 10 are for cancer 
therapy including rituximab (Rituxan
®
) (Coiffier, 2007), trastuzumab (Herceptin
®
) 
(Vogel et al., 2002) and bevacizumab (Avastin
®
) (Panares and Garcia, 2007) which 
have all reached sales of over 1 billion US dollars. Rituximab is a chimeric whole 
monoclonal IgG molecule and was the first of its kind to be approved for treatment of 
non-Hodgkins lymphoma targeting CD20 in 1997 (McLaughlin et al., 1998). CD20 is 
a receptor found on the cell surface in 99% of B-cell lymphomas and leukemias. Its 
biology is not well understood but binding of Rituximab to CD20 results in 
accelerated calcium ion flux rate and inhibition of anti-apoptotic survival pathways 
(Ben-Kasus et al., 2007). Trastuzumab is a humanised mAb targeting human 
epidermal growth factor receptor 2 (HER2). Early evidence suggested that HER2 is 
over-expressed in a variety of adenocarcinomas including breast, ovary, prostate, lung 
and gastrointestinal cancers (Slamon, 1987). HER2 over-expression leads to 
accelerated homodimer formation, deregulating signalling pathways involved in 
tumour cell survival, growth, metastasis and transformation (Wang and Greene, 
2008). Bevacizumab was designed as a treatment of metastatic colorectal cancer with 
VEGF as its target. The mechanism of action of this humanised mAb is to block the 
interaction of the tumour associated cytokine VEGF with its receptor VEGFR, 
ultimately inhibiting angiogenesis (Dvorak, 2002). The main disadvantages of IgG 
mAbs are the slow perfusion into tumours reflected by low tumour to normal tissue 
ratios (Jain, 1990) in addition to Fc-domain mediated cross reactivity with associated 
side effects. In contrast, fragments such as scFvs have shown better increased tumour 
penetration but faster clearance due to their reduced size and the lack of a Fc region 
(Schier et al., 1996). 
So far, all antibodies, in development or approved, bind to extracellular targets 
primarily to modulate/inhibit cell signalling (Chames et al., 2009). Engineering a cell-
permeable antibody format would enable the exploitation of a multitude of 
intracellular signalling pathways to affect cancer cells (section 1.4.4). 
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1.3 Phage display 
 
Phage display is a technique for high-throughput screening of molecular interactions 
using bacteriophage to connect genotype to phenotype. Practically, one of the binding 
partners is fused to a surface protein of a viral particle. The corresponding gene is 
found within the same virus. The high-throughput aspect of this technique consists of 
generating combinatorial libraries of such fusions and exposing them to a selected 
target molecule for the isolation of specific binders. The binders are amplified by a 
growth/infective stage to then isolate the gene corresponding to the positive binders.  
 A variety of molecules can be displayed on phage but antibody derivates are most 
common and relevant to this study. McCafferty et al. (McCafferty et al., 1990) first 
described the display of antibodies on phage and subsequent selection. Clackson et al. 
followed by constructing a combinatorial phage display library (Clackson et al., 
1991). Other than scFv clones, other antibody derivatives have since been displayed 
on phage including Fab fragments (de Haard et al., 1999), disulphide stabilised scFvs 
(Bera et al., 1998), diabodies (McGuinness et al., 1996), tandem-scFvs (Wright and 
Deonarain, 2007) and single domain antibodies (Holt et al., 2008).  
The most common viruses used in phage display are the non-lytic filamentous 
bacteriophage f1, M13 and fd (Marvin, 1998; Paschke, 2006). Their 6.5 kbp ssDNA 
genome includes nine genes encoding 11 proteins named pI to pXI. Proteins pIII and 
pVI are found at one end of the virus whereas pVII and pIX are found at the opposite 
end. pVIII is the major coat protein, present all around the surface (Figure 1.8). The 
other proteins are involved in the replication and control apparatus. The pIII coat 
protein specifically binds to the E.coli F-pilus, inducing its retraction and 
translocation of the phage genetic material in the bacterium. Once inside the host, 
genome replication is initiated followed by gene expression and assembly of the 
phage components at the inner membrane and periplasmic space of E.coli. Finally, the 
phage exits through the outer membrane. pIII is the most common fusion partner for 
phage antibody libraries although pVI (Hufton et al., 1999), pVII (Gao et al., 1999), 
pVIII (Felici et al., 1991) and pIX (Gao et al., 1999) have also been utilised.  
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Figure 1.8: Spatial distribution of coat proteins on filamentous phage. The commonly 
used pIII is composed of three domains (CT: C-terminal; N1 and N2: N-terminal). 
Taken from (Paschke, 2006). 
 
Both phage vectors and phagemid vectors are used in phage diplay (O'Connell et al., 
2002). In the phage vector system, the protein of interest is cloned next to a phage 
coat protein on the phage genome itself. Therefore, every copy of the phage coat 
protein displays the protein of interest on all progeny phage particles. This results in 
polyvalent display. This system is best suited for low affinity interactions allowing 
rapid and successful enrichment with increased diversity amongst output clones. 
However, the polyvalency aspect of this technique means that clones with poor 
intrinsic affinity may be selected and enriched. Generally, lower phage titers (smaller 
library diversity) have been observed when using the phage vector system.  
Phagemid libraries are the preferred system for antibody selection by phage display. 
In this set-up, the protein of interest is cloned next to a phage coat protein in a vector 
where no other phage component is present (Barbas et al., 1991). The vector contains 
an origin of replication for E.coli and a phage packaging signal. E.coli cells 
containing the phagemid vector are super-infected with helper phage which provides 
all the genetic material required for the production of functional phage particles. The 
characteristic of this system is that, due to competition between wild type coat 
proteins and fusion proteins, only 1-10% of progeny phage particles display the 
protein of interest. In addition, only 1 out of the 3-5 copies of pIII protein is fused 
with the protein of interest. This results in monovalent display, increasing the 
probability of isolating a high intrinsic affinity antibody fragment. On a practical 
level, the phagemid system allows for expression of the antibody portion alone thanks 
to the amber stop codon that precedes the coat protein gene. This allows read through 
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in amber suppressor strain E.coli XL1-blue but not in non-suppressing E.coli HB2151 
(McCafferty et al., 1990).  
 
Antibody display libraries 
There is a large diversity of antibody libraries described in various reviews (Benhar, 
2007; Marks and Bradbury, 2004; Hoogenboom, 2005; Mondon et al., 2008). Most of 
these libraries are for use in filamentous phage display selections using phagemid 
vectors.  The preferred antibody format is the scFv, fused to coat protein pIII. One of 
the early phagemid vectors pHEN1 (Marks et al., 1991) is the base for subsequent 
constructs such as the pCANTAB6 vector used in this study (McCafferty et al., 1990).  
Antibody libraries are defined as either immunised or naive. In immunised libraries, 
the V gene diversity is derived from humans (Zebedee et al., 1992) or mice (Ames et 
al., 1995) immunised against the target antigen. Consequently, target specific 
enrichment and affinity maturation have already occurred in vivo. Higher affinity 
antibodies are usually isolated from immunised libraries versus naive libraries of the 
same size. The library employed here is of human origin and naïve. Therefore, we 
expect isolation of low to medium affinity antibodies. 
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1.4 Strategies for crossing the cell membrane 
 
1.4.1 Cell-penetrating peptides 
The hydrophobic nature of the cell membrane constitutes a major obstacle for drug 
delivery. In fact, many drugs, peptides, proteins and the majority of hydrophilic 
macromolecules are excluded by the membrane phospholipid bilayer. Only molecules 
that fit within a particular size range, charge and polarity can cross the membrane 
directly. Consequently, various strategies have been developed for successful 
transport of drugs inside the cell. In the past, techniques such as electroporation, 
microinjection and liposome encapsulation were attempted (Luo and Saltzman, 2000). 
The drawbacks of these approaches included inefficient drug delivery, cellular 
damage and toxicity. Another strategy is based on the use of vector molecules 
(antibodies, peptides and sugar moieties) for transport via receptor-mediated 
endocytosis. The main disadvantage of highjacking the endocytic pathway is the lack 
of escape routes from the endosomal compartment in addition to limited diffusion, 
degradation and lack of nuclear uptake.    
Membrane translocating proteins present a promising tool for drug delivery across 
membrane barriers. The first naturally-occurring, shuttling protein to be described was 
the HIV-1 transactivating (Tat) protein which can translocate into cells and penetrate 
into the nucleus (Frankel and Pabo, 1988; Green and Loewenstein, 1988). Subsequent 
studies showed that when Tat protein was shortened to a few amino acids 
(
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YGRKKRRQRRR
57
), now known as the Tat peptide, this retained its translocation 
activity (Vives et al., 1997). In this study, a 60 amino acid residue, polycationic 
protein called Antennapedia (Antp) is used (Figure 1.9). Antp, a portion of the 
Drosophila transcription homeoprotein, was initially shown to be internalised by 
neuronal cells (Joliot et al., 1991). Following internalisation, Antp is directed to the 
cell nucleus. Early data also demonstrated that Antp can promote the internalisation of 
a peptide cargo when expressed as a fusion (Perez et al., 1992; Schutze-Redelmeier et 
al., 1996). The characterisation of Antp led to the discovery of the first cell 
penetrating peptide (CPP) named penetratin (Derossi et al., 1994). This corresponds to 
a 16 amino acid portion of the third helix of the Antp homeodomain (see arrow in 
Figure 1.9A and red sequence in Figure 1.9B). Penetratin can deliver molecules, such 
as doxorubicin (anti-cancer agent targeting brain tumours) (Rousselle et al., 2001) and 
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p16 (tumour suppressor protein) peptides, into tumour cells. Internalisation of p16 
results in decreased cancer growth and induction of apoptosis in cancer cells 
(Hosotani et al., 2002). Penetratin has also been used to deliver a p53 derived peptide 
which activates p53-mediated transcription ultimately blocking tumour growth (Tang 
et al., 2007). 
 
A 
 
B 
cgcaaacgcggaaggcagacatacacccggtaccagactctagagctagagaaagagttt 
R  K  R  G  R  Q  T  Y  T  R  Y  Q  T  L  E  L  E  K  E  F 
cacttcaatcgctacttgacccgtcggcgaaggatcgagatcgcccacgccctgtgcctc 
H  F  N  R  Y  L  T  R  R  R  R  I  E  I  A  H  A  L  C  L 
acggagcgccagataaagatttggttccagaatcggcgcatgaagtggaagaaggagaac 
T  E  R  Q  I  K  I  W  F  Q  N  R  R  M  K  W  K  K  E  N 
 
Figure 1.9: A) Antennapedia helical structure. The third helix containing penetratin is 
highlighted by the arrow. B) Antennapedia DNA and protein sequence. The sequence 
corresponding to penetratin is highlighted in red. 
 
 
1.4.2 Classification of CPPs 
Over the past 20 years, more than 100 CPPs (5-40 amino acids long) have been 
reported for transport into mammalian, plant and bacterial cells (Lindgren and Langel, 
2011; Hudecz et al., 2005; Stewart et al., 2008). Key CPPs are described in Table 1.3. 
CPPs can be classified according to their structure as either cationic or amphipathic. 
The first group is characterised by abundance of positively charged amino acids 
(mostly arginine and lysine) at physiological pH. These are thought to be involved in 
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electrostatic interactions with negatively charged glycoproteins on the extracellular 
side of the cell membrane. The guanidine head group of arginine is able to form 
hydrogen bonds with phosphates and sulfates, facilitating internalisation. Lysines, 
lacking the guanidine head group, are less effective at membrane penetration. The 
importance of the presence and distribution of arginine residues has been described 
(Lindgren and Langel, 2011). In addition, cationisation of macromolecules has been 
used as a strategy to improve cellular uptake (reviewed in (Blau et al., 2000). The Tat 
peptide, penetratin and polyarginines (Futaki et al., 2001) are part of this subclass of 
CPPs. 
The second group, comprised of amphipathic CPPs, includes model amphipathic 
peptide (MAP) (Oehlke et al., 1998), transportan (Pooga et al., 1998)  and Pep-1 
(Henriques and Castanho, 2008). The chimeric peptide transportan is composed of the 
N-terminal fragment of the neuropeptide galanin fused to the wasp venom peptide 
mastoparan. Transportan was used for proof of concept of the application of CPPs in 
vivo. In particular, transportan was used to deliver peptide nucleic acids (PNAs). 
Delivery of small peptides and large proteins in vivo was demonstrated by the Dowdy 
group (Schwarze et al., 1999). Pep-1 and MPG were the first non-covalent CPP for 
delivery of proteins/peptides and nucleic acids, respectively (Morris et al., 1997; 
Morris et al., 2001). 
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Peptides Origin Sequences Cargo type References 
Tat  HIV-Tat protein PGRKKRRQRRPPQ 
protein, peptide, 
siRNA, liposome, 
nanoparticle 
(Snyder and Dowdy, 
2005; Schwarze et 
al., 1999) 
Penetratin Homeodomain RQIKIWFQNRRMKWKK 
peptide, siRNA, 
liposome 
(Joliot and 
Prochiantz, 2004) 
Transportan Galanin-mastoparan GWTLNSAGYLLGKINLKALAALAKKIL 
protein, peptide 
nucleic acids, siRNA 
(Pooga et al., 1998) 
MPG 
HIV Gp41-SV40 
nuclear localisation 
sequence 
GALFLGFLGAAGSTMGAWSQPKKKRKV siRNA, plasmid (Morris et al., 2008) 
Pep-1 
Trp-rich motif-SV40 
nuclear localisation 
sequence 
KETWWETWWTEWSQPKKKRKV protein, peptide (Gros et al., 2006) 
MAP Chimeric KALAKALAKALA 
small molecule, 
plasmid 
(Oehlke et al., 1998) 
Oligoarginine Chimeric Arg8 or Arg9 
protein, peptide, 
siRNA 
(Futaki et al., 2001) 
Table 1.3: Examples of CPPs
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1.4.3 Mechanisms of CPPs internalisation 
Despite major research efforts, the mechanisms that govern CPPs internalisation are 
still not clear. The controversy in the field is partly due to research groups using 
different models and techniques in their studies. Research into CPPs also suffers from 
experimental artefacts due to the attachment of fluorescent labels to CPPs to follow 
their uptake into cells.    
It is generally believed that several factors influence the mechanism of uptake across 
the membrane including the properties of the CPP, such as length and charge 
distribution, as well as the characteristics of the cargo molecule such as size and 
charge. It has also become apparent that each CPP may employ a different entry route 
depending on the experimental context (choice of cell line, incubation conditions, cell 
stress environment). The mechanisms of cellular uptake can be classified into two 
groups: direct translocation across the cell membrane (energy-independent) and 
endocytosis (energy dependent) (Figure 1.10).  
A recent study by Duchardt et al. examined the cellular uptake of three CPPs: the 
antennapedia/penetratin peptide, Tat and nona-arginine (R9) (Duchardt et al., 2007). 
The aim of this study was to clarify the role of the endocytic pathway in the CPP 
uptake process. Their main conclusion was that the processes of macropinocytosis, 
clathrin-mediated endocytosis and caveloae/lipid raft mediated endocytosis all played 
a role in CPP cellular uptake, in contrast with the idea of a single pathway being 
involved. In general, the main difference between the three endocytic pathways is the 
size of the vesicles together with their regulation and intracellular trafficking route. 
This suggests that cargo size might impact the choice of internalisation mechanism. 
For example, macropinosomes (1-5 μm) are best suited for transport of large CPP 
conjugates rather than other vesicle types (<150 nm). The scale of importance of each 
pathway in the uptake of a particular CPP was dictated by the CPP’s sequence as well 
as its concentration. Tat and R9 are the peptides with most delocalised charge and 
share similarities on the pattern of both endocytic and direct uptake. At low CPP 
concentration, internalisation was not affected by inhibitors of clathrin-mediated 
endocytosis suggesting a main role for macropinocytosis and caveloae/lipid raft 
mediated endocytosis in this process. In contrast, at high Tat and R9 concentrations, 
peptide internalisation occurred independently of endocytic pathways, via direct 
uptake through specific nucleation zones. This effect was not observed for penetratin. 
Direct uptake of penetratin only occurred when macropynocytosis and caveloae/lipid 
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raft-mediated endocytosis were inhibited. Surprisingly, inhibition of clathrin-mediated 
endocytosis suppressed this effect. Another difference between penetratin and Tat/R9 
is that cellular uptake of the first CPP increases linearly with peptide concentration 
whereas cellular fluorescence is not proportional to the concentration of Tat/R9 in the 
media.  
 
 
 
 
Figure 1.10: Crossing the plasma membrane. The mechanisms of CPP entry into the 
cell are classified into endocytosis (macropynocytosis, clathrin-mediated, caveolin-
mediated) and direct translocation (carpet and barrel-stave models). Adapted from 
(Stewart et al., 2008).    
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1.4.4 Targeting antibodies to the cytoplasm 
CPPs are a successful tool for the transport of a variety of cargoes including: nucleic 
acids (plasmid DNA, siRNA, oligonucleotides), proteins and peptides, contrast agents 
(MRI), drugs and nanoparticulate pharmaceutical carriers (liposomes, micelles). Some 
examples of these are included in Table 1.4.  
 
Table 1.4: Examples of delivery of cargo by cell-penetrating peptides 
Category Cargo CPP Reference 
Nucleic acids 
siRNA penetratin (Davidson et al., 2004) 
siRNA Tat (Chiu et al., 2004) 
plasmid Tat (Ignatovich et al., 2003) 
Protein 
GFP Tat (Silhol et al., 2002) 
p21 Antp (Kousparou et al., 2012) 
Peptide 5-amino-acid peptide  Tat (Hallbrink et al., 2001) 
Contrast agent Magnetic nanoparticles Tat (Lewin et al., 2000) 
Quantum dots CdS:Mn/ZnS Tat (Lagerholm, 2007) 
 Liposomes Tat (Kale and Torchilin, 2007) 
 Micelles Tat (Sawant et al., 2006) 
 
 
This study focuses on the transport of proteins including antibody fragments (scFvs). 
Historically, the in vivo potency of CPPs was illustrated by the fusion of Tat to β-
galactosidase (Schwarze et al., 1999). Following intra-peritoneal injection in mice, 
successful delivery was observed in most tissues including the brain. Other CPPs have 
since been employed for delivery of proteins including penetratin and synthetic 
polyarginines. CPPs can be covalently linked to the cargo or expressed as a CPP 
fusion protein. It is interesting to note that derivatives of antibodies have themselves 
been used as carriers. In particular, the Fc portion of an antibody has previously been 
used to deliver p53, preventing liver metastasis in vivo (Hansen et al., 2007).     
The successful delivery of antibodies and antibody fragments into the cytoplasm 
would allow to fully exploit their potential, reaching a multitude of novel targets. 
Several strategies to achieve this are being investigated including intrabodies and 
transmabs/transbodies.  
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1.4.4.1 Intrabodies 
Intrabodies describe antibodies that are expressed in the cytosol.  Antibodies are 
extracellular proteins capable of surviving harsh conditions thanks to their rigid 
antiparallel β sheet core stabilised by disulphide bonds (Stocks, 2005). Antibody 
folding and disulphide bond occurs in the endoplasmic reticulum with the help of 
resident chaperones such as BiP and protein disulfide isomerase (PDI) (Kirkpatrick et 
al., 1995; Mayer et al., 2000). Intracellularly expressed antibodies were most 
successful when targeting antigens that follow the same secretory pathway (IL2 
receptor, ErbB-2 receptor, β-amyloid precursor protein and VCAM1) (Boldicke, 
2007; Beerli et al., 1994; Richardson et al., 1995; Kontermann, 2004; Paganetti et al., 
2005; Strebe et al., 2009). Retention of the complex in the ER is achieved by the 
presence of an ER retention sequence (e.g. KDEL peptide) at the C-terminal of the 
intrabody.  
The main challenge remains the direct expression of antibody fragments in the 
cytoplasm due to the reducing environment unfavourable for disulphide bond 
formation and lack of chaperones for folding (Biocca et al., 1994). Only in 1% of 
cases has the stability of an scFv being sufficient for its use as an intrabody (Auf der 
Maur et al., 2004; Visintin et al., 2004). Several strategies for improving cytosolic 
expression have been examined. These include the screening of antibodies for pre-
determined properties (e.g. no requirement for intra-domain disulphide bonds) that 
make cytosolic functioning favourable. This is illustrated by the crystallisation and 
functional characterisation of cysteine-deleted mutants of an anti-RAS intrabody 
(Tanaka and Rabbitts, 2008). Other strategies include fusing antibodies to a Cκ 
domain (Cohen et al., 1998; Mhashilkar et al., 1995) or N utilisation substance A 
(NusA) (Zheng et al., 2003) to enhance cytosolic expression.  
 
1.4.4.2 Transmabs/transbodies 
Various antibody formats have been fused to CPPs for intracellular delivery including 
scFvs, Fabs and whole IgGs. Most commonly, Tat and Antennapedia derivatives are 
used for transport (Anderson et al., 1993; Zhao et al., 2001; Niesner et al., 2002). 
Despite some encouraging attempts, this strategy of delivery is still challenging due to 
production problems. For example, when secretion of Tat-fusion proteins was 
attempted, the majority of fusion protein was in the cell lysate rather than in the 
supernatant fraction (Koutsokeras and Kabouridis, 2009). It was also shown that 
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secretion levels decreased with greater cationic charge, a characteristic of most CPPs 
including Antp (Shaw et al., 2008). Most of the fusions are expressed as inclusion 
bodies and refolded (Theisen et al., 2006). Classic chemical conjugation methods are 
also used to link the antibody format to CPPs despite numerous disadvantages 
including no control over stoichiometry or the site of linkage. In order to address 
these limitations, research is now focused on site specific coupling and native 
chemical ligation strategies.  
 
1.4.4.3 Penetratin-scFv fusions 
The genetic fusion of scFvs to Antp derivatives for their successful delivery across 
membrane barriers is most relevant to this study. At least two previous publications 
describe the use of this strategy. Avignolo et al. successfully delivered a scFv that 
recognises the transactivation domain of c-Myc (Avignolo et al., 2008). Successful 
internalisation of a fluoresceinated fusion was confirmed by confocal microscopy. 
The fusion was detected in both the cytoplasm and the cell nucleus. The study 
confirmed that cell membrane integrity was not affected during the experiment. A 
mutated (constitutively active) version of c-Myc is observed in a variety of cancers, 
making this protein a target for cancer therapy. Mutations of c-Myc result in 
deregulated expression of genes involved in cell proliferation, a situation favourable 
to the cancer cell. By successful delivery of an anti-c-Myc scFv, Avignolo et al. 
observed growth inhibition of HCT116 cells (human colon cancer line). 
The second study aimed to deliver a scFv specific to the matrix protein (M1) of the 
influenza A virus using penetratin (Poungpair et al., 2010). Internalisation of the 
genetic fusion was verified by immunofluorescent confocal microscopy and only 
negligible cytotoxic effects were observed on MDCK cells. On a functional level, the 
scFv-penetratin fusion reduced the number of viruses released from the cells.   
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1.5 Aims and Objectives 
 
The aim of this project is to study two novel strategies for inhibition of Notch 
signalling that target MAML using Antp as a delivery method. The first tool is a 
fusion protein composed of Antp fused to a dominant negative version of MAML-1 
(DN-MAML1). The second strategy of Notch signalling inhibition is the intranuclear 
delivery of scFv antibody fragments fused to Antp. 
 
The research objectives included: 
 
 Production of Antp (negative control), evaluating the use of a secretion 
system. 
 Production of Antp-DN-MAML1 followed by in vitro characterisation to 
determine its effect on Notch signalling and proliferation of MDA-MB-231. 
 In vivo characterisation of Antp-DN-MAML1 using a MDA-MB-231 
xenograft model in mice. 
 
 Production of DN-MAML1 as the antigen for phage display selection. 
 Undergo three rounds of phage display selection followed by screening of 
anti-DN-MAML1 scFv-phagemid by ELISA. 
 Production of candidate scFvs in order to perform binding studies by ELISA. 
 Production of Antp-scFv fusions, evaluating the use of a secretion system. 
 Determine the capability of Antp-scFv fusions to interact with DN-MAML1. 
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Chapter 2 
 
Materials and Methods 
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2.1 Materials  
 
2.1.1 Solutions and buffers 
As necessary, solutions were degassed using nitrogen gas exchange and filtered with a 
0.2μm vacuum filtration apparatus. The optimal pH for buffers was obtained with 
gradual addition of HCl (VWR) or NaOH (VWR). When required, sodium azide 
(Sigma) was added to a final concentration of 0.05%. Sterilisation was achieved by 
autoclaving. Deionised water (dH2O) was obtained from a Purite Select system. VWR 
Nuclease Free and DEPC-treated water was used for molecular biology applications. 
 
Table 2.1: Composition of solutions and buffers 
Solutions and Buffers Composition  
10x Phosphate buffered saline (PBS) 
80g NaCl, 2g KCl, 2.4g KH2PO4, 14.4g 
Na2HPO4 in 1L dH2O 
Tris-acetate EDTA buffer (TAE) 
242g TRIS base, 37.2g Na2EDTA.2H2O, 57.1 
ml glacial acetic acid in 1L dH2O 
PAGE Running Buffer 
3.03g TRIS base, 14.4g Glycine, 1g Sodium 
dodecyl sulphate (SDS) in 1L dH2O 
6x Sample loading buffer (DTT based) 
360 mM Tris-HCl pH 6.8, 36% Glycerol, 600 
mM DTT, 12% SDS, Bromophenol blue 
Stacking gel 
1.5 ml dH2O, 0.25 ml 1.5 M Tris-HCl pH 6.8, 
300 μl 30% Bis/Acrylamide, 20 μl 10% SDS, 
20 μl ammonium persulfate (APS), 2 μl 
N,N,N’,N’-Tetramethylethylenediamine 
(TEMED) 
12% Resolving gel 
1.7 ml dH2O, 1.25 ml 1.5 M Tris-HCl pH 8.8, 
2 ml 30% Bis/Acrylamide, 50 μl 10% SDS, 
50 μl ammonium persulfate (APS), 2 μl 
N,N,N’,N’-Tetramethylethylenediamine 
(TEMED) 
Semi-dry PAGE transfer buffer 
5.8g TRIS, 3g glycine, 0.4g SDS, 200 ml 
methanol in 1L dH2O 
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2.1.2 Bacterial strains and growth conditions 
The bacterial strains used in this project are listed in Table 2.2. The appropriate 
antibiotic concentration was added to the culture media from stock solutions 
(Carbenicillin: 100µg/µl; Chloramphenicol: 25 µg/µl; Tetracycline: 15 µg/µl; 
Kanamycin: 50 µg/µl). 
 
Table 2.2: List of E.coli strains 
Strain Genotype Source 
XL1-Blue 
F’::Tn10 proA+B+ laclq D(lacZ) 
M15/recA1 endA1 gyrA96 (Nalr) thi 
hsdR17 (rK
-
mK
+
) supE44 relA1 lac 
Stratagene 
HB2151 
nalr thi-1 ara ( (lac-proAB [F' 
proAB+ laciq lacZ(M15]) 
GE Heathcare 
TUNER (DE3) 
F
-
 ompT hsdSB(rB
-
mB
-
) gal dcm lacY1 
(DE3) 
Novagen 
JM109 (DE3) 
endA1, recA1, gyrA96, thi, hsdR17 
(rk
–
, mk
+
), relA1, supE44, Δ( lac-
proAB), [F´ traD36, proAB, 
laqIqZΔM15]. 
Promega 
BLR (DE3) 
F
-
 ompT hsdSB(rB 
- 
mB 
-
) gal dcm 
lacY1 (DE3) Δ (srl-recA)306::Tn10 
(Tet
R
) 
Novagen 
BLR (DE3) pLysS 
F
-
 ompT hsdSB(rB 
- 
mB 
-
) gal dcm 
lacY1 (DE3) Δ (srl-recA)306::Tn10 
pLysS (Cam
R
, Tet
R
) 
Novagen 
B21 (DE3) 
F
- ompT hsdSB (rB 
- 
mB 
-
) gal dcm 
(DE3)  
Novagen 
BL21 (DE3) pLysS 
F
- ompT hsdSB (rB 
- 
mB 
-
) gal dcm 
(DE3) pLysS (Cam
R
) 
Novagen 
BL21 (DE3) pLysE 
F
- ompT hsdSB (rB 
- 
mB 
-
) gal dcm 
(DE3) pLysE (Cam
R
) 
Novagen 
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Table 2.3: Culture media composition 
Culture media Composition in 1L dH2O 
2TY 
16g bacto tryptone, 10g bacto yeast, 5g 
NaCl  
2TY agar 
16g bacto tryptone, 10g bacto yeast, 5g 
NaCl, 15g bacto agar  
LB 
10g bacto tryptone, 5g bacto yeast, 5g 
NaCl 
LB agar 
10g bacto tryptone, 5g bacto yeast, 5g 
NaCl, 15g bacto agar 
10x M9 Salt Solution 
60g Na2HPO4, 30g KH2PO4, 10g NH4Cl, 
5g NaCl  
M9 minimal agar  
100 ml of 10x M9 salt solution, 1ml 1M 
MgSO4, 100μl 1M CaCl2, 5mg Vitamin 
B1, 10 ml 20% glucose solution 
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2.1.3 Plasmids and molecular techniques 
The list of plasmids used in this study can be found in Table 2.4. The gene encoding 
the Antp protein was amplified by PCR from the pds56 vector using primer pairs 1-2 
and 3-4 (Table 2.5) which allow the addition of essential restriction sites. For the 
future addition of a single chain variable fragment (scFv) gene upstream of the Antp 
gene, this was cloned into pET20b in-between the Nco I/Xho I sites (Figure 2.1A). To 
obtain the reverse order (Antp-scFv), the Antp gene was cloned into the same vector 
using the Pci I/Not I sites on the insert and the compatible Nco I/Not I sites on the 
vector (Figure 2.1B). Primer pair 2-5 (Table 2.5) was used to amplify Antp allowing 
the addition of Nde I and Xho I sites for subsequent cloning into the pET23b vector. 
BamHI was used to excise Antp from the pRSET A vector containing Antp-DN-
MAML1, leaving DN-MAML1 only. Primer 9 and FDSEQ1 were used to eliminate 
the accidental stop codon in the E7P3 scFv clone (t to c point mutation). Primer pair 
and 6-7 and 6-8 were used to amplify the Antp-scFv fusion and Antp, respectively. 
This allows the addition of the PciI and AgeI sites for subsequent cloning into the 
pcDNA4a vector for mammalian expression. Ligation reactions included T4 ligase 
and buffer (Fermentas) with vector and insert at a 1:3 molecular ratio. All ligations 
reactions consisted of incubation at 22°C and 16°C for 30 minutes, respectively, 
followed by 15 minutes at 65°C. This was followed by transformation into XL1-Blue 
chemo-competent cells. All constructs were verified by DNA sequencing (MWG) 
(data not shown). The LMB3 and FDSEQ1 primers were used to sequence the phage 
display derived scFvs. The BGH and CMV primers allowed the sequencing of 
pcDNA4a constructs. 
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Table 2.4: List of plasmids 
Plasmid Description Source 
pds56 Amp
R
, N-term His tag, Antp Trojantec 
pRSET A T7 promoter, Amp
R
, N-term His tag, Antp-DN-MAML1 Trojantec 
pET20b T7 promoter, Amp
R
, C-term His tag, pelB Novagen 
pET23b  T7 promoter, Amp
R
, C-term His tag Novagen 
pcDNA4a 
CMV promoter, Amp
R
, C-term His tag, N-term leader 
sequence (Δ Pci I) 
Dr. 
Constantinou, 
ICL 
pds56 Amp
R
, N-term His tag, Antp-DN-MAML1 Trojantec 
pCANTAB6 Lac promoter, Amp
R
, C-term His and myc tag, ScFv-pIII 
Cambridge 
Antibody 
Technology  
  
Table 2.5: List of primers (5’ to 3’ orientation) 
Number Sequence 
1 ATCCATGGTCATAGCGGCCGCACGCAAACGCGGA  
2 ATCTCGAGGTTCTCCTTCTTCCACTTCATGCGCCG  
3  TAATACATGTTACGCAAACGCGGAAGGCAGACATA  
4  TAATGCGGCCGCTATGACCATGGGGTTCTCCTTCTTC  
5 CTAATCCATATGCGCAAACGCGGAAGGCAG  
6 TAATACATGTCTCGCAAACGCGGAAGGCAGACATACACCCGG 
7 GGTCCACCGGTTGCGGCCGCACGTTTGATCTCCAGCTTGGTC 
8 GGTCCACCGGTGTTCTCCTTCTTCCACTTCATGCGCCGATTCTGGA 
9 CGGCCATGGCCCAGGTGCAGC 
LMB3 CAGGAAACAGCTATGAC 
FDSEQ1 GAATTTTCTGTATGAGG 
BGH AAG GCA CAG TCG AGG 
CMV CGC AAA TGG GCG GTA GGC GTG 
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Figure 2.1: strategy for cloning Antp in pET20b allowing for the subsequent addition 
of an scFv gene upstream (A) or downstream (B).T7: promoter, rbs: ribosome binding 
site, pelB:leader sequence, His: tag. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nco I Not I  Xho I 
Antp T7 rbs pelB His 
Pci I Not I  
Antp T7 rbs pelB His 
Nco I 
pET20b 
pET20b 
A) scFv-Antp 
B) Antp-scFv 
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Table 2.6: Antibodies  
Antibody Species Antigen  Working 
dilution  
Source 
9E10 IgG murine 
c-Myc epitope 
(EQKLISEEDL) 
1:5000 Sigma 
αMouse  
HRPO IgG 
goat murine Fc domain 1:10000 Sigma 
αHis HRPO IgG murine 
penta-histidine 
peptide tag 
1:4000 Sigma 
αM13 HRPO IgG murine 
phage major coat 
protein PVIII 
1:5000 
GE 
Healthcare 
 
Table 2.7: Speciality reagents 
Reagent Use Source 
extravidin  
peroxidase HRPO 
HRPO conjugated avidin, 
use 1:1000 
Sigma 
Milk powder 
blocking nitrocellulose and 
ELISA plates 
Marvel
®
 
BM-Blue POD 
chromogenic substrate for 
Peroxidase 
Roche 
ECL kit 
enhanced 
chemiluminescence 
detection kit 
GE Healthcare 
EZ-link
®
 Sulfo-NHS-LC-
LC-Biotin 
biotinylation reagent Pierce 
BSA ELISA blocking Sigma 
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Table 2.8: Cell lines 
Cell line Description Origin 
MDA-MB-231 human breast 
adenocarcinoma 
Prof. Djamgoz 
CHO Δ chinese hamster ovary 
cells transfected with the 
delta-like ligand 1 
Celldex therapeutics 
CHO N2 chinese hamster ovary 
cells transfected with the 
Notch receptor 2 
Celldex therapeutics 
CHO K chinese hamster ovary  Celldex therapeutics 
 
Small molecule inhibitors: 
∙ DAPT: N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester, 
inhibits γ-secretase activity (Calbiochem) 
∙ GSI-1: Z-Leu-Leu-Nle-CHO, inhibits γ-secretase activity (Calbiochem) 
∙ LiCl: Lithium chloride, inhibits GSK3β activity (Sigma) 
 
Kits: 
∙ Fugene® HD transfection reagent (Promega) 
∙ ONE-Glo® Luciferase assay system (Promega) 
∙ CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (MTS) 
(Promega) 
∙ MagMAX™ 96 total RNA isolation kit (Invitrogen) 
∙ High capacity cDNA Reverse Transcription kit (Applied Biosystems) 
∙ Taqman® Fast Real-Time PCR Universal Mastermix (2x) 
 
Taqman
®
 gene expression assays: 
Hes1 – Hs00172878_m1 
Hes1 – Mm00468601_m1 
18S rRNA – 4319413E 
p21 – Hs00355782_m1 
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Table 2.9 : Tissue culture reagents 
Tissue culture reagent Origin 
DMEM PAA Laboratories 
sterile PBS without Ca and Mg ions PAA Laboratories 
trypsin-EDTA Invitrogen 
geneticin Invitrogen 
hygromycin B Invitrogen 
zeocin Invitrogen 
FBS Invitrogen 
Jagged1-Fc R&D systems 
Human IgG1 Sigma 
phycoerythrin (PE) Annexin V  BD Biosciences 
10x Annexin V binding buffer 
0.1 M Hepes (pH 7.4), 1.4 M NaCl, 25 
mM CaCl2 in dH2O 
DAPI Sigma 
sodium pyruvate Sigma 
DMSO Sigma 
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2.2 Methods 
 
2.2.1 Bacterial culture 
 
2.2.1.1 Preparation of chemically competent E.coli cells 
A single colony was picked from a freshly streaked plate for overnight growth in 5 ml 
of media at 37°C with shaking (250 rpm). The culture was subsequently diluted 100 
fold and grown up to an OD600 of 0.6. At this point, the culture was placed on ice for 
15 minutes before centrifugation at 1500 g for 5 minutes at 4°C. Pellets were 
resuspended in half the culture volume of ice-cold sterile 0.1M CaCl2 and incubated 
for 30 minutes on ice. Following a centrifugation step, the pellet was resuspended in 
0.1M CaCl2 including 10% glycerol and aliquots were stored at -80°C. 
 
2.2.1.2 Tranformation of chemically competent E.coli by heat shock method 
Cells were placed on ice and incubated with plasmid DNA for 30 minutes. Heat shock 
was performed at 42°C for 45 seconds. One ml of growth media was added to the 
cells followed by incubation at 37°C with shaking (250 rpm) for one hour. A portion 
of the cell suspension was then plated and left growing overnight at 37°C. 
 
2.2.2 Expression, purification, labelling and analysis of recombinant proteins 
 
2.2.2.1 Expression of Antp as a secreted protein 
Antp in pET20b (section 2.1.3) was transformed in E.coli TUNER (DE3), JM109 
(DE3), BLR (DE3), BLR (DE3) pLysS, BL21 (DE3), BL21 (DE3) pLysS and BL21 
(DE3) pLysE cells. A single colony of each transformation was grown in 5 ml of 2TY 
including the appropriate antibiotic(s), shaking overnight at 37°C. The bacterial 
culture was diluted 1:100 in 5 ml of 2TY supplemented with the suitable antibiotic(s) 
and grown shaking at 37°C up to an OD600 of 0.8. The culture was then induced using 
either 0.1 mM or 1 mM isopropyl-1-thyo-β-D-galactopyranoside (IPTG) for 4 hours. 
The culture was centrifuged at 2000 g for 5 minutes before analysis of the supernatant 
and pellet fractions by Western blot using HRPO conjugated murine α-His antibody. 
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 2.2.2.2 Expression of Antp in the cytosolic fraction of E.coli BL21 (DE3) plysS 
and its purification 
This method was adapted from Joliot et al. 1991. A single E.coli BL21 (DE3) plysS 
colony transformed with Antp in pET23b (section 2.1.3) was grown in 5 ml of LB 
including carbenicillin and chloramphenicol, shaking overnight at 37°C.  The 
bacterial culture was diluted 1:100 in 500 ml of LB media containing carbenicillin 
and chloramphenicol and grown shaking at 37°C up to an OD600 of 1.2. The culture 
was then induced using 1 mM IPTG for 5 hours. The culture was centrifuged at 2000 
g for 30 minutes. The cell pellet was freeze-thawed and resuspended in 20 ml of 50 
mM sodium phosphate (pH 7.5), 2 mM EDTA, 1 mM DTE with the inclusion of a 
protease inhibitor tablet (Roche). Sonication was used to further lyse the cells before 
centrifuging at 25,000 g for 30 minutes at 4°C. The soluble fraction was applied to a 
pre-equilibrated SP sepharose fast flow (GE healthcare) ion exchange column (5 ml 
slurry). Antp was washed and eluted using increasing concentrations of NaCl (50mM-
1M) (25 ml each). The sample was concentrated 5 fold using a 3,000 kDa MWCO 
spin concentrator (Vivaspin, Generon) before being applied to a size exclusion 
chromatography column (Superdex-75) and eluted in PBS. The absorbance of 
fractions was measured at 214 nm and 280 nm using the QuadTec™ detector in 
combination with the Bio-Rad BioLogic Duo-Flow™ system. The collected fractions 
are named according to the fraction collector used. The first rack collected fractions 
A1 to A90; the second rack collected fraction B1 to B64 which corresponds to the run 
end.  
 
2.2.2.3 Expression of Antp-DN-MAML1 in the cytosolic fraction of BL21 (DE3) 
plysS 
A single E.coli BL21 (DE3) plysS colony transformed with Antp-DN-MAML1 in 
pRSET A (or pET23) was grown in 5 ml of LB including carbenicillin and 
chloramphenicol, shaking overnight at 37°C.  The bacterial culture was diluted 1:100 
in 500 ml of LB media containing carbenicillin and chloramphenicol and grown 
shaking at 37°C up to an OD600 of approximately 0.8. The culture was then induced 
using 1 mM IPTG overnight. The culture was centrifuged at 2000 g for 30 minutes. 
The pellet was lysed using of ice cold B-PER
®
 reagent (Pierce) with the addition of a 
protease inhibitor tablet (Roche) before spinning at 15000 g for 1 hour at 4°C. The 
resulting pellet was resuspended in 6 M guanidinium chloride in phosphate buffered 
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saline (PBS) and left incubating overnight before a final spin at 40000 g for 1 hour at 
15°C. At this stage Antp-DN-MAML1 is present as a solubilised, denatured inclusion 
body. 
 
2.2.2.4 Purification of Antp-DN-MAML1 using Immobilised Metal Affinity 
Chromatography (IMAC) 
Chelating sepharose (Fast Flow, GE Healthcare) was charged with nickel ions by 
applying two bed volumes of 500 mM NiCl2 to the column. The resin was washed 
with distilled water and equilibrated with PBS-8 M Urea. The soluble protein fraction 
was applied to the resin to allow Antp-DN-MAML1 binding. The column was washed 
extensively with PBS-8 M Urea. Increasing concentrations of imidazole were used to 
further wash and finally elute the protein. The elution samples were analysed by 
reducing 12% SDS-PAGE and stained using Coomassie Blue. A Western blot was 
also performed using HRPO conjugated murine α-His antibody. Antp-DN-MAML1 
refolding was attempted by dialysis in PBS with different combinations of L-Arginine 
(mediator of refolding) and Urea concentrations. Finally, the samples were 
concentrated using a 5000 kDa cut-off ultrafiltration column. 
 
2.2.2.5 Expression trial for Antp-DN-MAML1  
Expression was based on a method provided by Prof. Cole (University of 
Birmingham, personal communication). Antp-DN-MAML1 in pRSET A was 
transformed into the E.coli BL21 (DE3) plysS strain, plated on 2TY plates with 80 
μg/ml carbenicillin and grown overnight at 37°C. The following day, colonies were 
replated to purify them and grown at 37°C. Later the same day, single colonies were 
grown overnight in 20 ml of LB supplemented with carbenicillin at 30°C. All flasks 
and media were pre-warmed to 30°C before culturing to avoid a cold shock. The 
overnight starter culture was used to provide a 2% inocula for six flasks containing 50 
ml of LB medium/carbenicillin and shaken at 30°C.  When the OD (650 nm) reached 
0.5, IPTG was added to the following μM concentrations: 0, 5, 10, 20, 50 and 100. 
Samples were collected after 1, 2, 3, 4 and 20 h for measuring the soluble and 
insoluble protein content by SDS-PAGE and Western blotting. 
 
 
 66 
2.2.2.6 Expression of MAML-1 (13-74) in the cytosolic fraction of E.coli BL21 
(DE3) plysS and its purification/refolding 
This method was adapted from Nam et al., (2003). A single E.coli BL21 (DE3) plysS 
colony transformed with MAML-1 (13-74) in pRSET A was grown in 5 ml of LB 
including carbenicillin and chloramphenicol, shaking overnight at 37°C.  The 
bacterial culture was diluted 1:100 in 500 ml of LB media supplemented with 
antibiotics and grown shaking at 37°C up to an OD600 of approximately 0.8. The 
culture was then induced using 1 mM IPTG, overnight. The culture was centrifuged at 
2000 g for 30 minutes.  The resulting pellet was resuspended in 15 ml of 50 mM Tris 
(pH 8), 150 mM NaCl, 6 M guanidinium-HCl, 5 mM β-mercaptoethanol, including a 
protease inhibitor tablet. Following sonication, the mixture was centrifuged at 18,000 
g for 30 minutes. The resulting supernatant was applied for 1 hour at 4°C to pre-
equilibrated chelating sepharose charged with nickel ions (5ml slurry). The column 
was washed with 10 column volumes of 50 mM Tris (pH 8), 150 mM NaCl, 6 M 
guanidinium-HCl, 5 mM β-mercaptoethanol, 10 mM imidazole. One column volume 
of 50 mM Tris (pH 8), 150 mM NaCl, 6 M guanidinium-HCl, 5 mM β-
mercaptoethanol, 250 mM imidazole was added to elute the protein. This was 
dialysed against 5% acetic acid for 24 hours, lyophilised overnight and re-dissolved in 
dH2O. 
 
2.2.2.7 Expression of secreted scFv proteins in E.coli HB2151 
A single HB2151 colony transformed with scFv genes in the phagemid vector 
pCANTAB6 was grown in 5 ml of 2TY including carbenicillin, shaking overnight at 
37°C.  The bacterial culture was diluted 1:100 in 500 ml of LB media supplemented 
with antibiotics and grown shaking at 37°C up to an OD600 of approximately 0.8. The 
culture was then induced using 1 mM IPTG, overnight at 30°C. The culture was 
centrifuged at 2000 g for 30 minutes. Protease inhibitors were used throughout the 
purification steps. The supernatant was concentrated to one tenth of its original 
volume using a Vivaflow 200 10kDa MWCO peristaltic pump driven dia-filtration 
cassette (Vivascience) and then exhaustively dialysed into PBS pH 7.4. The 
supernatant was then applied to pre-equilibrated chelating sepharose charged with 
nickel ions (5 ml slurry), overnight at 4°C. The scFvs were washed and eluted using 
increasing concentrations of imidazole (10mM-250mM) (25 ml each). Finally, the 
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sample was dialysed into PBS pH 7.4 and concentrated using a 5,000 kDa MWCO 
spin concentrator. 
 
2.2.2.8 Antp-ScFv small scale expression trials 
  
Antp-N4 
A single E.coli BL21 (DE3) plysS colony transformed with Antp-N4 (anti TT-Hc 
scFv) in pET20b was grown in 5 ml of 2TY or LB including carbenicillin and 
chloramphenicol, shaking overnight at 37°C. The bacterial culture was diluted 1:100 
in 5 ml of 2TY/LB media containing carbenicillin and chloramphenicol and grown 
shaking at 37°C up to an OD600 of 0.8. The culture was then induced using 0.1 mM or 
1 mM IPTG for 4 hours at 37°C/30°C and centrifuged at 2000 g for 10 minutes. 
Pellets were resuspended in ice cold PBS containing 0.1% Igepal (Sigma) and 
sonicated on ice. Samples were spun at 2000 g for 15 minutes at 4°C before analysis 
of the soluble and insoluble fractions. 
 
Antp-E7P3 
A single E.coli BL21 (DE3) plysS colony transformed with Antp-E7P3 in pET20b 
was grown in 5 ml of 2TY including carbenicillin and chloramphenicol, shaking 
overnight at 37°C. The bacterial culture was diluted 1:100 in 5 ml of 2TY media 
containing carbenicillin and chloramphenicol and grown shaking at 37°C up to an 
OD600 of 0.8. The culture was then induced using 0.1 mM or 1 mM IPTG for 1, 2 or 4 
hours at 25°C/18°C and centrifuged at 2000 g for 10 minutes.  
 
Antp-E7P3 autoinduction 
A single E.coli BL21 (DE3) plysS colony transformed with Antp-E7P3 in pET20b 
was grown in 10 ml of LB including carbenicillin and chloramphenicol, shaking 
overnight at 37°C. The bacterial culture was diluted 1:100 in 1L of autoinduction 
media containing carbenicillin and chloramphenicol and grown shaking at 37°C for 2 
hours. The culture was transferred at 20°C shaking overnight. Finally, the culture was 
centrifuged at 2000 g for 30 minutes before analysis of the supernatant and cell pellet 
fractions. 
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2.2.2.9 Antp-ScFv large scale expression 
A single E.coli BL21 (DE3) plysS colony transformed with Antp-Scfv (scFv: G7P4, 
H8P5) in pET20b was grown in 10 ml of 2TY including carbenicillin and 
chloramphenicol, shaking overnight at 37°C. The bacterial culture was diluted 1:100 
in 1 L of 2TY media containing carbenicillin and chloramphenicol and grown shaking 
at 37°C up to an OD600 of 0.8. The culture was then induced using 1 mM IPTG for 5 
hours at 25°C and centrifuged at 2000 g for 30 minutes. Pellets were resuspended in 
25 ml of ice cold PBS containing 0.1% Igepal and sonicated on ice. The samples were 
spun at 2000 g for 15 minutes at 4°C before proceeding with the refolding protocol. 
 
2.2.2.10 Antp-ScFv refolding 
Inclusion bodies were resuspended in 25 ml of 50 mM Tris-HCl (pH 8), 20 mM 
EDTA before adding Triton X-100 to 2% and NaCl to 0.5 M final. This was 
centrifuged for 1 hour at 25,000 g before repeating the procedure twice. The final 
pellet was denatured in 10 ml of 100 mM Tris-HCl (pH 8), 2 mM EDTA, 6 M 
guanidinium-HCl before addition of DTE 0.3 M final. After rotating for 1 hour at 
room temperature, the mixture was centrifuged at 30,000 g for 30 minutes at room 
temperature. Five ml of the denatured inclusion bodies were added to a 500 ml 
solution of 100 mM Tris-HCl (pH 8), 0.4 M L-Arginine, 8 mM GSSG (oxidised 
glutathione), 2 mM EDTA chilled to exactly 10°C. The remaining 5 ml were then 
added in 0.5 ml aliquots. Refolding occurred overnight at 10°C.  Any precipitate was 
removed by centrifugation and the soluble fraction was dialysed in PBS buffer and 
concentrated using a 5000 kDa spin concentrator.  
 
2.2.2.11 Protein analysis by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (PAGE) and Western blotting 
Each test sample was mixed with loading buffer and boiled for 5 minutes. Typically 
10 μl of sample was loaded per well on duplicate gels (for Coomassie blue staining 
and Western blotting). A constant voltage of 200V was applied for 30 minutes. The 
gels included a pre-stained molecular weight marker as reference ladder (PageRuler
™ 
(Plus), Fermentas). For Western blotting, protein gels were transblotted onto a 
nitrocellulose membrane using a Bio-Rad Trans-Blot
®
 SD Semi-dry transblotter. All 
components, including a pair of thick Whatman
®
 filter paper slices, were briefly pre-
soaked in transfer buffer. Transfer occurred for 30 minutes under a constant voltage of 
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10V. The membrane was blocked for 1 hour at room temperature or overnight at 4°C 
with 3% milk powder in PBS pH 7.4. Antibody detection was performed in 1% milk 
powder for an hour per step. Washes consisted of 2x 10 minutes incubation with PBS 
pH 7.4 0.1% Tween-20 detergent followed by a 10 minutes PBS pH 7.4 wash. The 
ECL kit was used for detection and the chemiluminescent signal was imaged with the 
FujiFilm LAS-3000 laser scanning densitometer. The resulting image was later 
overlapped with the corresponding ladder picture. Protein concentration was 
determined by absorption at 280 nm using a NanoDrop
®
 Micro-Volume UV-Vis 
spectrophotometer (Thermo Scientific). 
 
2.2.2.12 Chemical biotinylation 
Thermo Scientific EZ-Link
®
 Sulfo-NHS-LC-LC-Biotin reagent (sulfosuccinimidyl-6-
[biotinamido]-6-hexanamido hexanoate), is a N-Hydroxysuccinimide (NHS) ester of 
biotin which reacts efficiently with primary amino groups (i.e. lysine side chain). In 
order to minimise epitope masking, we chose the 30.5Å spacer arm length and a 
reagent to protein molar coupling ratio of 1:10 (minimal ratio). One ml of DN-
MAML1 protein at a 0.15 mg/ml concentration was mixed with 2 μl of 1 mM biotin 
solution in dH2O. The mixture was incubated at room temperature for 1 hour. Free 
biotin was removed using a PD10 desalting column and eluted in PBS pH 7.4. 
 
2.2.2.13 Circular dichroism 
Circular dichroism was performed using a Chirascan™ CD Spectrometer (Applied 
Photophysics) and a 1mm path quartz cuvette. The sample analysed was at a 
concentration of 0.1 mg/ml and the machine was set with the following conditions: 
Temperature: 20°C 
Wavelength: 190-260 nm 
Step: 0.5 nm intervals 
Band width: 1nm 
Time per sec: 1 sec 
Characteristic CD spectra for α helix, β sheet and random coil are shown in Figure 2.2  
Data analysis was perfomed using the DichroWeb online software, with either the 
SELCON3 or K2D analysis programme (Whitmore and Wallace, 2008). Data was 
compared to values obtained using the CFSSP protein secondary structure prediction 
tool (ExPASy).  
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Figure 2.2: Theoretical circular dichroism profiles  
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2.2.3 Enzyme-Linked Immunosorbent Assay (ELISA) 
 
A MaxiSorp
®
 96 well ELISA plate (Nunc) was coated overnight at 4°C with 100 μl of 
antigen in PBS pH 7.4 (DN-MAML1: 20 μg/ml; Antp-DN-MAML1: 50 μg/ml or 5 
μg/ml ; TT-Hc: 200 μg/ml). No antigen was coated when testing for plastic binders. 
The following day, ELISA plates were washed three times with PBS and blocked 
using 250 μl of 3% Milk/PBS for 2 hours at 37°C. Different dilutions of scFv in 3% 
milk/PBS were added to the ELISA plate in triplicate and incubated for one hour at 
room temperature. Addition of 3% milk/PBS only was a control for cross reactivity 
between the antibodies and the coated antigen. Plates were washed three times with 
PBS-Tween and three times with PBS. Next, 9E10 IgG was added 1/5000 in 3% 
milk/PBS (100 μl per well), incubated and washed as before. Plates were then 
incubated with 100 μl of goat α-mouse HRPO conjugate diluted 1/10000 in 3% 
milk/PBS.  One hundred μl of BM-Blue POD substrate were added and incubated for 
10-30 minutes at room temperature. The reaction was quenched using 50 μl of 1M 
HCl before measuring the OD at 450nm. The curve was fitted using SigmaPlot
®
 
software to a sigmoidal, four parameter logistic equation.  
Variations of this protocol include coating tests in which different concentrations of 
antigen were coated overnight. Following blocking, the coated protein was detected in 
a one step reaction using α-His HRPO IgG. 
To test fusion protein binding, half of a 96 well ELISA plate was coated overnight at 
4°C with 100 μl of 200 μg/ml fusion in PBS pH 7.4. The other half was left empty to 
include negative controls. After blocking the whole plate, serial dilutions of 
biotinylated DN-MAML1 in 3% milk/PBS were added to the plate in triplicate and 
incubated for one hour at room temperature. Other controls included: addition of 3% 
milk/PBS only and addition of DN-MAML1 (no biotin) both on the coated and 
uncoated portion of the ELISA plate. After washing, extravidin peroxidase HRPO 
was added 1/1000 in 3% milk/PBS (100 μl per well), incubated, washed and 
developed as before. 
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2.2.4 Phage display 
 
2.2.4.1 Affinity selection (biopanning) on immunotubes 
Nunc-Immuno tubes were coated overnight at 4°C with 1 ml of 20 μg/ml DN-
MAML1 in PBS pH 7.4. The tubes were washed with PBS three times before 
blocking with 3% BSA/PBS for 2 hours at 37°C. After three PBS washes, 10
12
 library 
phage particles in 1 ml of 3% BSA/3% Milk/PBS were added and mixed for 2 hours 
at room temperature, rotating continuously. The tube was washed 10 times with PBS-
Tween and 10 times with PBS (increased to 20 times in the second and third round of 
selection). Any liquid was removed before the addition of 1 ml 100mM HCl, 
incubated at room temperature for 10 minutes with constant rotation. The resulting 
eluate was added to 1 ml of 1M Tris-HCl pH 7.4. One ml of eluate was then added to 
20 ml of exponentially growing (OD600 0.6-0.8) XL1-blue cells, previously 
maintained on minimal media plates. The culture was left at 37°C for one hour with 
no shaking. Dilute the culture 1/10, 1/100 and 1/1000 and plate 10 μl of each mixture 
in duplicate onto 2TY agar 1% glucose plates, supplemented with carbonicillin. This 
titration is necessary to determine the panning output. The leftover culture was spun at 
2000 g for 10 minutes at room temperature, resuspended in 500 μl of 2TY and split 
between two 150mm 2TY agar plates with 1% glucose and carbonicillin. All plates 
were incubated overnight at 37°C. 
 
2.2.4.2 Further cycles 
Five ml of 2TY media including 15% glycerol were added to the 150mm plate to 
retrieve the output colonies. Fifty μl of this mixture was diluted 1/1000 in 2TY 1% 
glucose, supplemented with carbonicillin (2TYGC). The remaining bacteria were 
stored at -80°C. The culture was grown at 37°C with shaking (250 rpm) until an 
OD600 of 0.5. Ten ml of culture were then infected with helper phage (VCSM13, 
prepared by Dr. Scott, ICL) in the ratio of 1:20. Infection took place at 30°C without 
shaking followed by 30 minutes shaking at 37°C. Cells were centrifuged at 2000 g for 
10 minutes at room temperature. The pellet was finally resuspended in 50 ml of 2TY 
supplemented with carbonicillin and kanamycin and incubated overnight at 30°C with 
shaking.  
The culture supernatant was isolated by centrifugation at 10,000 g for 10 minutes at 
4°C. Ten ml of ice-cold 10% PEG-8000 containing 2.5M NaCl were added to the 
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supernatant and left for 2 hours on ice. Rescued phages were pelleted at 10,000 g for 
10 minutes and resuspended in 2 ml of ice cold, sterile PBS pH 7.4. Any bacterial 
debris was removed by centrifugation at 10,000 g for 10 minutes at 4°C. To titre the 
resulting phage preparation, serial ten-fold dilutions were made in sterile PBS to 
infect XL1-blue cells, as previously described. The selection was repeated for a 
further two cycles. 
 
2.2.4.3 Identification of monoclonal phage by ELISA 
Individual colonies from the output plate of the final cycle (approximately 500 
colonies screened) were inoculated into 200 μl 2TYGC media in sterile 96 well plates 
(round bottom) and grown overnight at 37°C with shaking (200 rpm). Ten μl from 
each well were subcultured into 200 μl of fresh 2TYGC media in a 96 well format. 
These were grown for 2 hours at 37°C with shaking. The original overnight plate was 
stored after addition of 15% glycerol (final concentration). Following the 2 hour 
incubation, 25 μl of 2TYGC media containing 109 PFU of helper phage were added 
per well. Infection occurred at 37°C for 30 minutes without shaking followed by 30 
minutes with shaking. The plate was centrifuged at 1000 g for 10 minutes at room 
temperature. The cell pellets were resuspended in fresh 2TY supplemented with 
carbonicillin and kanamycin and incubated overnight at 30°C with shaking. A 96 well 
ELISA plate was coated overnight at 4°C with 100 μl of 20 μg/ml DN-MAML1 in 
PBS pH 7.4. The following day, ELISA plates were washed three times with PBS and 
blocked using 250 μl of 3% Milk/PBS for 2 hours at 37°C. The culture plates were 
centrifuged at 1000 g for 10 minutes at room temperature. The supernatant in 3% 
BSA/3%milk/PBS was added to the ELISA plate and incubated for one hour at room 
temperature. Addition of 3% BSA/3%milk/PBS only was a control for cross reactivity 
between the antibodies and the coated antigen. Plates were washed three times with 
PBS-Tween and three times with PBS. HRP-Anti-M13 was added 1/5000 in 3% 
milk/PBS (100 μl per well), incubated and washed as before. One hundred μl of BM-
Blue POD substrate were added and incubated for 10-30 minutes at room 
temperature. The reaction was quenched using 50 μl of 1M HCl before measuring the 
OD at 450nm. Promising candidates were screened again on a 5 ml culture format 
with recovery of rescued phages by PEG/NaCl precipitation, added to the ELISA 
plate in triplicate. Plastic binders were eliminated at this stage (binding to uncoated 
ELISA plates).   
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2.2.5 Molecular biology techniques 
 
2.2.5.1 Isolation and purification of DNA 
DNA was isolated using the QIAquick
®
 Spin range of DNA isolation and purification 
kits (QIAGEN). The miniprep, PCR purification and gel extraction kits were used to 
isolate and purify DNA from bacterial cultures, PCR/digest reaction mixtures and 
agarose gels, respectively. DNA concentration was determined by absorption at 260 
nm using a NanoDrop
®
 Micro-Volume UV-Vis spectrophotometer. 
 
2.2.5.2 Agarose gel electrophoresis 
Gels consisted of 1% agarose in TAE buffer with 1µg/ml ethidium bromide. DNA 
samples, mixed with loading buffer, were electrophoresed at 120V and bands were 
visualised using a UV transilluminator. Molecular weight markers were Hyperladder I 
(10kbp to 200bp) and IV (1000bp to 100bp). 
 
2.2.5.3 Restriction enzyme digests 
All restriction enzymes were purchased from Fermentas. Reactions were carried out at 
37°C for 2 hours, including 10 units of each enzyme.  
 
Table 2.10: Restriction enzymes and corresponding buffer 
Enzyme combination Buffer 
NcoI XhoI 1x Tango 
PciI NotI G 
NcoI NotI O 
NdeI XhoI Fast digest 
BamHI 1x Tango 
PciI 1x Tango 
AgeI O 
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2.2.5.4 Polymerase chain reaction (PCR) 
Generally, pfu DNA polymerase (Fermentas) was used to amplify DNA under the 
following cycling conditions:  
Step 1: 94°C for 3 minutes 
Step 2: 94°C for 45 seconds 
Step 3: 70°C for 45 seconds 
Step 4: 72°C for 45 seconds 
Repeat steps 2-4 35 times 
Step 5: 72°C for 10 minutes 
 
2.2.5.5 RNA extraction and cDNA synthesis 
Total cellular RNA was extracted using the MagMAX™ 96 total RNA isolation kit 
(Invitrogen) as per manufacturer’s instructions. Isolated RNA was quantified by 
absorbance at 260 nm using a NanoDrop
®
 Micro-Volume UV-Vis spectrophotometer. 
The 260/280 nm absorbance ratio was also monitored to assess purity and was 
expected to fall between the value of 1.9 to 2.3. Total cDNA was synthesised from 85 
ng of RNA using the high capacity cDNA reverse transcription kit. Synthesis was 
carried out at 25°C for 10 minutes (hybridisation), 37°C for 2 hours and 85°C for 10 
minutes (enzyme degradation). The resulting cDNA was stored at -20°C. 
 
2.2.5.6 Quantitative real-time PCR  
qRT-PCR allows to determine the relative expression of a gene between DNA 
samples based on the fluorescence emission during the amplification cycles of a PCR 
reaction. All reactions were performed in a volume of 10 µl consisting of 5 µl of 
Taqman
®
 Fast Real-Time PCR Universal PCR 2x Mastermix (buffer, polymerase and 
dNTPs included), 1 µl of cDNA sample, 0.5 µl of the relevant 20x primer and probe 
mix (Taqman
®
 gene expression assays) and 3.5 µl of molecular biology grade water. 
qRT-PCR was performed using an Applied Biosystems 7500 Fast Real-Time PCR 
system with a program of 95°C for 20 seconds followed by 40 cycles at 95°C for 3 
seconds and 60°C for 30 seconds. All samples were loaded in triplicate on a 96 well 
optical plate. The threshold value was set to 0.2 for all probes. Analysis of relative 
gene expression data was performed using the 2
-ΔΔCt
 method. The house-keeping gene 
18s rRNA was used to normalize the expression levels of target genes. This controls 
for potential discrepancies of cDNA content between samples. All samples are then 
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compared to an internal calibrator sample (ex. untreated control). The standard 
deviation of the difference between the average sample value and the average 18s 
rRNA value was calculated as follows: stdev = ((stdev sample)
2
 + (stdev 18s 
rRNA)
2
)
1/2
. Error in fold change was then calculated from this. 
 
2.2.6 Mammalian cell culture 
All procedures were carried out aseptically in laminar flow tissue culture hoods. All 
cell lines were cultured in a 37°C humidified incubator with 5% CO2 and passaged 
using trypsin-EDTA digestion. The Chinese hamster ovary (CHO) cell line was 
cultured in Dulbecco’s modified eagles medium (DMEM) and 10% Fetal Bovine 
Serum (FBS). CHO cells transfected with either the delta-like ligand 1 (CHO Δ) or 
the Notch receptor 2 (CHO N2) required addition of 0.5 mg/ml geneticin and 0.2 
mg/ml hygromycin (CHO N2 only). The MDA-MB-231 cell line was cultured in 
DMEM phenol red free media with 5% FBS and 1 mM pyruvate. Cells were stored in 
10% DMSO 90% FBS at -80°C. 
 
2.2.6.1 Luciferase reporter gene assay 
This assay requires the use of white 96 well plates (Nunc) for luminescent readings. 
All conditions are present as triplicates on duplicate (identical) plates. Ten thousand 
CHO N2 cells and 5,000 CHO Δ cells were plated together in a final volume of 180 µl 
of media per well with 10 mM LiCl. To test inhibition of Notch signalling, 20 µl of 
the appropriate drug concentration were added. The following controls were also 
included: Antp, 1% DMSO, CHO N2 only and combination of CHO N2 and CHO Δ 
in media only. After 24 hours, 100 µl of ONE-Glo™ reagent (Promega) was added to 
the wells and left for at least 3 minutes before measuring luminescence in a plate 
reader. The second identical plate was used for a parallel MTS assay where 20 µl of 
the MTS reagent were added per well. Following 2 hour incubation at 37°C, the 
absorbance was read at 490 nm on a plate reader. 
 
2.2.6.2 MDA-MB-231 treatment for qRT-PCR 
MDA-MB-231 cells were plated in a 48 well plate at 50,000 cells/ well in 250 µl of 
media. The following day, 20 µl of drug/control were added to 180 µl of cells in fresh 
media. Cells were incubated for 24 hours at 37°C, 5% CO2 before being harvested for 
qRT-PCR.    
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2.2.6.3 Generation and maintenance of mouse bone marrow-derived dendritic 
cells 
This procedure was carried out by Dr. Bugeon (ICL). The mice used for this 
procedure were wild-type C57BL/6 male, aged between 8 and 12 weeks. The femurs, 
tibias and humeri were removed from the mouse, sterilised and transferred into 
DMEM. The bone marrow was flushed out with a thin gauge needle (26G) connected 
to a syringe filled with media. The collected cells were washed and harvested by 
centrifugation at 500 g for 5 minutes. Cells were resuspended in complete DMEM 
(10% FBS, 50 units/ml penicillin, 50 µg/ml streptomycin and 2 nM glutamine) and 
passed through a 70µm cell strainer (VWR).  1 x 10
7
 cells were plated in a T25 flask 
(25 cm
2
) in DMEM supplemented with 20 ng/ml GM-CSF. After 3 days, half the 
media was replaced with fresh media supplemented with GM-CSF. A media change 
was performed on day 6 and the cells were ready to use on day 8. 
 
2.2.6.4 Stimulation of BMDC with recombinant Notch ligand 
This procedure was carried out by Dr. Bugeon (ICL). Recombinant rat Jagged1-
human IgG1 constant region fusion protein (Jagged1-Fc) was used to activate the 
Notch pathway. Human IgG1 (Sigma) was used in parallel to control for Fc-mediated 
effects. These lyophilised proteins were dissolved in 0.1% BSA-PBS, aliquoted and 
stored at -80°C. 
Jagged1-Fc was coated at 4°C overnight onto polysterene tissue culture plates at 10 
µg/ml, diluted in PBS. The next day, wells were washed twice with PBS. Twenty µl 
of drug/control were added to 180 µl of cells in media and incubated for 30 minutes at 
37°C, 5% CO2 prior plating. Following 4 hours incubation, cells were harvested for 
qRT-PCR.   
 
2.2.6.5 MTS cell proliferation assay 
The MTS cell proliferation assay consists in measuring the amount of formazan 
converted from the MTS reagent by dehydrogenase enzymes found in metabolically 
active cells. MDA-MB-231 cells were plated in a 96 well plate at a density of 5,000 
cells per well in 100 µl media. All conditions are present as triplicates. After 48 hours,   
100 µl of varying concentrations of Antp-DN-MAML1 in media were added to the 
appropriate wells. The following controls were also included: Antp, γ-secretase 
inhibitor 1 (GSI-1, Merck) diluted in dimethyl sulfoxide (DMSO)-media, cells in 
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media and cells in 1% DMSO-media. After 72 hours, 20 µl of the MTS reagent were 
added per well. Following 2 hour incubation at 37°C, the absorbance was read at 490 
nm on a plate reader.  
 
2.2.6.6 Flow cytometry 
MDA-MB-231 cells were plated in a 48 well plate at a density of 15,000 cells per 
well in 200 µl media. After 48 hours, 200 µl of varying concentrations (10 μM, 5 μM, 
2 μM) of Antp-DN-MAML1 or Antp were added to the appropriate wells, in 
quadruplicate. The following controls were also included: doxorubicin (2 μM and 0.2 
μM) and media only. After 24 hours, one sample of cells per treatment was harvested 
for p21 mRNA expression analysis by qRT-PCR. After 72 hours, cells were harvested 
and washed twice before incubation with 2.5 μl Annexin V PE in 250 μl of Annexin 
V binding buffer (1x) per sample. The incubation lasted 20 minutes at room 
temperature, in the dark. Samples were transferred on ice until analysis. DAPI stain 
was added to each sample at 200 ng/ml final concentration. Flow cytometry was 
carried out on a FACSCalibur
™
 and analysed using Flowjo
®
 software.  Debris were 
excluded based on the forward and side scatter (FSC/SSC) profile; duplets were 
excluded based on the side scatter width and side scatter area (SSCW/SSCA) profile. 
Data was recorded for 5000 events per sample. 
 
2.2.6.7 Transient transfection 
CHO cells were cultured onto 100 mm Petri dishes until they reached a confluence of 
50%. Cells were transfected with pcDNA4a encoding Antp and Antp-Scfv using 
Fugene
®
 HD transfection reagent (Roche), according to the manufacturer’s protocol. 
Cells were also transfected with pcDNA vector and no DNA as controls. Expression 
was monitored at 24, 48 and 72 hours post transfection. Media (concentrated x10) and 
lysed cell pellet samples were collected in order to analyse protein expression by 
Western blot.  
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2.2.6.8 Polyclonal stable transfection 
Same as transient transfection until one day after transfection when zeocin™ 
(Melford) was added to the media at a final concentration of 1mg/ml. In the following 
days, media was replaced when needed.  
 
2.2.7 In vivo mouse models 
All procedures were carried out by Mr. Daniel Wells of the CBS (ICL) under Dr. 
Deonarain’s Home Office Licence 70/6982. Eighteen female BALB/c nude mice (6-8 
weeks old) were inoculated with 2 million MDA-MB-231 tumour cells in ice-cold 
50% DMEM media/FBS and 50% matrigel, subcutaneously. The tumours were 
monitored until they reached a size of 32-126 mm
3
 (around 4-5 mm diameter). The 
mice were randomised and grouped as follows.  
Group 1: Antp-DN-MAML1, 4mg/kg, 3 times per week, 11 doses (approx. 
0.1mg/mouse) 
Group 2: paclitaxel, 10mg/kg, 3 times per week, 6 doses 
Group 3: Saline only, 0.1 ml, 3 times per week, 6 doses 
All administrations were blind and performed via the tail vein intravenous route in a 
volume of 0.2 ml.  The animals were culled and dissected after three and a half weeks 
or when tumours were greater than 15 mm diameter. Tumour sizes were calculated as 
(LxWxW)/2 and plotted as a percentage change from the day treatment started.  
 
2.2.8 Statistical analysis 
Statistical analysis was carried out using Excel. One-way ANOVA (analysis of 
variance) was employed to compare data sets. Two-way ANOVA was used to 
compare differences in response between two factors – i.e. to compare differences 
between cells stimulated with Jagged1-Fc in the presence or absence of an inhibitor. 
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Chapter 3 
 
Production and characterisation of the Antp-DN-MAML1 fusion 
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3.1 Introduction 
 
The first strategy to inhibit Notch signalling consisted of blocking transcription 
activation using a dominant-negative MAML1 delivered by Antp. A study by Weng 
et al. (Weng et al., 2003), described the 13-74 truncated MAML-1 as a strong 
dominant negative construct. MAML-1 (13-74) is still able to form the tripartite 
transcription activation complex but cannot recruit co-activators such as p300 (see 
Figure 1.3). In the same study, delivery of MAML (13-74) causes growth arrest and 
death of T-ALL cells. A similar strategy has since been employed by Moellering et al. 
(2010). They engineered a MAML-1 stapled peptide which interferes with 
endogenous MAML-1 to inhibit assembly of the active transcriptional complex. Thus, 
disruption of MAML function is considered a viable method for Notch inhibition, 
resulting in a therapeutic benefit.  
The first goal is to produce Antp-DN-MAML1 and Antp proteins. The helical 
structure of both constructs make soluble expression the preferred method of 
production. In order to achieve soluble expression, both cytosolic expression and 
secretion were attempted. Expression through the secretory pathway is the method of 
choice for proteins that require formation of disulphide bonds. The methods available 
for protein purification are based on charge (ion exchange), size (exclusion 
chromatography) or tag affinity (IMAC). In the case of insoluble expression, 
inclusion bodies need to be isolated, solubilised and refolded, each step requiring 
considerable optimisation.  
Circular dichroism was the preferred method to establish the secondary structure of 
Antp following expression and purification due to its strong and characteristic profile. 
It is important to confirm a strong helical content for Antp which is thought to be 
crucial for its function. Circular dichroism (CD) spectroscopy measures differences in 
the absorption of left-handed polarised light versus right-handed polarised light that 
relate to structural differences. The presence of alpha helices results in a distinct 
circular dichroism spectra. 
The first experiment chosen to assess Antp-DN-MAML1 potency in vitro is a 
luciferase reporter gene assay. In this established method, firefly luciferase is 
transcriptionally regulated by activated Notch 2 receptor (Figure 3.1). The 
luminescence signal is amplified due to the presence of ten CSL binding sites relying 
on endogenous CSL for transcriptional activation. Signalling is initiated by mixing 
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CHO cells transfected with the Notch receptor 2 (CHO N2) with CHO cells 
transfected with the delta-like ligand 1 (CHO Δ).  
The γ-secretase inhibitor DAPT (Figure 3.2A), is used as a positive reference in in 
vitro studies. This dipeptide analog has been shown to inhibit Notch signalling by 
acting on the γ-secretase complex (Morohashi et al., 2006). DAPT is considered a 
much cleaner inhibitor compared to GSI-1 (Z-LLNle-CHO) (Figure 3.2B), with 
decreased effects on other signalling pathways.  
The MDA-MB-231 cell line is used in this study as a model to examine the effects of 
Notch inhibition in human breast cancer. Stylianou et al. (Stylianou et al., 2006) 
showed that Notch signalling is increased in MDA-MB-231 cells and Western blot 
analysis revealed an upregulation of N
IC
 and Hey1. Rizzo et al. (2008) also employed 
MDA-MB-231 cells to study the cross talk between Notch and the estrogen receptor 
pathway in breast cancer. 
The expression of Hes1 is also evaluated in parallel in BMDC. These primary cells 
are an established model to study Notch signalling in our laboratory (Gentle et al., 
2012). Notch signalling can be stimulated by addition of Notch ligands to then 
examine inhibition by several compounds examined.  
CoA M
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Ligand
Notch 
receptor 
2
CSL
CSL
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Antp-DN-MAML1
Figure 3.1: Schematic illustration of the luciferase reporter gene assay. Notch 
signaling is initiated by mixing CHO cells transfected with the delta-like ligand 1 
(CHO Δ) with CHO cells transfected with the Notch receptor 2 (CHO N2) in which 
firefly luciferase is transcriptionally regulated by the activated receptor. This 
signaling cascade is affected at different levels by addition of DAPT or Antp-DN-
MAML1.  
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Figure 3.2: Structures of the γ-secretase inhibitors DAPT (A) and GSI-1 (B) (taken 
from (Groth and Fortini, 2012)). 
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3.2 Aims and objectives 
 
The aim of this project is to study the potential as a Notch inhibitor of a dominant 
negative version of MAML-1 fused to Antp for intracellular delivery.  
 
The objectives at a practical level are to: 
 
 Evaluate the possibility of expressing Antp as a secreted protein by cloning into 
the appropriate vector and using a panel of bacterial expression systems. 
 As an alternative, establish a protocol for expression of Antp as a soluble protein 
following cloning into a vector for cytoplasmic expression.  
 Attempt purification of Antp by exploiting the strong positive charge on this 
protein and its small size. 
 Carry out a circular dichroism analysis of the Antp protein to confirm its correct 
refolding. 
 
 Optimise the expression and purification protocol for production of Antp-DN-
MAML1 as an insoluble protein. 
 Evaluate various methods for refolding of the fusion protein. 
 Attempt soluble expression of Antp-DN-MAML1 by matrix expression trials and 
use of alternative vectors. 
  
 In vitro characterisation of Antp-DN-MAML1 to establish the effects of the fusion 
protein on Notch signalling. Perform luciferase reporter gene assays for a direct 
assessment of Notch signalling levels. Carry out qRT-PCR studies to examine the 
expression level of the Hes1 Notch target gene, both in the MDA-MB-231 cancer 
cell line and the BMDC model primary cells.  
 In vitro characterisation of Antp-DN-MAML1 to establish the effects of the fusion 
protein on proliferation of MDA-MB-231 cells upon inhibition of Notch 
signalling.  
 In vivo studies using a MDA-MB-231 mice xenograft model to establish the effect 
of Antp-DN-MAML1 on tumour growth. 
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3.3 Results 
 
3.3.1 Expression, purification and characterisation of Antp 
 
The cell penetrating protein Antp is the platform for the construction of all fusion 
proteins in this study. Therefore, its expression and purification is essential for its use 
as a negative control in functional assays of Notch signalling. The protocol for the 
production of Antp, previously used by Trojantec, consisted of expressing this protein 
in inclusion bodies, followed by refolding. This approach required optimisation 
because of poor yields and concerns about the correct folding of helical Antp.  
 
Table 3.1: Antp characteristics derived from ProtParam on the ExPASy Server  
parameter value 
Theoretical pI 11.18 
Molecular weight (Da) 7826.1 
Amino acid residues 60 
Extinction coefficient (M
-1
 cm
-1
)
 
15470 
 
The first strategy to improve production of Antp consisted of expressing it as a 
secreted protein. In this approach, the Antp gene, cloned in pET20b (see section 
2.1.3), is controlled by the T7 expression system which in turn is regulated by the lac 
operon/promoter system induced using IPTG. The pET20b vector allows fusion of 
Antp to a signal sequence which facilitates export into the periplasmic space. This 
vector also carries a C-terminal His tag sequence which enables purification.  
 
Small scale expression trials were carried out in a variety of E.coli host strains 
including TUNER (DE3), JM109 (DE3), BLR (DE3), BLR (DE3) pLysS, BL21 
(DE3) pLysE, BL21 (DE3) and BL21 (DE3) pLysS cells. BL21 (DE3) and JM109 
(DE3) are used for general protein expression. Expression in BLR (DE3) helps 
stabilising target plasmids. TUNER (DE3) cells allow control over protein expression 
levels throughout the cell culture to prevent protein misfolding and reduce toxicity 
effects. pLysS and pLysE hosts suppress basal protein expression facilitating 
expression of toxic proteins. Unfortunately, no or extremely low expression was 
obtained using the first five strains (data not shown).  
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Figure 3.3 illustrates the expression levels obtained when the Antp construct was 
transformed in BL21 (DE3) and BL21 (DE3) pLysS. Unexpectedly, expression is 
mostly cytoplasmic, with increased yields in the pLysS host. When BL21 (DE3) 
pLysS cells were induced using 0.1 mM IPTG, a portion of Antp is found in the 
supernatant. However, secretion could not be confirmed due to the observation of 
bacterial lysis during expression. Altogether, expression trials of Antp as a secreted 
protein suggest Antp toxicity to host cells.  
 
 
 
 
 
 
 
Figure 3.3: Small scale expression trials of Antp in pET20b transformed in BL21 
(DE3) and BL21 (DE3) pLysS cells. The bacterial culture was grown in 5 ml of 2TY 
up to an OD600 of 0.8 before induction with either 0.1 mM or 1 mM IPTG for 4 hours. 
The culture was centrifuged at 2000 g for 5 minutes before analysis of the secreted (S) 
and total cell pellet (P) fractions by α-His Western blot. Antp is present as a band 
migrating between 15 kDa and 10 kDa.  
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 87 
In order to overcome the toxicity effects observed upon Antp expression as a secreted 
protein, Antp was re-cloned into pET23b for cytoplasmic expression in BL21 (DE3) 
pLysS cells (see section 2.1.3). Antp was successfully expressed as a soluble protein 
(Figure 3.4).  
 
 
 
 
Figure 3.4: Cytoplasmic expression of Antp in pET23b transformed in BL21 (DE3) 
pLysS cells. The bacterial culture was grown in 500 ml of LB up to an OD600 of 1.2 
before inducing with 1 mM IPTG for 5 hours at 37°C. The supernatant (S) and cell 
pellet (P) fractions were analysed by reducing 12% SDS-PAGE, stained using 
Coomassie Blue (A). Antp is present as a band migrating between 15 kDa and 10 
kDa. The corresponding α-His Western blot is also shown (B). The cell pellet was 
resuspended in 15 ml of 50 mM sodium phosphate (pH 7.5), 2 mM EDTA, 1 mM 
DTE with the inclusion of a protease inhibitor tablet. Cells were lysed by sonication 
before centrifuging at 25,000 g for 30 minutes at 4°C. The soluble fraction was 
analysed by reducing 12% SDS-PAGE, stained using Coomassie Blue (C). The 
corresponding Western blot is also shown (D). 
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Ion exchange was the chosen method for Antp purification due to the protein’s high 
positive charge. The column fractions were analysed by reducing 12% SDS-PAGE 
and stained using Coomassie Blue (Figure 3.5A). As the vector carries a C-terminal 
His tag sequence, a Western blot using HRPO conjugated murine α-His antibody was 
also performed to confirm the identity of the purified protein (Figure 3.5B). It is 
important to note how the high salt interferes with gel electrophoresis. Antp migrates 
as a band between 15 kDa and 10 kDa which is greater than its predicted molecular 
weight of 7.8 kDa and could be due to its high positive charge (Table 3.1). A similar 
migration pattern was observed by (Muller et al., 1988). Antp is present in the last 
elution fraction (1M NaCl) although a considerable portion is lost in the flow-through 
and wash steps. This could be due to saturation of nickel on the column or poor 
affinity binding. It is interesting to note that Antp migrates as a band of different size 
between the wash, flow-through and elution fractions. This is thought to be due to the 
gel not running uniformly. The wash and flow-through fractions were subsequently 
reapplied to the resin to retrieve additional protein (data not shown). 
 
 
 
 
 
 
 
 
Figure 3.5: Purification of Antp by ion exchange chromatography. Ion exchange flow-
through, wash and elution fractions were analysed by reducing 18% SDS-PAGE and 
stained using Coomassie Blue (A). The corresponding α-His Western blot is also 
shown (B). Antp is present as a band migrating between 15 kDa and 10 kDa in the 
flow-through (FT), wash (W) and 1M NaCl elution fractions. 
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The ion exchange elution fractions containing Antp, were pooled and loaded onto a 
calibrated Superdex-75 gel filtration column. A peak of absorbance was observed at 
75 minutes, followed by two peaks at 100 and 105 minutes (Figure 3.6). According to 
the column equilibration (Figure 3.7) using cytochrome c (12 kDa) and aprotinin (6 
kDa), the peak at 75 minutes should correspond to Antp. Surprisingly, gel analysis 
showed Antp present in the fractions corresponding to the later peaks (Figure 3.8). In 
particular, fractions B54 and B61 (Figure 3.8A), representing the top absorbance 
values, show the highest Antp protein content. Antp is over 95% pure. 
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Figure 3.6: Size exclusion chromatography of recombinant Antp. Antp was 
fractionated on a Superdex-75 gel filtration column. The absorbance was monitored at 
214 nm and 280 nm. Every third fraction between B4 and B28 was analysed to 
examine the first peak at 75 minutes (see arrow). All fractions between B50 and B64 
were analysed to examine the second (100 minutes) and third peak (105 minutes).  
 
 
 
 
Figure 3.7: Calibration of a Superdex-75 gel filtration column. Cytochrome c and 
aprotinin were analysed using a Superdex-75 gel filtration column in order to verify 
its calibration prior to a sample run. 
 
1st peak 
75 minutes
2nd peak 
100 minutes
3rd peak 
105 minutes
Cytochrome c
12 kDa
Aprotinin
6 kDa
 91 
 
 
Figure 3.8: Analysis of size exclusion chromatography fractions from Antp 
fractionation. Antp was fractionated on a Superdex-75 gel filtration column and a 
selection of peak fractions analysed by reducing SDS-PAGE (stained using 
Coomassie) and corresponding α-His Western blot below. Fractions from B4 to B28 
(A) represent the first peak at 75 minutes, fractions between B50 and B64 (A and B) 
correspond to the second and third peak (at 100 and 105 minutes).  
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In order to confirm the secondary structure and folding properties of Antp, a circular 
dichroism analysis was performed on the purified protein. Different structural 
elements have characteristic CD spectra. For example, α-helical proteins have a 
minima at 222 nm and 208 nm and a maxima at 193 nm (Figure 2.2). As shown in 
Figure 3.9, the CD spectra of Antp confirms a strong α-helical content estimated to be 
between 42% and 57% depending on the algorithm used. This data is consistent with 
the predicted α-helical content of 60% assigned to Antp in silico.   
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Figure 3.9: Circular dichroism spectra of Antp at 100 μg/ml in PBS using a 1mm path 
cuvette. 
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3.3.2 Antp-DN-MAML1 expression and purification trials  
 
The Antp-DN-MAML1 gene was previously cloned by Trojantec in pRSET A (T7 
promoter) which is designed for cytoplasmic expression and carries a N-terminal His 
tag sequence for purification. The construct was transformed in the BL21 (DE3) plysS 
strain for expression. As illustrated in Figure 3.10A, Antp-DN-MAML1 is expressed 
as an insoluble form, therefore 6 M guanidinium chloride was used to solubilise the 
protein from the inclusion body pellet (Figure 3.10B).  
 
Table 3.2: Antp-DN-MAML1 characteristics derived from ProtParam on the ExPASy 
Server 
parameter value 
Theoretical pI 10.85 
Molecular weight (Da) 16352.9 
Amino acid residues 132 
Extinction coefficient (M
-1
 cm
-1
) 16960 
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Figure 3.10: Cytoplasmic expression of Antp-DN-MAML1 in pRSET A transformed 
in BL21 (DE3) pLysS cells. A) Western blot analysis of the soluble (S) and insoluble 
fractions (I) following B-PER
®
 treatment of the expression cell pellet. Antp-DN-
MAML1 is present as a band migrating between 28 kDa and 17 kDa. B) Western blot 
analysis of the soluble (S) and insoluble (P) fractions following treatment with 6 M 
guanidinium chloride of the expression pellet.  
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Antp-DN-MAML1 was purified under denaturing conditions by affinity 
chromatography. IMAC elution fractions were analysed by reducing 12% SDS-PAGE 
and stained using Coomassie Blue (Figure 3.11). A Western blot using HRPO 
conjugated murine α-His antibody was also performed to confirm the identity of the 
purified protein. The flow-through and wash samples were also included. Antp-DN-
MAML1 was present in the all elution fractions, starting from the addition of 20 mM 
imidazole, as a band migrating between 26 kDa and 17 kDa. This is greater than its 
predicted molecular weight of 16.35 kDa and could be due to the high positive charge 
of Antp-DN-MAML1 (Table 3.2). Overall, the (insoluble) expression yields and 
purification outcome (>50% pure) for this protein were satisfactory.  
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Figure 3.11: Purification of Antp-DN-MAML1 by affinity chromatography. IMAC 
flow-through (FT), wash (W) and elution fractions analysed by reducing 12% SDS-
PAGE and stained using Coomassie Blue. The corresponding α-His blot is also shown 
for the elution fractions. Antp-DN-MAML1 is present as a band migrating between 
26 kDa and 17 kDa in all elution fractions, starting from the addition of 20 mM 
imidazole (labelled). 
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Following purification, denatured Antp-DN-MAML1 was refolded in order to obtain 
the functional protein. Two refolding strategies were considered based on the 
assumption that Antp-DN-MAML1 does not form any disulphide bonds. The first 
strategy consisted of dialysis overnight at 4° C in PBS with the addition of 0.4 M L-
Arginine followed by dialysis in PBS over 1 day (Figure 3.12A). The second strategy 
consisted of serial dialyses over 4 days at 4° C using 6 M Urea, 4 M Urea, 2 M Urea 
with 0.4 M L-Arginine,1 M Urea with 0.2 M L-Arginine, 0.5 M Urea and 0.1 M L-
Arg and finally PBS (Figure 3.12B). In this method, the Antp-DN-MAML1 sample 
was centrifuged after each of the last four dialysis rounds in order to minimise 
precipitation. As illustrated in Figure 3.12, both strategies resulted in a minority of 
Antp-DN-MAML1 being present in the soluble fraction as a refolded protein. The 
majority of the sample precipitated due to the incorrect refolding. This represented a 
major hurdle in the production of functional and correctly folded Antp-DN-MAML1.  
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Figure 3.12: Antp-DN-MAML1 refolding trials. Analysis of the soluble (S) and 
insoluble (I) refolding fractions by reducing 12% SDS-PAGE, stained using 
Coomassie Blue. Antp-DN-MAML1 is present as a band migrating between 28 kDa 
and 17 kDa. A) First refolding strategy: dialysis overnight at 4° C in PBS with the 
addition of 0.4 M L-Arginine followed by dialysis in PBS over 1 day. B) Second 
refolding strategy: serial dialysis over 4 days at 4° C using 6 M Urea, 4 M Urea, 2 M 
Urea with 0.4 M L-Arginine,1 M Urea with 0.2 M L-Arginine, 0.5 M Urea and 0.1 M 
L-Arg and finally PBS. I1= spin after dialysis in 2 M Urea with 0.4 M L-Arginine, 
I2= spin after dialysis in 1 M Urea with 0.2 M L-Arginine, I3= spin after dialysis in 
0.5 M Urea and 0.1 M L-Arg, I4= spin after final dialysis in PBS. 
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An attempt to express Antp-DN-MAML1 as a soluble protein consisted of monitoring 
the soluble/insoluble protein content of cultures induced with increasing IPTG 
concentrations, over time. Overall, greater yields were observed with increased IPTG 
concentrations (Figure 3.13A-E). The results collected an hour post induction, 
suggested that, even at the highest IPTG concentration, a considerable portion of 
Antp-DN-MAML1 is expressed as a soluble protein (3.13A). In contrast, overnight 
expression results in all Antp-DN-MAML1 being insoluble (3.13E). This suggests a 
limited time frame for soluble expression of Antp-DN-MAML1.  
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Figure 3.13: Cytoplasmic expression of Antp-DN-MAML1 in pRSET A transformed 
in BL21 (DE3) pLysS cells, induced with increasing concentrations of IPTG. Western 
blot analysis of the soluble (S) and insoluble (I) fractions following B-PER
® 
treatment 
of six expression pellets. Antp-DN-MAML1 is present as a band migrating between 
25 kDa and 15 kDa. A) 1 hour induction B) 2 hour induction C) 3 hour induction D) 4 
hour induction E) 20 hour induction. 
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Based on the results obtained in the small scale expression trial with one hour 
induction, the protocol was scaled up to a 1 litre culture. As shown in Figure 3.14, the 
protocol was reproducible and Antp-DN-MAML1 was expressed as a soluble protein 
in the cytoplasm. The chemiluminescent signal on the first blot (Figure 3.14B) was 
bleached due to protein overload on the gel (Figure 3.14A); the signal is much clearer 
on the second blot with lower loading (Figure 3.14C). Interestingly, the α-His 
Western blot flags up several bands other than the one corresponding to Antp-DN-
MAML1, both of higher and lower molecular weight. This was also observed in the 
small scale expression trials. The lower bands might be due to partial degradation of 
the expressed protein. Further efforts to pursue this strategy were discouraged when 
all attempts at purification of the protein by both affinity and ion exchange 
chromatography failed (data not shown).    
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Figure 3.14: Large scale cytoplasmic expression of Antp-DN-MAML1 in pRSET A 
transformed in BL21 (DE3) pLysS cells. The bacterial culture was grown in 1L of LB 
up to an OD650 of 0.5 before inducing with 100 μM IPTG for 1 hour at 30°C. The 
soluble (S) and insoluble (I) fractions, following B-PER
®
 treatment of the expression 
pellet, were analysed by reducing 12% SDS-PAGE, stained using Coomassie Blue 
(A). Antp-DN-MAML1 is present as a band migrating between 25 kDa and 15 kDa. 
The corresponding α-His Western blot is also shown (B) with a clearer blot of the 
soluble fraction in C.  
 
 
 
Further trials of Antp-DN-MAML1 production are summarised in Table 3.3. Different 
aspects of the expression, purification and refolding protocols were tackled without 
success. In particular, expression trials of a codon optimised Antp-DN-MAML1 
construct in pET23 also resulted in inclusion body formation (Figure 3.15). Antp-DN-
MAML1 was finally manufactured as a custom peptide by Almac Ltd.  
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Table 3.3: Summary of Antp-DN-MAML1 production trials 
Strategy People 
Involved 
Detailed Method Outcome Decision 
SDS-Dialysis Dr Stylianou Boil expression pellet 
in SDS to lyse and 
solubilise  then 
dialyse SDS out 
Not reproducible, 
poor yields and 
purity. Unable to 
carry out IMAC in 
the presence of SDS 
Abandon and 
follow 
standard 
protein 
refolding 
methods 
Urea-Dialysis Ms Colucci Solubilise inclusion 
body pellet in 6M 
GuHCl, purify by 
IMAC under 
denaturing (8M Urea) 
conditions and step-
wise dialysis into 
PBS 
Pure Antp-DN-
MAML1 at IMAC 
stage, but poor yields 
due to multiple 
precipitation steps 
Try adding a 
redox couple 
to help with 
potential 
disulphides 
Codon 
optimised 
construct 
Ms Colucci Codon optimised 
construct with C-
terminal His tag, 
process as above 
Still insoluble 
expression and lower 
yields compared to 
original construct 
Abandon 
Urea-Dialysis 
with glutathione 
Ms Colucci & Dr 
Constantinou 
As above but include 
GSSG/GSH couple in 
the latter dialysis 
stages 
No real improvement 
over that seen above 
Hand over to 
Fusion 
Antibodies 
(Contract 
Manufacturer) 
to optimise 
Urea-Dialysis 
(Contract) 
Fusion 
Antibodies Ltd 
As above but with 
minor refinements 
Still low yields and 
non-reproducible 
Try and 
express it 
solubly 
Soluble 
expression 
Ms Colucci 
 
Identify time window 
when Antp-DN-
MAML1 is in the 
soluble phase and 
correlate with 
plasmid instability.  
Some soluble Antp-
DN-MAML1 seen 
within 1 hr of 
expression  
Hand over to 
Prof. Cole  
Soluble 
expression in 
Fermentor 
Prof J. Cole 
(Univ. of 
Birmingham) 
Use stress-resistant 
strains, fermentation 
and identify nature of 
soluble protein 
Antp-DN-MAML1 
found to be 
associated with the 
membrane. Small 
amount of soluble 
material isolated but 
hard to purify and 
needed detergent 
extraction  
Project on 
hold 
Pichia Pastoris Prof K. Chester 
(UCL) 
Re-clone into Pichia 
vectors, express using 
standard methods as a 
secreted protein 
Antp-DN-MAML1 
found to be mostly 
insoluble but some 
soluble secreted and 
pure. Yields are low 
Project on 
hold 
Peptide 
synthesis 
Almac Ltd Synthesise the Antp-
DN-MAML1 peptide 
and test if it behaves 
like the recombinant 
protein 
Synthesis successful 
with high degree of 
purity. Expensive but 
reliable. Antp-DN-
MAML1 peptide 
refolds upon 
dissolving in PBS 
and has biological 
activity 
Use this 
version of 
Antp-DN-
MAML1 until 
recombinant 
methods are 
fully 
developed 
 105 
 
 
 
Figure 3.15: Cytoplasmic expression of Antp-DN-MAML1 in pET23 transformed in 
BL21 (DE3) pLysS cells. Western blot analysis of the soluble (S) and insoluble 
fractions (I) following B-PER
®
 treatment (A) and 6 M guanidinium chloride 
denaturation (B) of the lysed expression cell pellet. Antp-DN-MAML1 is present as a 
band migrating between 28 kDa and 17 kDa.  
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3.3.3 In vitro characterisation of Antp-DN-MAML1 
 
In order to assess whether Antp-DN-MAML1 can repress Notch target gene 
expression, a luciferase reporter assay was used. In order to initiate signalling, CHO 
cells transfected with the Notch receptor 2 (CHO N2) were mixed with CHO cells 
transfected with the delta-like ligand 1 (CHO Δ) (Figure 3.16). Activation was 
minimal when CHO N2 are mixed with CHO K (wild type) due to the presence of 
endogenous ligand. Activation did not occur in the three cell types in isolation. A 
calibration curve (Figure 3.17A) showed a linear increase in luminescence signal with 
increasing CHO Δ cell numbers. A ratio between CHO N2 and CHO Δ of 1:0.5 was 
chosen as activation is significant (see enlarged Figure 3.17B) and there is no over 
stimulation of the system such that inhibition of Notch signalling could be readily 
observed in subsequent experiments.  
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Figure 3.16: Establishment of the CHO luciferase report-gene assay system. CHO N2, 
CHO Δ and CHO K are plated alone or in combination (CHO N2 + CHO Δ, CHO N2 
+ CHO K). Luminescence is read after a 24 hour incubation.  Error bars represent the 
standard deviation between triplicates. One-way ANOVA was used to statistically 
compare conditions; p ≤ 0.05 was considered significant. ***p ≤ 0.001. 
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Figure 3.17: Calibration curve to determine the optimal ratio of CHO Δ to CHO N2 
cells in the luciferase reporter-gene assay. 10,000 CHO N2 cells were plated with 
CHO Δ cells in the ratios of: 1:0.125, 1:0.25, 1:0.5, 1:1, 1:2 and 1:4 (A) with lower 
range expanded in (B). Luminescence was measured 24 hours after plating. Error bars 
represent the standard deviation between triplicates. 
 
 
 
 
 
 
 
 109 
Antp-DN-MAML1 was then tested in the luciferase reporter-gene assay. The data 
shown is from a single representative experiment out of three repeats which showed 
the same trend. As expected, treatment with Antp-DN-MAML1 resulted in a dose-
dependent decrease in luminescence compared to the Antp and cells in media controls 
(Figure 3.18A). This corresponds to an inhibition of Notch signalling. A strong 
decrease in luminescence was also observed with the γ-secretase inhibitor DAPT 
compared to 1% DMSO (vehicle control). Basal levels of luminescence in the CHO 
N2 alone control are due to lack of activation of the Notch 2 receptor. Altogether, this 
suggests that Antp-DN-MAML1 is able to translocate into cells and inhibit Notch 
signalling specifically. An MTS assay, set up in parallel, confirmed that decrease in 
luminescence was not due to Antp-DN-MAML1 cytotoxicity (Figure 3.18B). 
Addition of Antp-DN-MAML1 at 30 μM, resulted in an unexpected increase in 
absorbance. As expected, a lower absorbance is observed in the CHO N2 alone 
control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 110 
 
Figure 3.18: Inhibition of Notch signalling by Antp-DN-MAML1 in the luciferase 
reporter-gene assay. CHO-N2 and CHO-Δ cells were plated at a 1:0.5 ratio in the 
presence of drug/controls. Each bar represents the mean + standard deviation of 3 
replicates. A) Luminescence was measured after 24 hours. One-way ANOVA was 
used to statistically compare conditions; p ≤ 0.05 was considered significant. **p ≤ 
0.01, ***p ≤ 0.001. B) The MTS reagent was added after 24 hours to account for cell 
death and plot shows absorbance at 490 nm. 
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In order to support the results obtained in the luciferase assay, the effect of Antp-DN-
MAML1 on the expression of Notch target genes in MDA-MB-231 was investigated 
by qRT–PCR. MDA-MB-231 cells were plated and treated the following day with 
two doses of Antp-DN-MAML1 and Antp for 24 hours. Cells were also treated with 
DAPT and 1% DMSO vehicle control. 
A dose-dependent decrease in expression of the Notch target gene Hes1 was observed 
after treatment with Antp-DN-MAML1 relative to controls (Antp and cells only) 
(Figure 3.19). As expected, Hes1 expression was also downregulated with DAPT 
treatment. 
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Figure 3.19: Assessment of Notch target gene expression in MDA-MB-231 cells 
treated with Antp-DN-MAML1. MDA-MB-231 cells were plated in a 48 well plate at 
a density of 50,000 cells per well. The following day, cells were treated with varying 
concentrations of Antp-DN-MAML-1/Antp and DAPT/DMSO as controls. After 24 
hours, cells were harvested and Hes1 mRNA expression analysed by qRT-PCR. Ct 
were normalized to 18s mRNA and relative expression compared to a cell-only 
control. Data are mean + standard deviation of triplicate experiments. One-way 
ANOVA was used to statistically compare conditions; p ≤ 0.05 was considered 
significant. ****p ≤ 0.0001 (n=9). 
 
 
Antp-DN-MAML1 effects on Notch signalling were further investigated in BMDC. 
Hes1 expression was induced in these primary cells by culture with immobilised 
Jagged1-Fc. The Jagged1-Fc protein used was a fusion between rat Jagged1 and the 
Fc portion of IgG1 and therefore immobilised IgG1 was used as a control in these 
experiments. Cells stimulated by the Notch ligand show a significant increase in Hes1 
expression corresponding to activation of Notch signalling (Figure 3.20). This 
increase was reduced in the presence of either Antp-DN-MAML1 or DAPT compared 
to controls (Figure 3.20). 
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Figure 3.20: Assessment of Hes1 expression in BMDC cells treated with Antp-DN-
MAML1. BMDC, pre-treated with Antp-DN-MAML1 and controls, were stimulated 
with plate-bound Jagged1-Fc (Jgd) or IgG1 (Fc control). After 4 hours, cells were 
harvested and Hes1 mRNA expression analysed by qRT-PCR. Ct were normalized to 
18s mRNA and relative expression compared to Antp + IgG control. Data are mean + 
standard deviation of triplicate experiments. Two-way ANOVA with replicates was 
used to statistically compare conditions; p ≤ 0.05 was considered significant.  
**p ≤ 0.01 (n=9), ns: not significant. 
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At this point of the study, different experiments suggested that Antp-DN-MAML1 
could repress Notch target gene expression. The following experiment was designed 
to examine whether Antp-DN-MAML1 had any effect on the proliferation of MDA-
MB-231 cells. In order to determine the optimal number of MDA-MB-231 cells for an 
MTS assay, a calibration curve was generated (Figure 3.21) and 5000 cells/well was 
chosen for all future assays to ensure sufficient sensitivity. Addition of Antp-DN-
MAML-1 to MDA-MB-231 cells had a growth-inhibitory effect compared to Antp at 
intermediate concentrations (Figure 3.22). Addition of the commercial γ-secretase 
inhibitor 1, GSI-1, also had a strong inhibitory effect on cell proliferation. As the GSI-
1 was diluted in DMSO, 1% DMSO was also added to the cells as a vehicle control 
and this had no effect on cell proliferation compared to untreated control. Using 
SigmaPlot
®
 fitted curves, calculated IC50 values were 0.55 μM, 1.61 μM and 7.03 μM 
for GSI-1, Antp-DN-MAML1 and Antp, respectively.  
 
Figure 3.21: Effect of cell number on absorbance at 490 nm measured using the MTS 
Assay. Various numbers of MDA-MB-231 cells were added to the wells of a 96 well 
plate. The MTS reagent was added after 120 hours and plot shows absorbance at 490 
nm. Each point represents the mean ± standard error of 8 replicates.  
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Figure 3.22: Proliferation of MDA-MB-231 cells upon exposure to Antp-DN-
MAML1. Cells were plated in a 96 well plate at a density of 5,000 cells per well. 
Cells were treated 48 hours after plating. The MTS reagent was added following a  
further 72 hours incubation. Each point represents the mean ± standard deviation of 
triplicates. 1% DMSO (OD490= 0.85) does not affect cell proliferation compared to 
the untreated control (OD490= 0.89). One-way ANOVA was used to statistically 
compare conditions; p ≤ 0.05 was considered significant. *p ≤ 0.05, **p ≤ 0.01, ***p 
≤ 0.001. 
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A further experiment was performed using the alternative γ-secretase inhibitor DAPT 
because GSI-1 has previously been shown to inhibit a variety of other signalling 
pathways in addition to Notch. DAPT did not affect proliferation of MDA-MB-231 at 
any concentration tested and even with repeated dosing (data not shown). Since 
DAPT had previously been shown to inhibit Hes1 transcription following the 
activation of Notch signalling in both MDA-MB-231 cells and BMDC it seems 
probable that the inhibitory effects of GSI-1 on MDA-MB-231 cell proliferation were 
unrelated to an effect on Notch signalling.  As inhibition of Notch signalling by 
DAPT did not result in inhibition in MDA-MB-231 cell growth, a question was raised 
about whether the effects of Antp-DN-MAML1 on MDA-MB-231 cell proliferation 
were related to inhibition of Notch signalling. 
 
This possibility led to the investigation of other effects that Antp-DN-MAML1 could 
have on MDA-MB-231 to induce a slow down in growth. MAML1 has been 
described to interact with p53 through its N-terminal region (1-302) and function as a 
co-activator (Zhao et al., 2007). In addition, the same study demonstrated that 
MAML-1 is part of the activator complex that binds to the native promoter of p21. 
Crucially, MAML-1 increases p53-mediated trans-activation of its target gene p21.     
 
It was hypothesised that the N-terminal portion of MAML-1 (13-74) could still bind 
to and stabilise p53, increasing p21 expression, resulting in cell death via apoptosis. In 
order to assess this, the effect of Antp-DN-MAML1 on the expression of p21 in 
MDA-MB-231 was investigated by qRT–PCR (Figure 3.23). Treatment with Antp-
DN-MAML1 shows a strong dose-dependent increase in expression of the p21 gene 
relative to controls. 
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Figure 3.23: Assessment of Notch target gene expression in MDA-MB-231 cells 
treated with Antp-DN-MAML1. MDA-MB-231 cells were plated in a 48 well plate at 
a density of 50,000 cells per well. The following day, cells were treated with varying 
concentrations of Antp-DN-MAML1/Antp and DAPT/DMSO as controls. After 24 
hours, cells were harvested for p21 mRNA expression analysis by qRT-PCR. Results 
were normalized to 18s mRNA and relative expression compared to a cell-only 
control. Data are mean + standard deviation of multiple independent experiments. 
One-way ANOVA was used to statistically compare conditions; p ≤ 0.05 was 
considered significant. ***p ≤ 0.001 (n=9) ****p ≤ 0.0001 (n=9). 
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Consequently, we also assessed if MDA-MB-231 cells treated with Antp-DN-
MAML1 were undergoing apoptosis. For this purpose, treated cells were stained with 
Annexin V. The human vascular anticoagulant Annexin V is a Ca
2+
 dependent 
phospholipid binding protein that binds phosphatidylserine with high affinity. This 
phospholipid is located on the cytoplasmic side of the cellular membrane. When a cell 
undergoes apoptosis, phosphatidylserine flips to the outside where it can be detected 
by Annexin V conjugates. This staining is specific for early apoptosis when dyes such 
as DAPI are still excluded by the plasma membrane. In this experiment, different 
doses of doxorubicin were used a control for early and late apoptosis based on a 
calibration curve (Figure 3.24). Doxorubicin IC50 was determined to be 0.16 μM (72 
hour treatment). An IC50 value of 1.26 ± 0.39 is reported in the literature for 
doxorubicin treatment of MDA-MB-231 cells for 24 hours.  
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Figure 3.24: Proliferation of MDA-MB-231 cells upon exposure to doxorubicin. Cells 
were plated in a 96 well plate at a density of 5,000 cells per well. Cells were treated 
with doxorubicin at the concentrations shown 48 hours after plating. The MTS 
reagent was added following a further 72 hours incubation. Each point represents the 
mean ± standard deviation of triplicates. Curve fitted using SigmaPlot
®
 software. 1% 
DMSO (OD490= 0.79) does not affect cell proliferation compared to the untreated 
control (OD490= 0.7). 
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MDA-MB-231 cells treated with Antp-DN-MAML1 show a dose dependent increase 
in Annexin V (early apoptosis) and Annexin V/DAPI positive cells (late apoptosis) 
compared to Antp (Figure 3.25). The cell population shifts from the bottom left 
quadrant towards the right (Annexin V positive) and up (Annexin V and DAPI 
positive) with increasing drug concentration. A similar pattern is observed in the 
positive control doxorubicin where cells treated with the low dose are undergoing 
early apoptosis whereas those treated with a high concentration are in the late 
apoptosis phase. Data collected from three independent experiments was combined 
and plotted in Figure 3.26. In parallel, cells were also collected for qRT-PCR analysis 
of p21 gene expression levels (Figure 3.27). As expected, p21 expression in MDA-
MB-231 cells was increased in a dose-dependent manner upon exposure to Antp-DN-
MAML1 compared to controls. The dose response curves for p21 and induction of 
apoptosis were very similar. 
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Figure 3.25: Apoptotic cells determined with Annexin V-DAPI staining followed by 
flow cytometry. MDA-MB-231 cells were plated in a 48 well plate at a density of 
15,000 cells per well. After 48 hours, cells were treated with varying concentrations 
of Antp-DN-MAML1 or Antp, in triplicate (a singe plot representative of the 
triplicates is shown). The following controls were also included: doxorubicin (2 μM 
and 0.2 μM) and media only. After 72 hours, cells were stained with Annexin V PE 
and DAPI. Bottom left quadrant: live cells, bottom right: early apoptosis, top right: 
late apoptosis, top left: dead cells. 
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Figure 3.26: Induction of apoptosis by Antp-DN-MAML1 shown by Annexin V-
DAPI staining. Error bars represent the standard deviation between triplicates from 
three independent flow cytometry experiments. Data for the bottom right and top right 
quadrants of Figure 3.25 was combined as annexin V positive.  
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Figure 3.27: p21 expression in MDA-MB-231 cells treated with Antp-DN-MAML1. 
MDA-MB-231 cells were plated in a 48 well plate at a density of 15,000 cells per 
well. After 48 hours, cells were treated with varying concentrations of Antp-DN-
MAML-1 or Antp. After 24 hours, cells were harvested and p21 mRNA expression 
analysed by qRT-PCR. Ct were normalized to 18s mRNA and relative expression 
compared to cell only control. Data are mean + standard of multiple independent 
experiments. One-way ANOVA was used to statistically compare conditions; p ≤ 0.05 
was considered significant. **p ≤ 0.01 (n=6), ****p ≤ 0.0001 (n=9). 
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3.3.4 In vivo characterisation of Antp-DN-MAML1 
 
The effects of Antp-DN-MAML1 on MDA-MB-231 proliferation were assessed in in 
vitro models. It was also necessary to assess the compound’s efficiency in vivo. For 
this, BALB/c nude mice were inoculated with MDA-MB-231 cells subcutaneously. 
The tumours were left to grow to an appropriate size before the start of treatment. 
Antp-DN-MAML1 was injected at 4mg/kg, 3 times per week for a total of 11 doses. 
Control groups consisted of paclitaxel treatment at 10mg/kg and saline only (0.1 ml). 
Tumour sizes were calculated as (LxWxW)/2 and plotted as a percentage change from 
the day treatment started (Figure 3.28). The data shown is from a single representative 
experiment out of three repeats. Tumours treated with Antp-DN-MAML1 only 
marginally increased in size compared to controls. In fact, the animals in both control 
groups had to be culled before the end of Antp-DN-MAML1 treatment for humane 
reasons. In conclusion, Antp-DN-MAML1 inhibits MDA-MB-231 tumour growth in 
vivo.  
 
Figure 3.28: Antp-DN-MAML1 therapy of MDA-MB-231 tumours in BALB/c nude 
mice. Control animals (PTX: paclitaxel and PBS) had to be culled early for humane 
reasons. Tumour sizes were calculated as (LxWxW)/2 and plotted as a percentage 
change from the day treatment started. One-way ANOVA was used to statistically 
compare conditions; p ≤ 0.05 was considered significant. *p ≤ 0.05, **p ≤ 0.01, ***p 
≤ 0.001. All procedures were carried out by Mr. Daniel Wells of the CBS (ICL).  
 
*
***
**
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Discussion 
In order to test the effects of the Antp-DN-MAML1 fusion protein as a Notch 
inhibitor, it was necessary to produce this protein and the negative control Antp. It 
was important to assess Antp in parallel due to its interactions with the membrane and 
possible disruption of cellular functions. The effects of DN-MAML1 alone were not 
assessed as this protein can not cross the membrane or disrupt cellular signalling. The 
aim for the production of Antp was to express it as a soluble protein. Refolding of 
Antp is not advisable due to its strong α-helical content and previous experience at 
Trojantec. Expression of Antp as a secreted protein was attempted as this strategy is 
best suited for expression of Antp-scFv fusions, to allow the formation of disulphide 
bonds. Despite numerous attempts, Antp expression as a secreted protein was 
unsuccessful. The observation of bacterial lysis upon addition of IPTG suggested 
severe toxicity of Antp to the host cells. Interestingly, Palm et al. describe the 
internalisation of penetratin into E.coli with an associated antimicrobial effect (Palm 
et al., 2006). Antp was finally produced by cytoplasmic expression and purified based 
on its high positive charge and small size. Circular dichroism analysis of Antp 
confirmed the correct folding of this protein. Future studies involving the use of more 
elaborate methods such as NMR could provide more detailed structural information 
about recombinant proteins produced. 
The initial attempts of Antp-DN-MAML1 production showed expression of this 
protein in inclusion bodies. The purification of Antp-DN-MAML1 was carried out 
under denaturing conditions, making use of the N-terminal His tag. Despite 
encouraging expression yields and successful purification, refolding of denatured 
Antp-DN-MAML1 was unsuccessful. Improvement of the expression and purification 
protocols was attempted in this study and by several collaborators and contractors. It 
is important to note that protocols in the literature for production of DN-MAML1 
involve refolding (Nam et al., 2003). Thus, it is possible that the insolubility of DN-
MAML1 underlies the production problems encountered for the fusion protein. 
Expression of Antp-DN-MAML1 as a soluble protein was achieved in an expression 
trial where different IPTG concentrations and induction times were evaluated. Soluble 
expression was dependent on the length of induction. Whereas a portion of Antp-DN-
MAML1 is soluble in the first hours following induction, the same protein is insoluble 
following an overnight incubation. This suggests a strain on the host cells in 
producing soluble protein resulting in loss of plasmid and cell death. Interestingly, 
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further studies by Prof. Cole (University of Birmingham) found Antp-DN-MAML1 to 
be associated with membranes rather than in inclusion bodies (personal 
communication). This highlights the difficulty of producing a protein that interacts 
with membranes by a mechanism that is not well understood. Several attempts to 
purify soluble Antp-DN-MAML1 by both affinity and ion exchange chromatography 
were unsuccessful. The inability of the His tag to bind the resin under native 
conditions was also observed by our collaborators. This suggests that Antp-DN-
MAML1 folds in such a way to render the tag inaccessible. It is important to note that 
the positive charge on Antp might also interfere with the affinity binding. Affinity 
chromatography is a powerful tool especially for the isolation of small amounts of 
recombinant protein from complex mixtures. Consequently, future studies should 
attempt the use of different tags (GST, FLAG or other) and/or alternative positions 
(C-terminal, different linker lengths). In particular, epitope based tags such as FLAG 
have been shown to yield comparatively higher purity protein but require expensive, 
low capacity resins. In the future, one could also explore the use of antibodies against  
the His tag in order to successfully isolate the protein of interest. Finally, Antp-DN-
MAML1 was produced as a synthetic peptide. The relatively small size of the fusion 
is at the limit of what synthesis can achieve. Despite this, synthesis was successful 
producing a protein with high degree of purity.  
The luciferase reporter-gene assay allows for a direct assessment of Notch signalling 
as activation of Notch2 receptor leads to quantifiable luciferase readouts. 
Consequently, this method can provide information about the mode of Antp-DN-
MAML1 action, specifically related to Notch signalling. We observed a significant 
inhibition of luminescence compared to controls induced by Antp-DN-MAML1. This 
was not due to cytotoxicity as CHO cell viability was unaltered. These results suggest 
that Antp-DN-Maml-1 is able to translocate into cells and inhibit Notch-mediated 
transcriptional activation.  
Inhibition of Notch signalling and Antp-DN-MAML1 functionality was further 
assessed by analysing expression levels of the Hes1 gene as it is known to be a target 
gene of Notch signalling. Hes1 expression was assessed in both MDA-MB-231 and 
BMDC models. It is important to note that basal levels of Hes1 expression are 
considerably elevated in the cancer cell line compared to the primary cells. This 
supports the observation that Notch signalling is deregulated in MDA-MB-231 cells. 
By contrast, there is low constitutive expression of Hes1 in BMDC and therefore 
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Notch signalling was stimulated in these cells with immobilised Jagged1. It is 
interesting to note that TNF-α cytokine expression levels, examined in parallel with 
Hes1 expression, were elevated upon addition of Antp-DN-MAML1, compared to 
controls (data not shown). This is unlikely to be due to bacterial products such as 
lipopolysaccharide in the protein as it had been produced by peptide synthesis. 
However, the fusion of the Drosophila protein Antp and a truncated MAML1 might 
create new epitopes recognised by the TLR/NLR receptors.  
Several lines of evidence suggest that Antp-DN-MAML1 can repress Notch target 
gene expression. However, it is unclear whether Antp-DN-MAML1 affects 
proliferation of MDA-MB-231 cells through inhibition of Notch signalling. The MTS 
cell proliferation assay revealed that Antp-DN-MAML1 had a strong growth-
inhibitory effect (IC50: 1.61μM) when added to MDA-MB-231 cells for 72h. The 
commercial GSI-1, used as a positive control, showed an IC50 of approximately 0.55 
µM, consistent with the value of 1.3 µM obtained by (Rizzo et al., 2008) at 48 hours. 
The difference between Antp-DN-MAML1 and the GSI-1 could be explained by the 
ability of GSIs to inhibit a variety of other signalling pathways in addition to Notch 
(Beel and Sanders, 2008). In the same experiment, addition of a different GSI, DAPT, 
did not have any effect on MDA-MB-231 cell proliferation, despite its effect on Hes1 
expression. This is consistent with the findings of a study by Han et al. They argue 
that the observed cytotoxicity of GSI-1 on breast cancer cells in not due to disruption 
of γ-secretase activity but to proteasome inhibition (Han et al., 2009). Therefore, the 
MTS experiment does not demonstrate a direct link between inhibition of Notch 
signalling and inhibition of proliferation of the MDA-MB-231 breast cancer cell line. 
A previous study by Moellering et al., showed inhibition of Notch signalling using 
stapled MAML-1 peptides (Moellering et al., 2009). This inhibition resulted in the 
arrest of T-ALL cell proliferation. As a causative role for deregulated Notch in T-
ALL is well established, this model is best suited to study the consequences of Notch 
inhibition on cell proliferation. In this study, the T-ALL model could have been useful 
to study the biological effects of Antp-DN-MAML1 and should be considered for 
future studies.   
In order to understand the anti-proliferative effect of Antp-DN-MAML1 on MDA-
MB-231, it was important to consider other functions of MAML-1 aside from its 
effects on the Notch pathway. A study by Zhao et al. revealed that MAML-1 can 
interact with p53 via its N-terminal region (1-302), increasing transactivation of the 
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target gene p21 (Zhao et al., 2007). Therefore, it was possible that MAML-1 (13-74) 
could bind and stabilise p53, increasing p21 expression and leading to cell death by 
apoptosis (see section 1.1.11). In future studies, binding of MAML-1 (13-74) to p53 
should be assessed. Assessment of p21 expression levels by qRT-PCR revealed an 
increase upon treatment of MDA-MB-231 cells with Antp-DN-MAML1 but not with 
controls. Experiments using flow cytometry confirmed that MDA-MB-231 cells died 
by apoptosis rather than necrosis. p21 expression showed an increase when assessed 
in parallel. Doxorubicin was used as a positive control, showing an IC50 value of 0.16 
μM (72 hour treatment). An IC50 value of 1.26 ± 0.39 is reported for doxorubicin 
treatment of MDA-MB-231 cells for 24 hours (Costantini et al., 2010). 
Based on the results obtained in the in vitro studies using Antp-DN-MAML1 to 
inhibit MDA-MB-231 cell proliferation, an in vivo study was designed to test the 
effect of this drug on tumour growth in mice. Mice were xenografted with the same 
cells, MDA-MB-231, the choice of doses and therapy schedule being based on 
previous experience in the laboratory. Antp-DN-MAML1 was injected in parallel 
with PBS and paclitaxel as controls. Paclitaxel (Taxol) is a mitotic inhibitior used as a 
standard for chemotherapy of breast cancers. Antp-DN-MAML1 treatment resulted in 
tumours only marginally increasing in size compared to controls. In these 
experiments, the reasons for inhibition of tumour growth were not assessed but, given 
the in vitro data, it is possible that they are unrelated to the inhibitory effect of Antp-
DN-MAML1 on Notch signalling but related to its effects on promoting apoptosis.  
 
Concluding remarks 
This study showed successful production of the control protein Antp confirming 
soluble expression as the preferred method of expression for the correct folding of this 
protein. Native folding with the characteristic triple helix is believed to be a key factor 
in the function of this protein as a carrier for intracellular delivery.  
Fusion of the Antp protein to its cargo DN-MAML1 increased the difficulty in the 
production of this fusion. Despite several attempts to optimise the expression and 
refolding protocols, Antp-DN-MAML1 was finally obtained through peptide 
synthesis. 
In vitro studies demonstrated the ability of Antp-DN-MAML1 to inhibit the Notch 
pathway although it was also shown to affect p53 target gene expression. The fusion 
protein affects proliferation of MDA-MB-231 cells in vitro and in vivo. The study 
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suggests that this effect might be due to concurrent modulation of cellular pathways 
including Notch and p53 signalling. 
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CHAPTER 4 
 
Phage display selection of a scFv against DN-MAML1 and its fusion 
to Antp 
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4.1 Introduction 
 
The aim of this part of the project was to inhibit Notch signalling using antibody 
fragments fused to Antp to enable their successful intracellular delivery. Once 
internalised, the fusion should block tripartite complex formation by targeting 
MAML-1 interactions with N
IC
 and CSL. As residues 13–74 constitute the minimal 
MAML-1 portion necessary to form the active complex, we expected any scFv that 
binds this portion to inhibit downstream signalling. As a scFv binding to MAML-1 
(13-74) is not readily available, the technique of phage display was employed to select 
such scFv from an ample library.  
Several factors affect the successful outcome of a phage display selection (Figure 4.1) 
including: 
 
Antigen utility 
The quality and condition of the target antigen are of extreme importance for a 
successful selection. Two strategies of antigen exposure are widely used: direct 
immobilisation of the antigen on microtitre plates (Marks et al., 1991) or solution 
capture with biotinylated antigen (Hawkins et al., 1992; Sawyer et al., 1997). In the 
latter, isolation of the biotinylated antigen following binding is achieved using 
paramagnetic beads coupled to avidin.  
 
Selection strategy 
When the phage library is exposed to the antigen, there are various variables to take 
into account including: the length of binding time, pH and ionic strength, temperature, 
coated antigen levels and the stringency of washes. In the first round of selection, 
washes are less stringent to account for the low presence of individual clones (Schier 
and Marks, 1996). Washes become more stringent in subsequent rounds to select high 
affinity binders. In an industrial setting, multiple combinations of different settings 
would be assessed using a robotic system. 
 
Elution 
Various methods are used to elute the bound phages: alterations in pH using glycine 
or TEA based buffers (Griffiths et al., 1993), elution with excess antigen (Clackson et 
al., 1991), proteolytic/chemical cleavage between the coat protein and antibody 
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fragment (Goletz et al., 2002). Following elution, output phages are amplified by 
infection of E.coli before a second round of selection. In most cases, 3-4 rounds of 
phage display are sufficient for successful enrichment of high-affinity antigen binding 
clones.  
 
Screening 
Screening of output clones can occur at various stages of the phage display selection. 
This consists of phage-ELISAs to assess antigen specificity and ELISAs with soluble 
scFvs to check for functional expression levels. Further analysis includes DNA 
sequencing.  
 
 
Figure 4.1: The phage display selection cycle. Taken from Current Protocols in 
Immunology (2002) Unit 10.19B. 
 
The phage display vector system allows for expression of scFvs fused to pIII and 
scFvs alone without the need for re-cloning. Expression is switched between the two 
types depending on which bacterial strain is employed. In the amber suppressor strain 
XL1-blue, the amber stop codon present between the scFv and pIII is read through as 
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a Glu residue. In non-suppressing E.coli HB2151 the presence of the stop codon halts 
transcription. 
Binding of the scFv-phagemid or purified scFv candidates to MAML-1 (13-74) is 
verified by ELISA binding studies. This colorimetric assay allows the detection of 
protein binding to a coated antigen. Measurement of binding relies on substrate 
conversion by an enzyme conjugated onto a primary or secondary antibody.  
 
4.2 Aims and objectives 
 
 Following a cloning step, express, purify and refold DN-MAML1 according to 
an established protocol. Carry out a circular dichroism analysis of the DN-
MAML1 protein to confirm its correct refolding. 
 Verify successful coating of DN-MAML1 onto the surface of phage display 
tubes and undergo three rounds of phage display selection. 
 High through put screening of anti-DN-MAML1 scFv-phagemid by ELISA 
followed by selective screening on a bigger production scale. 
 Sequencing analysis of the scFv candidates in order to eliminate any identical 
clones and to identify any stop codons.  
 Carry out the expression of candidate scFvs as secreted proteins using the 
HB2151 E.coli strain and purify the proteins by affinity chromatography. 
 scFv binding studies by ELISA to determine the individual Kd values. 
 Following cloning, optimise the expression protocol for production of Antp-
scFv fusions, evaluating the use of a secretion system. 
 Determine the Kd value for Antp-scFv fusions binding to DN-MAML1. 
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4.3 Results 
 
4.3.1 Expression, purification and characterisation of DN-MAML1 
 
To our knowledge, a scFv binding MAML-1 (13-74) is not available. Therefore, it 
was necessary to express and purify this truncated version of MAML-1 as the antigen 
for a phage display selection. MAML-1 (13-74) corresponds to the DN-MAML1 
portion of our fusion protein Antp-DN-MAML1. Following a cloning step to excise 
Antp from the pRSET A construct (see section 2.1.3), DN-MAML1 was successfully 
expressed intracellularly in BL21 (DE3) pLysS cells (Figure 4.2).  
 
Table 4.1: DN-MAML1 characteristics derived from ProtParam on the ExPASy 
Server 
parameter value 
Theoretical pI 10.76 
Molecular weight (Da) 7454.6 
Amino acid residues 62 
Extinction coefficient (M
-1
 cm
-1
)
 
1490 
 
However, solubilisation of DN-MAML1 from inclusion bodies was necessary (Figure 
4.2). The denatured protein was purified by IMAC. All samples were analysed by 
reducing 12% SDS-PAGE and stained using Coomassie Blue (Figure 4.2A). A 
Western blot using HRPO conjugated murine α-His antibody was also performed to 
confirm the identity of the purified protein (Figure 4.2B). DN-MAML1 was present in 
the elution fractions as a band migrating between 15 kDa and 10 kDa. This is greater 
than its predicted molecular weight of 7.5 kDa and could be due to the high positive 
charge on DN-MAML1 (Table 4.1). 
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Figure 4.2: Expression and purification of DN-MAML1 in pRSET A transformed in 
BL21 (DE3) plysS cells.  The bacterial culture was grown in 500 ml of LB media up 
to an OD600 of 0.8. The culture was then induced using 1 mM IPTG overnight at 
37°C. The supernatant (S) and pellet (P) fractions of the expression culture were 
analysed by reducing 12% SDS-PAGE, stained using Coomassie Blue (A). The 
corresponding α-His Western blot is also shown (B). DN-MAML1 is present, as a 
band migrating between 15 kDa and 10 kDa. The cell pellet was lysed under 
denaturing conditions. DN-MAML1 is present exclusively in the soluble (S) fraction 
as a denatured protein.  This was applied to an IMAC column. The column was 
washed (W) extensively before elution (E) of DN-MAML1. 
 
 
 
DN-MAML1 was refolded by extensive dialysis against 5% acetic acid. As illustrated 
in Figure 4.3A, the majority of DN-MAML1 was recovered in the soluble phase 
whereas most contaminants precipitated upon refolding. Finally, DN-MAML1 was 
lyophilised overnight and re-dissolved in dH2O (Figure 4.3B). The DN-MAML1 prep 
is over 90% pure.   
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Figure 4.3: DN-MAML1 refolding. A) Following dialysis against 5% acetic acid for 
24 hours, the insoluble (I) was separated from the soluble (S) material by 
centrifugation. Both fractions were analysed by reducing 12% SDS-PAGE, stained 
using Coomassie Blue. The corresponding α-His Western blot is also shown. B) DN-
MAML1 was lyophilised overnight and re-dissolved in dH2O. 
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In order to confirm the secondary structure and folding properties of DN-MAML1 
following refolding, circular dichroism analysis was performed on the purified 
protein. Different structural elements have characteristic CD spectra (Figure 2.2). As 
shown in Figure 4.4, the CD spectra of DN-MAML1 suggests a strong α-helical 
content of 41%. This value is inferior to the predicted α-helical content of 63% 
assigned to DN-MAML1 in silico. This could be due to sub optimal refolding of the 
protein.  
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Figure 4.4: Circular dichroism spectra of DN-MAML1 at 100 μg/ml in dH2O using a 
1mm path cuvette. 
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In order to determine the coating efficiency of DN-MAML1 on ELISA plates, this 
protein was serially diluted in PBS pH 7.4 and coated overnight. Following blocking, 
coated protein was detected using α-His HRPO IgG (Figure 4.5). A concentration of 
20 μg/ml was chosen for further experiments.  
 
 
 
 
Figure 4.5: ELISA showing coating efficiency of DN-MAML1 on plastic plates. DN-
MAML1 was serially diluted, coated onto an ELISA plate overnight and detected by 
α-His IgG. Absorbance values at 450 nm were measured and background signals (no 
coated protein) were deducted. Error bars represent the standard deviation between 
triplicates. Curve fitted using SigmaPlot
®
 software.  
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4.3.2 Phage display 
 
After three rounds of affinity selection (biopanning), approximately 500 colonies 
were screened on a 96 well plate format to identify antigen-binding scFv-displaying 
monoclonal phage. Briefly, single colonies were grown in order to rescue monoclonal 
phage and assess its binding on ELISA plates coated with 20 μg/ml of DN-MAML1. 
The results of this initial screening are shown in Figure 4.6, where ‘hits’ have been 
highlighted with arrows and colony reference name.  
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Figure 4.6: Screening of candidate monoclonal phage by ELISA (plates 1 to 5). 
Binding of the scFv-diplaying phage to DN-MAML1 was detected using Anti-M13 
and is represented by high absorbance reading at 450 nm. The background absorbance 
value was deducted from all readings. Clones were selected based on high absorbance 
values relative to the corresponding plate and are indicated by an arrow. 
 
 
 
 
Promising candidates were subsequently screened on a 5 ml culture format with 
recovery of rescued phages by PEG/NaCl precipitation. At this screening stage, 
E11P5 and G5P5 rescued phage did not show consistent strong binding to DN-
MAML1 and was consequently discarded (Figure 4.7).  
The remaining rescued phage candidates (excluding E12P4) showed strong binding to 
DN-MAML1 but not to uncoated ELISA plates, thus eliminating the possibility of 
having selected plastic surface binders (Figure 4.8). The reason for E12P4 not 
showing any binding, could be the unsuccessful precipitation of rescued phage or the 
instability of this clone. 
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Figure 4.7: Binding of rescued E11P5 and G5P5 scFv-phagemid to DN-MAML1. 
Binding was detected using Anti-M13 and is measured by an absorbance reading at 
450 nm. Error bars represent the standard deviation between triplicates. 
 
 
 
Figure 4.8: Screening of rescued monoclonal scFv-phagemid by ELISA. Binding of 
the scFv-displaying phage to DN-MAML1 (grey bars) was detected using Anti-M13 
and is represented by high absorbance reading (>0.5) at 450 nm. The background 
absorbance value was deducted from all readings. Binding to uncoated ELISA plates 
was assessed in parallel to eliminate any plastic surface binders (red bars). Error bars 
represent the standard deviation between triplicates. 
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In order to distinguish between identical and unique clones amongst positive binders, 
their DNA was sequenced. As shown in Figure 4.9, the seven candidates resulted to 
be three unique clones. In particular, G7P4 = G7P5 = E12P4 = D7P5 and E7P3 = 
F5P3. Sequence analysis also revealed a stop codon at the start of the E7P3 (F5P3) 
open-reading frame which had to be removed by single point mutation (section 2.1.3) 
before expression in the HB2151 strain.   
 
G7P4            PAMAQVQLLQSAGGLVQPGGSLRLSCAASGFNFNNYAMSWVRQAPGKGLEWVSDISGTGG  
G7P5            PAMAQVQLLQSAGGLVQPGGSLRLSCAASGFNFNNYAMSWVRQAPGKGLEWVSDISGTGG  
E12P4           PAMAQVQLLQSAGGLVQPGGSLRLSCAASGFNFNNYAMSWVRQAPGKGLEWVSDISGTGG  
D7P5            PAMAQVQLLQSAGGLVQPGGSLRLSCAASGFNFNNYAMSWVRQAPGKGLEWVSDISGTGG  
H8P5            PAMAQVQLLQSAGGLVQPGGSLRLSCTASGFIFN-YAMSWVRQAPGKGLEWISGISLGGD  
E7P3            PAMA-VQLQESGPRLVKPSETVSLRCAVSGASVTSYSWNWIRQAPGKGLEWIGYFSKYG-  
F5P3            PAMA-VQLQESGPRLVKPSETVSLRCAVSGASVTSYSWNWIRQAPGKGLEWIGYFSKYG-  
                    x   ** ***  * ***** * **  ***** *** *          **** ** * 
                                          #    #  #                # #  ## # 
 
G7P4            TTKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCAKRYCSGGSCYSIDHWGQGT  
G7P5            TTKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCAKRYCSGGSCYSIDHWGQGT  
E12P4           TTKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCAKRYCSGGSCYSIDHWGQGT  
D7P5            TTKYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCAKRYCSGGSCYSIDHWGQGT  
H8P5            TTKYADSVKGRFTISRDTSKNTLYLQMSSLRAEDTAVYYCARRYCSGGSCYSIDHWGKGT  
E7P3            NDRYNPSYKSRVTVSVDTSNNQFSLRLGSVTAADTAIYYCAK---WNDEFRAFDIWGQGT  
F5P3            NDRYNPSYKSRVTVSVDTSNNQFSLRLGSVTAADTAIYYCAK---WNDEFRAFDIWGQGT  
                *** ** * * * * * * * *** *** ** *   *    ************ *        
                                 #                  #    #               #    
 
G7P4            LVTVSSGGGGSGGGGSGGGGSDIQMTQSPSTLSASIGDRVTITCRASEGIYHWLAWYQQK  
G7P5            LVTVSSGGGGSGGGGSGGGGSDIQMTQSPSTLSASIGDRVTITCRASEGIYHWLAWYQQK  
E12P4           LVTVSSGGGGSGGGGSGGGGSDIQMTQSPSTLSASIGDRVTITCRASEGIYHWLAWYQQK  
D7P5            LVTVSSGGGGSGGGGSGGGGSDIQMTQSPSTLSASIGDRVTITCRASEGIYHWLAWYQQK  
H8P5            MVTVSSGGGGSGGGGSGGGGSDIQMTQSPSTLSASIGDRVTITCRASEGIYHWLAWYQQK  
E7P3            MVTVSSGGGGSGGGGSGGGGS-SELTQDP-AVSVALGQTVRITCQGDSLRSYYTNWFQQK  
F5P3            MVTVSSGGGGSGGGGSGGGGS-SELTQDP-AVSVALGQTVRITCQGDSLRSYYTNWFQQK  
                *                    ****  * *** *** ** *   *********** *     
                #                                                             
 
G7P4            PGKAPKLLIYKASSLASGAPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQY--SNYPLT  
G7P5            PGKAPKLLIYKASSLASGAPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQY--SNYPLT  
E12P4           PGKAPKLLIYKASSLASGAPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQY--SNYPLT  
D7P5            PGKAPKLLIYKASSLASGAPSRFSGSGSGTDFTLTISSLQPDDFATYYCQQY--SNYPLT  
H8P5            PGKAPKLLIYKASSLASGAPSRFSGSGSGTDFTLTISSLRPDDFATYYCQQY--SNYPLT  
E7P3            PGQAPLLVVYAKNKRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCHSRDSSGNHVL  
F5P3            PGQAPLLVVYAKNKRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCHSRDSSGNHVL  
                  *  **** ******  * *        ****   ******** *   ***** ***** 
                                                       #                     
 
G7P4            FGGGTKLEIKRAAAHHHHHH  
G7P5            FGGGTKLEIKRAAAHHHHHH  
E12P4           FGGGTKLEIKRAAAHHHHHH  
D7P5            FGGGTKLEIKRAAAHHHHHH  
H8P5            FGGGTKLEIKRAAAHHHHHH  
E7P3            FGGGTKLTVLGAAAHHHHHH  
F5P3            FGGGTKLTVLGAAAHHHHHH  
                       **** 
                    
 
yellow: end of leader sequence  blue: vH  red: linker  green: vL  pink: His tag 
x: stop codon  
*: difference between G7P4 and E7P3 #: difference between G7P4 and H8P5 
 
Figure 4.9: Amino acid sequence alignment for 7 α-DN-MAML1 scFv candidates. 
The amino acid sequences of 7 scFvs were aligned using ClustalW (Thomson et al. 
1994).   
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 4.3.3 Expression and purification of candidate α-DN-MAML1 scFvs 
 
The DNA construct of each remaining candidate (G7P4, E7P3 and H8P5) was 
transformed in HB2151 cells for expression of secreted scFvs on a large scale. Each 
culture supernatant was concentrated, dialysed into PBS pH 7.4, and applied to an 
IMAC column (nickel). All samples were analysed by reducing 12% SDS-PAGE and 
stained using Coomassie Blue (Figure 4.10A, 4.11A, 4.12A). A Western blot using 
HRPO conjugated murine α-His antibody was also performed in parallel (Figure 
4.10B, 4.11B, 4.12B). ScFvs run as a band migrating between 35 kDa and 25 kDa 
corresponding to their predicted molecular weight of 30 kDa and are present in the all 
elution fractions. Analysis of the flow-through sample reveals that not all the His-
tagged protein is bound to the affinity column. This could be due to poor affinity 
binding or saturation of the nickel column. It is important to note the multiple bands 
detected by the Western blot. In the early elutions, there are two close bands on the 
blot. The second band is likely to correspond to scFv still attached to its leader 
sequence for secretion. In the latter elutions, a band corresponding to 15 kDa is also 
present. This suggests cleavage in the exposed linker region. The imidazole eluted 
protein samples were pooled together, concentrated and dialysed before final gel 
analysis (Figure 4.13). The final scFv preparations are over 90% pure. 
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Figure 4.10: Purification of H8P5 scFv by affinity chromatography. IMAC flow-
through (FT), wash (W) and elution fractions analysed by reducing 12% SDS-PAGE 
and stained using Coomassie Blue (A). The corresponding α-His Western blot is also 
shown (B). H8P5 scFv is present as a band migrating between 35 kDa and 25 kDa in 
the FT and all elution fractions, starting from the addition of 10 mM imidazole.  
S= soluble fraction before column. 
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Figure 4.11: Purification of E7P3 scFv by affinity chromatography. IMAC flow-
through (FT), wash (W) and elution fractions analysed by reducing 12% SDS-PAGE 
and stained using Coomassie Blue (A). The corresponding α-His Western blot is also 
shown (B). E7P3 scFv is present as a band migrating between 35 kDa and 25 kDa in 
the FT and all elution fractions up to 100 mM imidazole. S= soluble fraction before 
column. 
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Figure 4.12: Purification of G7P4 scFv by affinity chromatography. IMAC flow-
through (FT), wash (W) and elution fractions analysed by reducing 12% SDS-PAGE 
and stained using Coomassie Blue (A). The corresponding α-His Western blot is also 
shown (B). G7P4 scFv is present as a band migrating between 35 kDa and 25 kDa in 
the FT, wash and all elution fractions. S= soluble fraction before column.  
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Figure 4.13: scFv samples following final concentration and dialysis. A) H8P5 B) 
E7P3 C) G7P4 analysed by reducing 12% SDS-PAGE and stained using Coomassie 
Blue. The corresponding α-His Western blot is also shown. scFvs are present as a 
band migrating between 35 kDa and 25 kDa. 
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4.3.4 ScFv binding studies 
 
The antigen used in the phage display selection includes some extra sequence other 
than DN-MAML1:  the vector encoded N-terminal His tag, the T7 gene 10 sequence 
and the N-terminal Xpress™ epitope tag. It was thus necessary to determine whether 
any of the binding scFv candidates recognised this extra sequence rather than the 
relevant antigen DN-MAML1. For this, scFvs were screened again for binding to 
synthetic Antp-DN-MAML1. This protein was coated at 50 μg/ml giving a similar 
coating efficiency to DN-MAML1 at 20 μg/ml (data not shown). Two concentrations 
of pure E7P3 scFv were added in triplicate to a plate coated with DN-MAML1 or 
Antp-DN-MAML1.  Incubation with 9E10 IgG (α-c-Myc), followed by goat α-mouse 
HRPO, was used to detect binding. Background signals (antigen replaced by PBS) are 
plotted as a negative control. As shown in Figure 4.14, E7P3 did not bind to Antp-
DN-MAML1 therefore this candidate was discarded. In contrast, binding to Antp-DN-
MAML1 was confirmed for H8P5 and G7P4 (Figure 4.15).  
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Figure 4.14: ELISA showing binding of E7P3 to DN-MAML1 but not to Antp-DN-
MAML1. Two concentrations of E7P3 were added to a plate coated with DN-
MAML1 (20 μg/ml) or Antp-DN-MAML1 (50 μg/ml) and detected by α-c-Myc. 
Absorbance values at 450 nm were measured and background signals (antigen 
replaced by PBS) are plotted as a negative control. Error bars represent the standard 
deviation between triplicates. One-way ANOVA was used to statistically compare 
conditions; p ≤ 0.05 was considered significant. *p ≤ 0.05, **p ≤ 0.01; ns: not 
significant. 
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Figure 4.15: ELISA showing binding of G7P4 and H8P5 to immobilised Antp-DN-
MAML1. Two concentrations of G7P4 and H8P5 were added to a plate coated with 
Antp-DN-MAML1 (50 μg/ml) and detected by α-c-Myc. Absorbance values at 450 
nm were measured and background signals (antigen replaced by PBS) are plotted as a 
negative control. Error bars represent the standard deviation between triplicates. One-
way ANOVA was used to statistically compare conditions; p ≤ 0.05 was considered 
significant. **p ≤ 0.01; 
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The only extra sequence in common between the synthetic Antp-DN-MAML1 
construct and the vector encoded extra sequence is the His tag. In order to exclude 
binding of H8P5 and G7P4 to the tag, an irrelevant His-tagged protein (Tetanus toxin 
heavy chain: TT-Hc) was coated in parallel with Antp-DN-MAML1. Coating 
efficiency was very low for TT-Hc in both PBS pH 7.4 and carbonate buffer (data not 
shown) even when coated at a maximum of 200 μg/ml. Antp-DN-MAML1 was 
coated at 5 μg/ml to achieve comparable coating levels (similar α-His signals, data not 
shown). Due to the minimal coating, binding signals are lower than usual but it is 
clear that G7P4 and H8P5 bind to Antp-DN-MAML1 but not to His-tagged TT-Hc 
(Figure 4.16).   
 
 
 
 
Figure 4.16: ELISA showing binding of G7P4 and H8P5 to Antp-DN-MAML1 but 
not to tetanus toxin heavy chain (TT-Hc). Several concentrations of G7P4 and H8P5 
were added to a plate coated with Antp-DN-MAML1 (5 μg/ml) or tetanus toxin (200 
μg/ml) and detected by α-c-Myc. Absorbance values at 450 nm were measured and 
background signals (antigen replaced by PBS) are plotted as a negative control. Error 
bars represent the standard deviation between triplicates. One-way ANOVA was used 
to statistically compare conditions; p ≤ 0.05 was considered significant. *p ≤ 0.05, 
**p ≤ 0.01, ***p ≤ 0.001. 
 
***
*
*
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The Kd for the H8P5 and G7P4 scFv was determined by ELISA on DN-MAML1 
coated plates. Incubation with 9E10 IgG, followed by goat α-mouse HRPO, was used 
to detect binding. The calculated Kd value was 114 nM for G7P4 and 98 nM for H8P5 
(Figures 4.17 and 4.18).  
 
 
 
Figure 4.17: ELISA showing binding of G7P4 to immobilised DN-MAML1. G7P4 
was serially diluted against a DN-MAML1 (20 μg/ml) coated plate and detected by α-
c-Myc. Absorbance values at 450 nm were measured and background signals (no 
antigen) were deducted. Error bars represent the standard deviation between 
triplicates. Curve fitted using SigmaPlot
®
 software.  
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Figure 4.18: ELISA showing binding of H8P5 to immobilised DN-MAML1. H8P5 
was serially diluted against a DN-MAML1 (20 μg/ml) coated plate and detected by α-
c-Myc. Absorbance values at 450 nm were measured and background signals (no 
antigen) were deducted. Error bars represent the standard deviation between 
triplicates. Curve fitted using SigmaPlot
®
 software.  
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4.3.5 Production of Antp-scFv fusions 
Production of Antp fused to an irrelevant scFv (N4), in both orientations, was carried 
out in parallel with phage display selection in order to determine which expression 
and purification strategies are best suited for antibody-based fusion constructs. 
N4 was subcloned upstream and downstream of Antp in the pET20b vector which 
includes a signal sequence, facilitating export into the periplasmic space (section 
2.1.3). This strategy is best suited for expression of soluble fusions as it promotes 
correct folding and disulfide bond formation of the scFv portion. 
Despite numerous trials, varying several conditions (media, IPTG concentration, 
temperature and OD600 value upon induction) no expression was obtained for the N4-
Antp orientation in BL21 (DE3) pLysS cells (data not shown). Good expression levels 
were achieved for the Antp-N4 construct although this was not secreted (Figure 4.19). 
As illustrated in Figure 4.20, Antp-N4 is present in the pellet fraction of lysed cells 
suggesting that this protein is expressed insolubly.  
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Figure 4.19: Small scale expression trials of Antp-N4 in pET20b transformed in BL21 
(DE3) pLysS cells. The bacterial culture was grown in 5 ml of 2TY (A) or LB (B) up 
to an OD600 of 0.8 before induction with either 0.1 mM or 1 mM IPTG for 4 hours at 
37°C/ 30°C. The culture was centrifuged before analysis of the secreted (S) and cell 
pellet (P) fractions by α-His Western blot. Antp-N4 is present as a band migrating 
between 40 kDa and 35 kDa.  
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Figure 4.20: Antp-N4 is expressed in inclusion bodies. Gel and α-His Western blot 
analysis of the soluble (S) and insoluble fractions (I) following 0.1% Igepal treatment 
and sonication of the expression pellet. 
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Expression studies for the α-DN-MAML1 scFvs fused to Antp in both orientations, 
were carried out in parallel with binding studies for the scFv alone. Although E7P3 
did not bind to DN-MAML1, it is still an acceptable model to study expression due to 
the similarity of the constructs. E7P3 was subcloned upstream and downstream of 
Antp in the pET20b vector (section 2.1.3). No expression was ever obtained for the 
E7P3-Antp orientation in BL21 (DE3) pLysS cells (data not shown). An expression 
trial for Antp-E7P3 at a lower temperature (25°C) using two IPTG concentrations was 
monitored at 1, 2 and 4 hours post-induction (Figure 4.21). Good expression levels 
with increased yield over time were achieved but the fusion was not secreted. 
Additional expression trials at 18°C (data not shown) or by autoinduction (Figure 
4.22) did not improve on this approach. 
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Figure 4.21: Small scale expression trials of Antp-E7P3 in pET20b transformed in 
BL21 (DE3) pLysS cells. The bacterial culture was grown in 5 ml of 2TY up to an 
OD600 of 0.8 before induction with either 0.1 mM or 1 mM IPTG for 1,2 and 4 hours 
at 25°C. The culture was centrifuged before analysis of the secreted (S) and cell pellet 
(P) fractions by reducing 12% SDS-PAGE stained using Coomassie Blue and α-His 
Western blot. Antp-E7P3 is present as a band migrating between 40 kDa and 35 kDa 
in the pellet fractions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
40 kDA
35 kDA
40 kDA
35 kDA
S P
0.1 mM 0.1 mM1 mM 1 mM [IPTG]
1h 2h 4h 1h 2h 4h 1h 2h 4h 1h 2h 4hLadder
Antp-E7P3
 160 
 
 
Figure 4.22: Expression of Antp-E7P3 in pET20b transformed in BL21 (DE3) pLysS 
cells by autoinduction. The overnight culture, grown in autoinduction media at 20°C 
overnight, was centrifuged before analysis of the secreted (S) and cell pellet (P) 
fractions by reducing 12% SDS-PAGE stained using Coomassie Blue and α-His 
Western blot. Antp-E7P3 is present as a band migrating between 40 kDa and 35 kDa 
in the pellet fraction.  
 
 
 
 
 
 
 
Antp-G7P4 and Antp-H8P5 were expressed on a large scale with induction by 1 mM 
IPTG at 25°C (Figue 4.23). Both inclusion body pellets were processed and 
solubilised. A refolding strategy was attempted for Antp-H8P5 only, due to limitation 
of resources (Figure 4.24). The protocol, previously optimised for Antp-N4, is 
tailored to the refolding of antibody fragments by including the presence of a redox 
reagent. Refolding occurred overnight at 10°C. Overall, yields after refolding were 
low due to precipitation. The soluble fraction was dialysed in PBS buffer and 
concentrated using a 5000 kDa spin concentrator. Antp-H8P5 is over 85% pure 
(Figure 4.25).  
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Figure 4.23: Expression of Antp-G7P4 and Antp-H8P5 in pET20b transformed in 
BL21 (DE3) pLysS cells. Each bacterial culture was grown in 1L of 2TY up to an 
OD600 of 0.8 before induction with 1 mM IPTG for 5 hours at 25°C. The culture was 
centrifuged before analysis of the secreted (S) and cell pellet (P) fractions by reducing 
12% SDS-PAGE stained using Coomassie Blue and α-His Western blot. Antp-G7P4 
and Antp-H8P5 are present as a band migrating between 40 kDa and 35 kDa in the 
pellet fractions.  
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Figure 4.24: Analysis of the soluble fractions during denaturation and refolding of 
Antp-H8P5. Fractions were analysed by reducing 12% SDS-PAGE, stained using 
Coomassie Blue. Antp-H8P5 is present as a band migrating between 40 kDa and 35 
kDa. The corresponding anti-his Western blot is also shown. 
1= soluble fraction following denaturing of the inclusion body pellet using 6M 
guanidinium chloride. 2= soluble fraction following refolding at 10°C. 
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Figure 4.25: Soluble Antp-H8P5 following final dialysis and concentration. The 
sample was analysed by reducing 12% SDS-PAGE stained using Coomassie Blue and 
α-His Western blot. Antp-H8P5 is present as a band migrating between 40 kDa and 35 
kDa in the pellet fractions. 
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Finally, it was necessary to determine whether H8P5 scFv retained its binding 
properties when fused to Antp, following refolding. The fusion protein did not contain 
a c-Myc tag for detection so another strategy was chosen. In this experiment, the 
fusion was coated onto ELISA plates. The antigen DN-MAML1 was biotinylated for 
detection using extravidin peroxidase HRPO (Figure 4.26). Binding to the plastic 
surface was assessed along with other controls including: PBS instead of antigen and 
addition of DN-MAML1 (no biotin) both on the coated and uncoated portion of the 
ELISA plate. 
A Kd value of 438 nM was calculated for Antp-H8P5. This is not directly comparable 
to H8P5 scFv binding as the detection method is entirely different. Nevertheless, 
binding between the fusion and DN-MAML1 was confirmed. 
 
 
 
Figure 4.26: ELISA showing binding of biotinylated DN-MAML1 to immobilised 
Antp-H8P5. In triplicate, biotinylated DN-MAML1 was serially diluted against a 
Antp-H8P5 coated plate. Extravidin peroxidase HRPO was used to detect binding. 
Absorbance values at 450 nm were measured and background signals (no antigen) 
were deducted. Curve fitted using SigmaPlot
®
 software.  
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4.3.6 Mammalian expression trials for Antp-H8P5 
Testing of the Antp-H8P5 scFv fusion in the luciferase reporter-gene assay was 
necessary to verify whether delivery of a scFv against DN-MAML1 successfully 
inhibits Notch signalling. However, the refolding protocol did not scale enough to 
achieve the amount needed for addition of this potential drug at high doses. Next, we 
investigated whether mammalian expression in CHO cells could give better, soluble 
yields of fusion protein. The wild type CHO K cell line was used as the standard 
expression system. Transfection was also attempted in CHO N2 cells to explore the 
recombinant protein’s action in the CHO luciferase system itself, without purification. 
For this, Antp-H8P5 and Antp were cloned into pcDNA4a (Δ Pci I) containing a 
leader sequence. Both transient and polyclonal stable expression were attempted. No 
fusion protein was ever detected by anti-His Western blot either in the concentrated 
supernatant or lysed cell pellet fractions. Antp was detected in the lysed cell pellet 
exclusively but this result was not reproducible. This suggests the protein is produced 
in an inactive form as it is unable to cross the cellular membrane. In the polyclonal 
stable expression system, zeocin selection confirmed that transfection was successful. 
It is important to note that detection relies on the presence of the His tag at the C-
terminal end of the protein. If the His tag had been removed by proteolytic cleavage, 
the protein would not be detectable on the Western blot. A commercial anti-Antp is 
available although, when previously tested on Antp produced in-house, the Western 
blot had a negative outcome. Our collaborators also tested this antibody and binding 
was only observed to Pichia expressed Antp-DN-MAML1 protein. This suggests that 
the antibody binds to Antp after it has undergone some form of post-translational 
modification.      
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4.4 Discussion 
The aim of this study was to select anti-MAML (13-74) scFvs and fuse them to Antp 
for inhibition of Notch signalling. The antigen MAML (13-74), also known as DN-
MAML1 was produced following an established protocol involving refolding of the 
protein using acetic acid. The published structures of DN-MAML1 in complex with 
CSL and N
IC
 were also obtained using refolded protein (Nam et al., 2006). This is 
encouraging for recovery of the original fold of DN-MAML1. A circular dichroism 
analysis of DN-MAML1 showed a high helical content, confirming successful 
refolding. Three rounds of phage display selection on immobilised DN-MAML1 were 
carried out using a human naïve scFv library. In order to maximise the chances of 
selecting a high affinity antibody fragment, it would have been preferable to employ 
an immunised library. However, this was not readily available and would yield 
murine/rabbit scFvs to be subsequently humanised.  
A first high-through put screening of colonies revealed a number of positive 
phagemid binding to DN-MAML1. Sequencing analysis of positive clones revealed 
the presence of duplicate phagemids, restricting the analysis to three clones: H8P5, 
G7P4 and E7P3. It is interesting to note the similarity between H8P5 and G7P4. The 
low number of different clones is expected as the library used is naïve and of human 
origin, like the antigen.  
In order to further characterise the scFv candidates, these were expressed in the 
HB2151 strain which does not allow read-through to the pIII sequence. Expression 
was successful for all clones, with slight differences in yields. This observation could 
be related to the small variations in the genetic sequences and the presence of 
more/less favourable codons.    
The antigen used in the phage display selection included some extra vector encoded 
sequence other than DN-MAML1. Binding studies revealed that E7P3 did not bind 
the relevant DN-MAML1 sequence and was discarded. The key point to study 
binding of scFv to different portions of the DN-MAML1 construct is to achieve 
similar binding onto the plastic surface. This is essential in order to obtain comparable 
and reliable results. Equal starting antigen concentrations do not guarantee similar 
coating. Coating efficiency varies for each protein depending on their 
hydrophobic/hydrophilic profile and can be improved by the use of different buffers. 
In this study, similar development values (absorbance at 450nm) were considered as 
the best read out for coating efficiency. 
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ELISA binding studies allowed the calculation of a Kd value of 114 nM and 98 nM for 
G7P4 and H8P5, respectively. These values are within the range expected from naïve 
library selections (Griffiths et al., 1993). Further studies should include the study of 
binding kinetics using surface plasmon resonance. This method is widely used in the 
field of antibody technology and provides additional information in order to compare 
one scFv to the other and perform competition studies.   
In order to achieve cell penetration, scFvs were fused to Antp, considering both 
orientations (Antp-scFv and scFv-Antp). Expression trials revealed that only the 
Antp-scFv orientation was successfully produced. Therefore, scFv-Antp fusions were 
not characterised further. One possibility is that the scFv-Antp fusion was produced as 
a truncated protein lacking the C-terminal tags and therefore could not be detected by 
Western blot.  
Despite employing a vector for secretion of the expressed protein to facilitate folding, 
Antp-scFv fusions were never detected in the culture supernatant. Initial studies using 
Antp-N4 as a model (N4 being an irrelevant scFv with expression yields of >20 
mg/L) showed that the fusion was expressed insolubly in the cytoplasm. Further 
efforts to express the fusions solubly included the use of: different media (LB, 2TY, 
autoinduction), temperatures (18°C, 20°C, 25°C, 30°C, 37 °C), IPTG concentrations 
(0.1 mM and 1 mM), induction length (1h, 2h, 4h, 5h and overnight). Generally, 
alternative conditions such as different media, lower temperatures and lower IPTG 
concentrations were explored in order to attenuate the stress to cells during 
expression. In particular, the use of autoinduction media has proven successful for a 
variety of proteins that were otherwise produced insolubly (Studier, 2005). Exploring 
different induction times was related to the observations made during expression trials 
for Antp-DN-MAML1. There are various examples of scFv fusion proteins that fail to 
secrete and are insoluble even if the scFv alone was successfully secreted and soluble 
(Linardou et al., 2000; Kipriyanov et al., 1996; Cooke et al., 2002). The insoluble 
protein was refolded following a protocol optimised for the processing of antibody 
fragments. The yields for soluble, refolded protein were very low. Nevertheless, 
enough Antp-H8P5 protein was produced to characterise its binding to DN-MAML1. 
In this experiment, Antp-H8P5 was coated onto the plastic surface of ELISA plates. 
This alternative strategy is convenient because less protein is used but also necessary 
because of the lack of c-Myc tag in the fusion construct. Working in the context of 
cancer signalling pathways, it seemed inappropriate to include the sequence of a 
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previously described oncogene to be carried inside the cell. A Kd value of 438 nM was 
calculated for Antp-H8P5. This can not be directly comparable with H8P5 binding 
because of the different detection methods used. However, this bigger value suggests 
a detrimental effect of refolding on the binding capabilities of Antp-H8P5. Another 
possibility is a small interference of binding due to fusion with Antp. It is also 
important to note that coating protein onto the plate surface can change its 
conformation. Therefore, it is possible that coated DN-MAML1 differs slightly from 
its soluble version. The same consideration applies to the fusion Antp-H8P5 which is 
coated prior to assessing its binding to the antigen.  
Mammalian expression was also investigated for production of Antp-scFv fusion 
proteins. Mammalian expression systems are usually preferred when working with 
larger and complex fusion proteins. Two strategies of expression were designed and 
attempted. Although zeocin selection suggested successful transfection, neither 
method resulted in the production of active Antp-H8P5 and Antp control proteins. 
Future studies should aim to detect the mRNA corresponding to each construct in 
order to confirm a problem at the protein expression level. The loss of tags is a 
common problem in recombinant expression systems. Therefore, this project would 
benefit from the availability of tools such as a reliable anti-Antp antibody to follow 
the fusion protein directly. The impossibility of producing substantial amounts of 
fusion protein meant that characterisation of this protein was halted. In the future, it 
will be necessary to confirm internalisation and successful inhibition of Notch 
signalling by the methods established in Chapter 3.  
 
Concluding remarks 
This study allowed the isolation of two candidate antibody fragments that successfully 
bind DN-MAML1 with affinities in the mid nanomolar range. This result is even 
more significant considering that the phage display selection was carried out using a 
naïve library. Expression trials of Antp fused to scFv in both orientations revealed a 
preference for the Antp-scFv constructs. Despite successful expression, fusion 
proteins were produced as inclusion bodies and yields were minimal. Binding of the 
Antp-H8P5 fusion to DN-MAML1 was mostly conserved upon refolding. No further 
characterisation was possible even when resorting to a mammalian system. 
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CHAPTER 5 
 
General Discussion 
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The aim of this study was to evaluate novel strategies for Notch inhibition, targeting 
MAML. The choice of target was influenced by various considerations. Firstly, it is 
important to think about the difference between targeting a signalling pathway 
through extracellular versus intracellular components. Generally, antibodies and other 
protein inhibitors are designed to target the interactions between a receptor and its 
ligand(s) at the cell surface. The inhibition of the initiation of signalling itself is 
believed to be a powerful tool to modulate cellular pathways. However, this strategy 
does not take into account the overlap and redundancy of intracellular signalling 
modulators between different pathways. It is rational for the cell to evolve multiple 
and intricate mechanisms for tight regulation of crucial intracellular signalling 
molecules. In normal conditions this allows control of signalling in the event of 
‘misfiring’ from a particular pathway. However, in the context of cancer, this same 
regulatory system can lead to drug resistant cancer cells. When a signalling pathway 
is inhibited, the cell can activate a parallel pathway that acts on the same modulators 
inside the cell or on different signalling molecules that have the same downstream 
effect (e.g. survival, proliferation). Targeting signalling inside the cell, aiming for the 
bottom of the signalling chain, is a viable option to consider. This strategy is better 
suited for ‘funnel’ pathways such as Notch, where multiple signalling routes through 
different receptors binding several ligands converge into a single event: the formation 
of the N
IC
, CSL and MAML tripartite complex for transcriptional activation. In the 
context of Notch, this strategy also allows to differentiate between the canonical and 
non canonical Notch pathways. In fact, by targeting the tripartite complex, our 
molecules should not interfere with CSL-independent signalling. It follows that the 
fusion proteins examined in this study could potentially be used to better understand 
the Notch pathway as a whole.  
In this study, two different strategies for inhibition of signalling were examined. The 
first includes the use of a dominant-negative version of MAML. Dominant-negative 
molecules outcompete the wild-type molecule for binding and act antagonistically, as 
they are not able to carry out the same function. Dominant-negative molecules have 
been commonly used as tools to better dissect and understand complex signalling 
pathways. However, the use of dominant-negative proteins as therapeutic agents has 
its limitations. In fact, only a minority of signalling molecules have a characterised 
dominant negative version. For other molecules, a dominant negative has yet to be 
identified. In contrast, our second strategy of delivering antibody fragments promises 
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to be suited to virtually any molecule in any pathway. Thanks to continuously 
evolving antibody isolation techniques, antibody and antibody fragments can be 
raised or selected from libraries against any antigen. Thus, this study provides a 
proof-of-concept applicable to other pathways or even to other molecules involved in 
Notch signalling.  
The development of strategies for intracellular delivery is a vibrant field and several 
methods have been explored in the past years. The choice of using Antennapedia in 
this study is predicated on its ability to cross the cellular membrane as well as the 
nuclear membrane. This is crucial for reaching nuclear MAML. It is important to note 
that the full length Antennapedia protein is used in this study rather than the 
corresponding cell-penetrating peptide penetratin. The reasoning behind this choice is 
that the full-length Antennapedia is thought to be more suitable for the delivery of 
larger cargoes. 
There is one main difference between the standard cancer therapy strategy and the 
approaches described in this study. Standard therapies are aimed to target cancer cells, 
specifically. Chemotherapy drugs affect rapidly dividing cells and antibody therapies 
target receptors/ligands overexpressed by cancer cells. In contrast to this, our cargoes 
DN-MAML1 and scFvs have the potential to be delivered to every cell in the body. 
This raises the question of the effect of inhibiting a crucial pathway such as Notch 
signalling in healthy cells alongside cancer cells. Studies in mice have highlighted the 
importance of Notch receptor and ligand genes for development. In fact, knock-out 
mice for Notch1, Notch2, DLL1 and Jagged-1 are embryonic lethal (Swiatek et al., 
1994; Shimizu et al., 1999; Hrabe de Angelis et al., 1997; Xue et al., 1999). In 
addition, mice heterozygous for DLL4 inactivation also die before birth (Gale et al., 
2004). Our in vivo study did not show obvious side effects in adult mice upon 
injection of Antp-DN-MAML1. This highlights the difference between tempering 
with Notch in the context of development versus altering its function in adult tissue 
renewal. Nevertheless, future studies should investigate potential side effects in more 
depth in order to confirm Notch as a viable target for the development of therapies in 
the adult. 
This project involved production of Antp fusion proteins which was very challenging 
on a technical level. The presence of recombinant proteins in inclusion bodies is a 
well-known obstacle in protein production. Refolding protocols need to be tailored to  
each protein and thus require extensive optimisation. In addition, refolding is not 
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favoured in biopharmaceuticals due to inconsistency and production of mixtures. 
Thus, multiple attempts at producing Antp fusion proteins in a soluble form were 
performed before resorting to a refolding strategy. It is important to note that 
modification of the expression protocol for Antp was a successful strategy for 
production of this protein in the soluble phase. However, fusion of Antp to DN-
MAML1 increased the difficulty of producing this protein. The expressed protein was 
insoluble in multiple experimental settings suggesting that there is an unavoidable 
biological or toxic constraint on bacterial expression of Antp-DN-MAML1. 
Expression using a mammalian system was considered as a portion of the fusion 
protein is of human origin, but was never attempted. However, CHO cells were used 
for expression trials of Antp-scFv and Antp, with no success. It is possible that 
interactions with the membrane impede the successful production of these proteins. 
Alternative host systems such as expression in yeast should be considered in future 
studies. It would also be interesting to explore whether the use of alternative cell-
penetrating proteins or peptides would relieve the production problems observed 
when using Antp. Although satisfactory expression yields were obtained for 
expression of insoluble Antp-DN-MAML1, refolding was unsuccessful. Soluble 
expression of Antp-DN-MAML1 was achieved but its purification was not possible.  
Increasing evidence is available supporting a role for Notch in cancer stem cells 
(CSC). It is believed that targeting Notch will enable manipulation of the elusive CSC 
population. CSC have been described as a small population within the cancer cell 
population (Al-Hajj et al., 2004; Donnenberg and Donnenberg, 2005; Kakarala and 
Wicha, 2007; Korkaya and Wicha, 2007; Yang and Wechsler-Reya, 2007). These 
‘tumour initiating cells’ are hypothesised to possess some biological properties 
characteristic of normal stem cells such as unlimited self-replication, asymmetric cell 
division and resistance to toxic molecules through increased expression of ABC 
transporters amongst other mechanisms. The origin of CSC is the subject of 
continuing debate amongst scientists. Three hypotheses have been formulated. First, 
scientists believe that CSCs derive from normal tissue stem cells that have undergone 
some form of transformation. According to this model, the CSCs are proposed to 
generate other cancer cells by aberrant differentiation, evading normal regulatory 
mechanisms (Song and Miele, 2007). Supporting this hypothesis is the finding of 
stem cell markers in CSC from primary tumours such as, CD133 (promimin-1), 
nestin, c-kit, sox2, Oct4 and musashi-1 (Hemmati et al., 2003; Singh et al., 2003; 
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Singh et al., 2004; Eramo et al., 2008; Ricci-Vitiani et al., 2007; Collins et al., 2005). 
The second hypothesis states that stem cell characteristics can be acquired by any cell 
through transformation. For example, normal fibroblasts acquire stem cell qualities by 
expression of Oct4, Sox2, Nanog and LIN28 (Yu et al., 2007) or Oct3/4, sox2, Klf4 
and c-Myc (Takahashi et al., 2007). In epithelial cancers, epithelial-mesenchymal 
transition (EMT) has been described as a process of partial dedifferentiation (Hugo et 
al., 2007). In this process, epithelial-specific cytokeratins and E-cadherin are lost and 
replaced by mesenchymal markers such as vimentin and N-cadherin. Transcription 
factors Twist, Snail or Slug and TGF-β have been implicated in the initiation of EMT. 
Recent publications by the Weinberg group support the idea that cancer cells can re-
acquire stem cell characteristics as they undergo EMT, a process linked to invasive 
and metastatic tumour behaviour (Mani et al., 2008). A third hypothesis proposes an 
“intermediate” mechanism. In this model, CSCs are thought to originate from 
particular cell populations such as tissue stem cells and immature progenitors that 
have short-term self-replication capabilities. Research supporting this idea showed 
that estrogen receptor (ERα)-negative breast cancers and aggressive ERα-positive 
cancers originate from ERα-negative primitive mammary stem cells whereas less 
aggressive ERα-positive cancers originate form ERα-positive intermediate 
progenitors (Dontu et al., 2004). It is important to note that there three models are not 
necessarily mutually exclusive and may explain different stages of cancer or may 
underlie the differences observed between different types and different subtypes of 
cancer.  
The study of CSCs has been limited so far by the lack of universal markers specific 
for these cells that would allow their isolation from the tumour mass. In addition, 
some of the markers identified so far are not found in different malignancies (O'Brien 
et al., 2010). Previous studies have also highlighted the importance of considering the 
cellular microenvironment and the role of the immune system when studying CSCs 
(LaBarge, 2010). Taking into account the cellular microenvironment is particularly 
crucial when studying Notch signals which are transmitted by cell to cell contact. The 
role of the immune system was highlighted by studies in mice, where tumorigenicity 
of CSCs in different mice models varied depending on the levels of 
immunodeficiency (Schatton et al., 2008; Quintana et al., 2008).  
There is accumulated evidence for a role of Notch in CSC in breast cancer (Farnie and 
Clarke, 2007; Farnie et al., 2007; Sansone et al., 2007), embryonal brain tumours (Fan 
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et al., 2006) and gliomas (Fan et al., 2010; Wang et al., 2010). GSIs have been shown 
to inhibit formation of secondary mammospheres in multiple human breast cancer cell 
lines and primary patient samples (Grudzien et al., 2010).  Mammospheres are 
considered as an indicator of stem-like cells. GSIs and a Notch4 monoclonal antibody 
also inhibited formation of mammospheres in breast ductal carcinoma, in situ (Farnie 
et al., 2007). A study by Sansone et al. highlighted a cross talk between IL6 and 
Notch in mammospheres from human breast cancers. IL6 is shown to induce Notch3 
signalling specifically, increase Jagged-1 expression and promote resistance to 
hypoxic conditions through Notch3 (Sansone et al., 2007). Other studies showed that 
Notch inhibition results in the depletion of medulloblastoma and glioblastoma CSCs 
(Fan et al., 2010; Fan et al., 2006).  
It is generally believed that current cancer therapeutics do not allow adequate 
targeting of CSCs. It is proposed that long-lasting remissions or cures will require the 
complete abolition of CSCs. Based on the evidence of a role for Notch in CSC, Notch 
inhibitors are considered promising tools to target CSCs for cancer therapy. In this 
study, the effect of novel Notch inhibitors was not investigated in the context of 
CSCs. Future studies should investigate the potential of the fusions as therapeutic 
agents in such a model. Also, the tools developed in this study can be employed to 
better understand the role of canonical Notch signalling in the context of CSCs.  
The study of Notch signalling has led to the development of various inhibitors. These 
can be divided in two categories: pan-Notch inhibitors versus specific inhibitors. As 
previously described, Notch signalling can be initiated by binding to four different 
receptors in mammals. In the canonical pathway, signals from all receptors are 
believed to converge into a single event: the formation of the active tripartite 
transcription complex in the nucleus. The structure of the Notch pathway is such that 
depending at which level they target the pathway, inhibitors can affect Notch 
signalling as a whole or signalling originating from a single receptor only. At present, 
there is no clear advantage of one strategy versus the other. Both categories have their 
advantages and disadvantages and might be applicable to different biological 
scenarios. As inhibitors of γ-secretase activity, GSIs are pan-Notch inhibitors but also 
block the cleavage of other γ-secretase substrates. It is believed that off-target effects 
might be different depending on the inhibitor used. Developers of these drugs argue 
that inhibition of other γ-secretase targets might be beneficial in some cases, 
contributing to therapeutic efficacy. Advantages of GSIs include ease of 
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administration, oral bioavailability and low cost. Research by Moellering et al. has 
revolutionised the field of Notch inhibition by developing pan-Notch inhibitors 
without the off-target effects of GSIs (Moellering et al., 2009). Specificity to the 
Notch pathway is achieved by targeting formation of the CSL-N
IC
-MAML complex. 
This study described the development of two alternative strategies that promise to be 
more suitable for use in the clinic. In particular, the delivery of antibody fragments 
means that higher binding affinities can potentially be obtained compared to peptide 
drugs (picomolar compared to micromolar). The scFv fusion developed in this study 
has affinity in the nanomolar range. This can be improved by random mutagenesis 
followed by additional rounds of phage display selection. This is a common strategy 
used in the development of antibodies, especially when the initial selection is 
performed using a naïve library (Pini et al., 1998). Another common practice to 
improve on affinity is to combine two scFvs in an IgG format. This is not applicable 
to this study as a high affinity monovalent binder is needed to block a single complex 
on DNA. Antibodies are also used for selective inhibition of Notch signalling, 
targeting single receptors/ligands. These tools are best suited where a specific Notch-
ligand combination is involved in malignancy. For example, antibodies against DLL4 
have been developed following the discovery of this ligand’s specific involvement in 
angiogenesis. In the context of CSCs, Notch3 could be targeted to attain hypoxia-
resistant cells specifically.    
 
Future work   
 
This study involved extensive work on expressing and purifying several protein 
constructs. The production of these proteins is crucial in order to test their effect in 
vitro. Therefore, future work should involve optimisation of these protocols in order 
to obtain improved protein yields and to ensure correct folding of these proteins. The 
first protein produced in this study is Antp. The protocol for isolation of this cell 
penetrating protein is satisfactory. However, since Antp is a Drosophila protein, the 
use of insect cells as a recombinant system is worth investigating in the future. 
Regarding Antp-DN-MAML1, extensive work has been carried out in this study and 
by our collaborators in order to determine a successful strategy for production of this 
fusion protein. Despite multiple efforts, currently production of Antp-DN-MAML1 
relies on its synthesis as a custom peptide. This procedure is costly and could not be 
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applied to larger fusions. One strategy that was not attempted is the expression of 
Antp-DN-MAML1 using a mammalian expression system. This is worth considering 
in future studies as the DN-MAML1 portion of the protein is of mammalian origin. 
However, expression trials of Antp and Antp-scFv in CHO cells have shown that, 
even in this system, protein production is problematic. A second strategy for future 
production of Antp-DN-MAML1 is to further investigate its expression as a soluble 
protein within the first hour post induction and attempt its purification. As ion 
exchange and affinity chromatography showed disappointing results, successful 
isolation of this protein might rely on changing the position or the nature of the tag. 
The fusion between Antp and a scFv is the construct that requires most attention in 
future studies. Production of this fusion protein currently relies on expression in 
inclusion bodies followed by a refolding protocol. There is scope for improvement of 
the refolding method, but soluble expression should be the target in the future. 
Recently, a collaborator has successfully expressed scFv antibody fragments in the 
cytoplasm. This strategy requires the fusion of the scFv to an ‘expression partner’ and 
the use of a particular E.coli strain that presents the suitable conditions for formation 
of disulphide bonds in the cytoplasm (oxidising environment and presence of 
chaperones). Expression of the Antp-scFv fusions should be assessed in this novel 
system.          
The novel tools employed in this study for the inhibition of Notch signalling, rely on 
the Antp protein for successful intracellular delivery. The study of the internalisation 
mechanism of Antp was beyond the scope of this study. However, further studies 
should aim at further investigating this system. In particular, it is of interest to 
determine whether the internalisation process is dependent on endocytosis and if there 
are any specific interactions with particular membrane components.  
The study of Antp internalisation should include a direct comparison with its 
derivative penetratin including an evaluation of their respective toxic effects. Further 
studies should also evaluate the ability of Antp and penetratin to transport cargoes of 
different sizes. In order to avoid the artefacts observed when using fluorescence to 
track protein internalisation, the use of radioactivity constitutes a suitable alternative. 
Using a radioactive marker enables quantification of internalisation. One of the 
limitations of using this technique is the measure of particles stuck to the membrane 
as internalised protein. Extensive washing can minimise this artefact.  
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Hes1 gene expression levels were used as a read out of Notch activity in in vitro 
assays. Hes1 is a well-characterised Notch target gene and its expression levels can 
confidently be related to Notch signalling activation/inhibition. Future studies should 
explore the expression of alternative genes (i.e. Hey1) upon treatment with Notch 
inhibitors. It is important to verify that the genes analysed are in fact direct Notch 
target genes. Ideally, their expression should not be influenced by other systems of 
regulation.  
The observations made in this study that point to a possible interaction of DN-
MAML1 with p53 should be further investigated. It is important to verify binding of 
truncated MAML1 to p53 to support our model. This will involve production of the 
p53 protein to carry out binding studies by ELISA. It is important to note that increase 
in p21 might rely on a different mechanism related to inhibition of Notch. This 
possibility should be investigated in the future.  
The inhibitors studies in this project should also be tested in alternative cancer models 
such as T-ALL cells and CSCs. In a T-ALL model, it is well established that 
inhibition of Notch results in cell death. Therefore, this model offers a clear readout 
for testing of the Notch inhibitors. The effect of Notch inhibitors in CSCs should be 
investigated to better understand the role of canonical Notch signalling in this context. 
Future studies should investigate the potential of the fusions as therapeutic agents in 
this model.  
The in vivo experiments presented in this study provide initial evidence supporting the 
use of Antp-DN-MAML1 as a therapeutic agent. In the future, in vivo experiments 
should be carried out on a bigger scale with the addition of all relevant control groups. 
A range of dosages and different administration routines should be envisaged. In 
order to study a possible role for the immunise system in the effect of Antp-DN-
MAML1 on tumour growth, it would be interesting to collect blood samples during 
the in vivo study to monitor the immune system’s levels of activation. Tumour 
samples should also be collected to study the cellular composition and morphology in 
addition to gene expression profiles. In particular, Ki-67 staining is useful to 
determine the levels of cellular proliferation in the tumour and surrounding tissue. 
Staining for CD44, CD24 and ALDH1 is also of interest as this allows the 
identification of cancer stem cells within the breast cancer population. Analysis of 
tumour samples could also reveal the presence of apoptosis (cleaved caspase 3) and 
metastasis (uPA and PAI1) markers.  
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In relation to the work on the Antp-scFv fusions, additional time will allow to better 
characterise the pool of antibody fragments isolated by phage display selection. In this 
study, screening of candidate scFvs was based on the binding to DN-MAML1. 
Ideally, a functional screening should be carried out to determine successful inhibition 
of tripartite complex formation upon binding. This was not possible due to the 
unavailability of the CSL and N
IC
 proteins. By choosing the minimal portion of 
MAML required for complex formation as the antigen in our phage display selection, 
the chances of selecting an appropriate scFv are maximised.  If future studies revealed 
that the affinity of selected scFvs is not sufficient to have an effect on initiation of 
signalling, it will be necessary to carry out random mutagenesis of the scFv pool 
followed by an additional phage display round. This is a common practice in the field 
of antibody engineering. Mutagenesis could also be employed to engineer the 
antibody fragment’s linker region to prevent cleavage as observed during production.  
In this study, ELISA was chosen as a technique to detect binding between two 
proteins. Other methods are available to study binding including surface plasmon 
resonance, isothermal titration calorimetry (ITC) and bandshift gel retardation assay 
on native gels. While ELISA allows end-point measurements, rate constants can be 
measured using surface plasmon resonance. An alternative method named ITC allows 
direct measurements of the heat absorbed or released during binding, providing a 
complete thermodynamic profile of molecular interactions. The limitation of ITC is 
the requirement for vast amounts of protein to perform the assay. Thus, ITC was not 
applicable to this study. The least sophisticated method is the use of native gels to 
observe bandshifts on gels upon binding. This method only allows the detection of 
strong interactions and requires considerable optimisation to achieve the optimal 
running conditions.  
A critical tool that was missing from this study is a reliable antibody against Antp in 
order to track this protein and the corresponding fusions. It is desirable to be able to 
detect the proteins of interest directly rather than relying on tags. Future studies 
should include the development of such tool or the verification of the antibody 
available on the market.   
Overall, future studies building on the results obtained during this project will provide 
interesting insights on the biology of Notch and help establish the intracellular 
inhibition of Notch as a valid strategy for cancer therapy. 
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